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Abstract 
Eukaryotic translation initiation factor 5A (eIF5A) is the only known protein to contain 
hypusine, formed by post-translational modification of a highly conserved lysine residue. 
Hypusination is essential for eIF5A function, being required for binding of a specific subset of 
mRNAs necessary for progression of eukaryotic cells through the G1-S checkpoint.  Little 
structural information is available for eIF5A other than that derived from archaeal 
homologues.  The aim of this study was to conduct structure-function studies on 
Saccharomyces cerevisiae (yeast) eIF5A, encoded by TIF51A.  Homology models of eIF5A 
were generated from the Methanococcus jannaschii archaeal homologue (aIF5A) and two 
Leishmania eIF5As.  The models, along with secondary structure predictions identified an α-
helix on the C-terminal domain, unique to eukaryote eIF5A.  The Neurospora crassa 
structural analogue, HEX-1, which dimerises in three configurations, was used to generate 
similar dimeric model configurations of eIF5A.   
 
A biochemical and functional analysis was used to validate the homology models of eIF5A.  
Since the crystal structures of aIF5A and eIF5A were solved from unhypusinated protein 
produced in Escherichia coli, 6 x His-tagged eIF5A (His-eIF5A) was used for biochemical 
analysis.  This analysis revealed that eIF5A existed as a dimer in solution, dependent on the 
presence of the highly conserved Cys 39 residue.  A yeast TIF51A/TIF51B null yeast strain, 
with a chromosomal copy of TIF51A under control of PGAL1, was used to confirm that His-
eIF5A and selected eIF5A mutants were functional in vivo.  Biochemical analysis showed that 
hypusinated His-eIF5A also exists as a dimer, but neither the dimerisation, nor the function of 
eIF5A are dependent on the presence of Cys 39.  Rather they depend on the presence of 
hypusine (Hpu) 51 and the presence of RNA leading to the conclusion that RNA and hypusine 
are required for dimerisation and hence function, of native eIF5A in vivo.  In contrast, a Lys 
51 to Arg 51 substitution or RNase treatment of His-eIF5A produced in E. coli did not 
 ii 
destabilize the dimeric form, suggesting different folding/dimerisation mechanisms in E. coli 
and yeast cells.  The information obtained from the initial homology models, together with the 
results of the biochemical analysis was used to propose a mechanism for dimerisation of yeast 
eIF5A involving both hypusine and RNA. 
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Chapter 1:  Literature Review 
 
1.1  The eukaryotic translation initiation factor 5A  
The eukaryotic translation initiation factor 5A (eIF5A) is a highly conserved protein that is 
essential in all eukaryotes and archaebacteria, but not in eubacteria (Schnier et al., 1991; Chen 
& Liu, 1997; Park et al., 1997) and is the only protein known to contain the unique amino 
acid hypusine (Cooper et al., 1983).  Hypusine was first isolated in its free form in 
trichloroacetic acid soluble bovine brain tissue (Shiba et al., 1971) and was named hypusine 
as an abbreviation from hydroxyl putrescine and lysine.  Originally eIF5A was thought to be 
involved in translation initiation as it could enhance the synthesis of methionyl-puromycin, 
which suggested that the protein was involved in the formation of the first peptide bond in 
translation (Benne & Hershey, 1978).  Further experiments conducted by Cooper et al. in 
1983 showed that not only was eIF5A involved in translation, but it also functioned in cell 
cycle regulation.  eIF5A is an abundant factor, but unlike other initiation factors, it is largely 
present in the cytoplasm.  Only a small amount of the protein is directly associated with the 
ribosomes (Park et al., 1993).   
 
Hypusine is essential for the biological functioning of eIF5A and is formed by the post-
translational modification of a highly conserved lysine residue (Park, 1989).  This lysine 
residue is flanked by a stretch of six amino acid residues on either side with a high degree of 
conservation among different eIF5A species (Park et al., 1986).  The two-step process of 
modification (known as hypusination) is dependent on the enzymes deoxyhypusine synthase 
(DHS) and deoxyhypusine hydroxylase (DOHH) (Murphey & Gerner, 1987).  While 
inhibition of either of these enzymes affects cell growth in mammalian cells (Park et al., 
1993), only DHS (yDHS or Dys1) is essential in the yeast Saccharomyces cerevisiae (referred 
hitherto as "yeast") (Sasaki et al., 1996; Park, 2006).  DOHH does not appear to be essential 
in yeast since a DOHH (yDOHH or Lia1) null strain grows only slightly slower than the 
parent strain (Park et al., 2006).  
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1.1.1  The yeast eIF5A and eIF5Ab  
The yeast genome was the first eukaryotic genome to be completely sequenced (Goffeau et 
al., 1996; Cherry et al., 1997).  Since there are numerous genes in yeast and humans that 
encode similar proteins (Botstein & Fink, 1988) and because yeast is amongst the best-studied 
experimental organisms, the yeast TIF51A gene has been the subject of many investigations 
on eIF5A.  This section will deal with eIF5A, specifically in the context of yeast as a model to 
study higher eukaryotes. 
 
In yeast, eIF5A is encoded by one of two essential genes, namely HYP2 (TIF51A) or ANB1 
(TIF51B) mapping to chromosomes V and X, respectively (Wöhl et al., 1992; Mehta et al., 
1990).  TIF51A encodes eIF5A (isoelectrically more acidic), expressed under aerobic 
conditions, while TIF51B encodes eIF5Ab (isoelectrically more basic), expressed under 
anaerobic conditions. eIF5A and eIF5Ab, which share 90 % similarity to each other, both 
carry the hypusine modification and either is sufficient to maintain growth of yeast cells 
(Schnier et al., 1991; Wöhl et al., 1993; Schwelberger et al., 1993, Magdolen et al., 1994).  In 
exponentially-growing cells, eIF5A is more abundant than eIF5Ab, and eIF5A is prone to 
proteolytic breakdown in vitro (Schwelberger et al., 1993).  Expression of eIF5Ab can, in the 
presence of oxygen, reverse the lethality of an eIF5A knockout, and eIF5A is able to reverse 
the lethality of an eIF5Ab knockout under anaerobic growth conditions (Wöhl et al., 1993; 
Schwelberger et al., 1993).  The human cDNA encoding eIF5A, which is about 60 % identical 
to the yeast homologue, can substitute for the yeast protein in vivo (Schwelberger et al., 
1993).  However, archaeal eIF5A (aIF5A) expressed in yeast is neither hypusinated nor able 
to rescue growth in eIF5A/b deficient cells (Magdolen et al., 1994).   
 
Both TIF51A and TIF51B encode proteins of 157 residues with predicted molecular weights 
of between 17 - 20 kDa with similar isoelectric points (pI of between 5.1-5.5) and a mean 
half-life of about 33 hours (yeast eIF5A: Mehta et al., 1990; Schwelberger et al., 1993;  
mammalian eIF5A: Cooper et al., 1983; Chung et al., 1991; Gerner et al., 2002).  In 
individual knockout experiments to determine the role of eIF5A and eIF5Ab, it was 
determined that TIF51A-disrupted strains grew more slowly, while strains lacking TIF51B 
showed no growth phenotype (Schnier et al., 1991).  Strains lacking both TIF51A and TIF51B 
were non viable, showing that eIF5A is essential for cell growth in yeast cells (Schnier et al., 
1991).   
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1.1.2  Biosynthesis of active eIF5A  
Synthesis of the active eIF5A protein results from the addition of a spermidine moiety (from 
polyamine synthesis) to the eIF5A precursor, such that a specific lysine residue in eIF5A is 
modified.  The two-step post-translational modification is represented schematically in Figure 
1.1A.  During polyamine synthesis, spermidine is dehydrogenated in an NAD-dependent 
manner to form dehydrospermidine.  The 4-aminobutyl moiety from spermidine 
(dehydrospermidine) is transferred to the specific lysine residue of eIF5A precursor by the 
enzyme DHS.  The intermediate formed is a covalent enzyme-imine.  Next, hydroxylation of 
the eIF5A intermediate (deoxyhypusine) is catalyzed by DOHH (Abbruzzese et al., 1986) to 
form the hypusinated protein and thus complete eIF5A activation (Figure 1.1A).  DHS is able 
to equally modify the two forms of precursor eIF5A protein, eIF5A and eIF5Ab (Sasaki et al., 
1996).  The intricate specificity of DHS activity has been examined using spermidine, NAD 
and putrescine, which can replace the eIF5A precursor as an acceptor of the 4-aminobutyl 
moiety of spermidine to form homospermidine (Park et al., 2003) (Figure 1.1B).  The initial 
conversion of eIF5A precursor to deoxyhypusine is reversible, while the hydroxylation step is 
irreversible (Park et al., 2003).  In addition, spermidine, but not spermine is essential for 
hypusination and consequently growth of yeast cells (Chattopadhyay et al., 2003).  However, 
in the presence of the enzyme amine oxidase (coded by FMS1), spermine could be oxidised to 
spermidine. 
 
Site-directed mutagenesis of the lysine residue that is hypusinated, to an arginine residue, 
resulted in inactive eIF5A (yeast eIF5A: Schnier et al., 1991; mammalian eIF5A: Gordon et 
al., 1987; archaeal aIF5A: Bartig et al., 1992).  Other modifications observed in the yeast 
eIF5A include the phosphorylation of one serine residue near the N-terminus (Kang et al., 
1993).  Thus there are two post-translational modifications that occur in eIF5A, hypusination 
and phosphorylation, but the activity of the protein is solely dependent on hypusination 
(Schnier et al., 1991; Kang et al., 1993).   
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Figure 1.1:  The modification of eIF5A.  (A)  The 4-aminobutyl moiety from spermidine 
(dotted oval) is transferred to the lysine-containing eIF5A precursor, eIF5A (lys), in the 
presence of DHS to form the deoxyhypusine (DHP) intermediate.  DHP is then hydroxylated 
by DOHH to form the active, hypusinated eIF5A.  The forward reaction resulting in DHP is 
reversible in the presence of NAD, forming spermidine as the end product (dashed arrow). (B)  
Spermidine can also be converted by DHS in the presence of NADH + H+ to 
homospermidine, in the presence of putrescine as the acceptor.  The figure was generated in 
part using ACD/ChemSketch, 2005 and adapted from information in Murphey & Gerner, 
1987; Park et al., 1982, 1993, Park et al., 2003; Park, 2006.  
 
 
1.2  The eIF5A modifying enzymes 
1.2.1 Deoxyhypusine synthase (DHS) 
In yeast, DHS is a 369 amino acid cytosolic protein encoded by the YHR068w (DYS1) gene on 
chromosome VIII existing as a homotetramer (160-170 kDa in size) with a subunit size of 43 
kDa and a proposed half-life in the region of 10 hours (Kang et al., 1995; Dou & Chen, 1990; 
Thompson et al., 2003).  DHS is essential for cell viability (Kang et al., 1995; Sasaki et al., 
1996).  Depletion of DHS results in the enlargement of cells followed by a cessation of 
growth (Park et al., 1998).    This observation of cessation of growth, accompanied by a 
marked cell enlargement in cells lacking DHS, is attributed to the role of eIF5A in cell 
division or on cell cycle progression (Kang et al., 1995; Sasaki et al., 1996; Park et al., 1998).  
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Structure-function studies have been conducted using recombinant human DHS as well as 
truncated mutant proteins (Joe et al., 1995). The human DHS sequence shows a high degree 
of identity (58 %) and similarity (73 %) with yeast DHS and both proteins are phosphorylated 
by protein kinase C (Kang et al., 1995; Kang & Chung, 1999; Kang et al., 2002).  E. coli cells 
expressing recombinant human DHS effectively synthesise deoxyhypusine in vivo and regions 
of DHS critical for enzyme activity have been identified, including a well-conserved internal 
region of 56 amino acids (Asp 262 – Ser 317), and less conserved regions in the amino 
terminal and carboxy terminals (Joe et al., 1995).   
 
Refinement of the first crystal structure of the human DHS complexed with the NAD co-
factor and crystallised in the presence of the known inhibitor, 1,7-diaminoheptane (DAH), 
showed a ball-and-chain mechanism for the blocking each of the deep active sites (Liao et al., 
1998).  A similar structure for DHS was solved by Umland et al. (2004).  The crystals were 
obtained under conditions of high ionic strength and acidic pH. Analysis of the data 
confirmed that the human DHS protein is a homotetramer, comprising of four potential active 
sites formed by two tightly-associated dimers with each of the four identical subunits 
containing a nucleotide-binding (Rossmann) fold (Liao et al., 1998; Umland et al., 2004).  
Several conformational changes have been proposed to increase the accessibility of the 
substrate-binding site.  It is likely, however, that the conditions under which the crystals were 
obtained resulted in an inactive DHS because X-ray diffraction studies on crystals grown at 
low ionic strength and pH 8.0 (near pH optimum for DHS) have revealed a new configuration 
of the DHS-NAD complex, more representative of the active form (Murphey & Gerner, 1987; 
Lee et al., 1999; Lee & Park, 2000; Umland et al., 2004).  This new data showed that the 
previous ball-and-chain motif was structurally different, allowing accessibility of the 
previously buried active sites (Umland et al., 2004).  The dimer configurations of these two 
structures are represented in Figure 1.2.  The structure obtained from crystals soaked in the 
potent inhibitor, N1-guanyl-1,7-diaminoheptane (GC7), resulted in the novel DHS-NAD-
inhibitor ternary complex, providing new insights into the mode of substrate binding and 
reaction mechanism (Figure 1.2B). 
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Figure 1.2:  Crystal structures of the tightly-associated human DHS dimer.  (A):  Cartoon 
model of DHS complexed with NAD, as determined from crystals produced in high ionic 
strength and low pH conditions.  NAD is represented as sticks in the buried active site, 
forming part of the proposed ball-and-chain mechanism.  (B):  Cartoon model of DHS 
complexed with both NAD and GC7, as determined from crystals produced in low ionic 
strength and high pH conditions.  The complexed NAD and GC7 are represented as sticks in 
the more accessible active site, forming part of a unique conformational change upon 
substrate binding.  The models (PDB codes 1RLZ and 1RQD for A and B, respectively) were 
generated using Pymol (DeLano, 2002). The figure was adapted from information in Liao et 
al., 1998 and Umland et al., 2004. 
 
The stoichiometry of the components in the human DHS-eIF5A (precursor) complex has been 
approximated to be 1 DHS tetramer to 1 eIF5A (precursor) monomer, and confirmed by 
equilibrium ultracentrifugation data (Lee et al., 1999).  In addition, the formation of the 
complex is neither dependent on the presence of NAD+ nor on spermidine (Lee et al., 1999).  
The human enzyme appears to be different from the Neurosporra crassa DHS, in that the 
latter depends on the presence on NAD+ for substrate binding (Tao & Chen, 1994, 1995; Dou 
& Chen, 1990).  Further analysis of the structure-function relationship of human DHS has 
identified critical amino acids involved in the binding of spermidine, NAD+ and eIF5A 
precursor (Lee et al., 2001).  Alanine substitutions of amino acids Asp 243, Trp 327, His 288, 
Asp 316 and Glu 323 in the predicted spermidine-binding sites, results in a dramatic loss of 
spermidine binding and enzyme activity, while substitutions of His 288 to Ala also lead to the 
abolishment of NAD-binding.  Similarly, mutation of nearly all the potential NAD-binding 
site amino acid residues results in a reduction of NAD-binding ability (Lee et al., 2001). 
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1.2.2  Deoxyhypusine hydroxylase (DOHH) 
DOHH catalyses the formation of hypusine from deoxyhypusine, the precursor of active 
eIF5A (Abbruzzese et al., 1986).  Characterisation of DOHH from partially purified from rat 
testis suggested the enzyme might have a mode of action similar to propyl and lysyl 
hydroxylases, members of a group of α-ketoglutarate dioxygenases (Abbruzzese et al., 1986).  
In addition, it seemed likely that the metal ion (Fe2+) required for catalysis was tightly 
associated with the enzyme, thus eliminating the need for the addition of metal ions during 
purification procedure (Abbruzzese et al., 1986). 
 
Inhibition of DOHH from rat testis has been studied in vitro using a variety of polyamines 
including spermine and its homologue, thermine as well as spermidine and its homologue, 
caldine.  Spermidine and thermine exhibit the strongest inhibition, while spermidine and 
caldine display less potent inhibitory effects.  Spermidine analogues, diamines, including 
putrescine, free hypusine and deoxyhypusine display little to no inhibition of DOHH activity 
(Abbruzzese et al., 1989).  Designed for their ability to anchor in the DOHH active site, 
catecholpeptides (CCPs) have been found to strongly inhibit hypusine formation in vitro 
(Abbruzzese et al., 1991).  In addition, their involvement in the utilisation of catechol-
mediated chelation provides evidence that a metal ion forms as integral part of the DOHH 
catalytic centre (Abbruzzese et al., 1991).  This has been confirmed by Csonga et al. (1996), 
using HeLa cells to determine which metal ion is involved in the action of DOHH.  Both 
Fe(II) and Fe(III) display equal abilities in restoring the hydroxylase activity to control levels 
following inhibition with ciclopiroxolamine (CPX), a potent metal chelator (Csonga et al., 
1996). 
 
In yeast, the YJR070C (LIA1) gene encodes DOHH, while HLRC1 (MGC4293) encodes the 
human homologue (Thompson et al., 2003; Park et al., 2006).  Highly conserved DOHH gene 
homologues have also been identified in a variety of eukaryotes from yeast to mammals.  
Based on sequence profile data, it has been found that DOHH (325 residues in yeast) belongs 
to a group of HEAT-repeat containing metalloenzymes, typified by eight tandem repeats of an 
α-helical hairpin superstructure known as a HEAT motif (Andrade et al., 2001).  DOHH is 
organised in a symmetrical dyad.  HEAT-repeat proteins mediate protein-protein interactions 
and are involved in cytoskeletal organisation, nucleocytoplasmic and vasuolar transport 
(Andrade et al., 2001).  The DOHH structure is dissimilar to the double-stranded β-jelly roll 
type structures of the dioxygenases, lysyl and collagen propyl hydroxylase, which are 
dependent on Fe(II) and 2-oxoacid but metal co-ordination site sequences are conserved.  This 
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suggests that the iron-dependent DOHH is a structurally distinct protein hydroxylase (Park et 
al., 2006).  Two potential iron co-ordination sites, comprising of two strictly-conserved His-
Glu motifs are present in DOHH (Kim et al., 2006).  Mutation of any of these conserved His-
Glu residues abolishes DOHH activity, providing evidence that Fe(II) binding to each of the 
sites is required for DOHH catalysis (Kim et al., 2006).  A binuclear iron binding reaction 
mechanism, distinct from that of other Fe(II)-dependent protein hydroxylases has been 
proposed (Kim et al., 2006). 
 
Critical amino acids required for the binding of substrate to the human DOHH have been 
identified using alanine substitution.  Of the 36 conserved residues within the His-Glu motifs, 
Glu 57 and Glu 208 were identified as being required for substrate binding, although they are 
not involved in iron co-ordination.  DOHH also specifically recognises only the 
deoxyhypusinated form of eIF5A, but not the lysine form, and a large portion (20-99 amino 
acids) of this substrate is required for hydroxylation by DOHH (Kang et al., 2007).  A model 
of the deoxyhypusine-DOHH complex has been proposed, whereby the Glu 57 and Glu 208 
residues form ionic bridges, anchoring the amino groups of the deoxyhypusine side chains to 
the active site (Kang et al., 2007).  Ultimately, a crystal structure for DOHH, may clarify the 
structure-function relationship of this unique hydroxylase. 
   
1.3  Functions of eIF5A 
1.3.1  Role in the cell cycle 
Eukaryotic ribosomes are comprised of a 60S large subunit and a 40S small subunit, which 
together form the 80S particle.  Translation occurs by a sophisticated mechanism of 
recruitment of the ribosome to the mRNA and relies on protein-RNA and protein-protein 
interactions.  While at least eleven translation initiation factors have been identified in the 
translation machinery, eIF5A is not one of them (Benne & Hershey,1978; Unbehaun et al., 
2004).  Hypusinated eIF5A has, however, been implicated in playing a role in the expression 
of proteins regulating the transition of the G1-S phase of the cell cycle in eukaryotic cells 
(Kang & Hershey, 1994; Hanauske-Abel et al., 1994; Jin et al., 2003).  A schematic 
representation of the eukaryotic cell cycle is shown in Figure 1.3. 
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Figure 1.3:  Schematic representation of the eukaryotic cell cycle, with its major 
checkpoints. The G1 (Gap 1), S (Synthesis) and G2 (Gap 2) phases together are called 
interphase and cells occupy between 90-95 % of their time in these phases.  Cells spend a 
short time in the M (Mitosis) phase, where nuclear and cytoplasmic divisions occur.  The G1 
and G2 phases are typified by time delays to allow the cell to monitor the internal and external 
environments before committing to the next stage.  eIF5A, its precursor enzymes, and the 
substrate spermidine have been shown to be especially important at the G1-S transition (Start) 
(Adapted from Alberts et al., 2002). 
 
Modified (hypusinated) eIF5A plays a role in cell growth and differentiation, specifically in 
cell proliferation (Abbruzzese, 1988; Beninati et al., 1990; Caraglia et al., 1997) and growth 
of yeast (Schnier et al., 1991).  Inhibition of hypusination results in reduced growth of 
mammalian cells (Park et al., 1984, Abbruzzese, 1989, 1991; Jakus et al., 1993; Park et al., 
1993) and induces the reversible arrest in the G1-S phase of the cell cycle (Figure 1.3) (Park et 
al., 1981; Park, 1987).  Polyamines in general, but specifically spermidine, have been 
implicated in cellular proliferation, differentiation and embryonic development (Tabor & 
Tabor, 1985; Pegg 1988) and because spermidine is the direct precursor of hypusine, it has 
been proposed to be one of the fundamental endogenous components in cellular regulation.  
Furthermore, active eIF5A has been implicated in determination of cell integrity and cell 
polarity (Valentini et al., 2002; Zanelli & Valentini, 2005).   
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The establishment of actin polarity involves cytoskeletal reorganisation, secretion and cell 
wall deposition.  All these activities are essential for bud formation and the G1-S transition in  
yeast (Zanelli & Valentini, 2005) and rely on the presence of hypusinated eIF5A.  It has also 
been suggested that eIF5A works in tandem with yeast protein transport-GTPase (Ypt-
GTPase) to enhance protein synthesis and secretion required in bud formation during the S-
phase transition (Frigieri et al., 2007).  The small Ypt-GTPase, a member of the rab family 
and encoded by the essential gene YPT1, is involved in vesicular trafficking between the 
endoplasmic reticulum and the Golgi (Martinez & Goud, 1998; Clague, 1998). 
 
A role of eIF5A in the establishment of cell polarity in a temperature-sensitive mutant strain 
of TIF51A (tif51A-1) has also been proposed.  The PKC1 gene, encoding the only yeast 
protein kinase C (Pkc1), controls a number of cellular processes including as cell-cycle 
progression and structural organisation of the cytoskeleton (Heinisch et al., 1999).  At a high 
copy number, PKC1 suppresses growth defects and cell polarity defects of the tif51A-1 strain  
(Zanelli & Valentini, 2005), which has led to the suggestion that eIF5A plays a role in the 
Pkc1 pathway essential for bud formation and the G1/S transition (Zanelli & Valentini, 2005).   
 
The reversible metal chelating inhibitor of DOHH, mimosine, suppresses DOHH activity and 
thus inhibits hypusine formation and activation of eIF5A, resulting in inhibition of S-phase 
entry (Watson, et al., 1991; Hanauske-Abel et al., 1995).  Upon removal of the inhibitor, 
DOHH and thus DNA synthesis resume, and once cells enter the S-phase, re-addition of the 
inhibitor fails to suppress further progression through the cell cycle.  This led to the 
hypothesis that the highly conserved domain bearing the hypusination site, could act as a 
selector for a class of specific mRNA substrates (Hanauske-Abel et al., 1994).  These 
substrates would be utilised by polysomes allowing for synthesis of DNA to commence.  In 
this case, the mRNA species should disappear and reappear at polysomes upon inhibition and 
removal of inhibition, respectively of cellular hypusine formation.  This was found to be the 
case, and as a result a subset of polysomal mRNAs were detected and classified, that were 
associated with the mimosine-mediated modulation of hypusine formation, and subsequent 
transition of the G1-S phase (Hanauske-Abel et al., 1995).      
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1.3.2  Role of eIF5A in HIV-1 replication as a potential antiretroviral target 
Both the human T-cell leukemia virus type 1(HTLV-1) and human immunodeficiency virus 
type 1 (HIV-1) encode a trans-acting protein that regulates viral gene expression (Feinberg et 
al., 1986; Sodroski et al., 1986; Terwilliger et al., 1988).  Theses nuclear phosphoproteins 
(Rev in HIV-1 and Rex in HTLV-1) are essential for viral replication and affect the transport, 
stability, splicing and translation of viral mRNA and accumulate in the nucleoli of infected 
cells (Sadaie et al., 1988; Malim et al., 1989; Arrigo & Chen, 1991; Cochrane et al., 1990).  
Rex is functionally interchangeable with Rev in the HIV-1 replication cycle, despite Rex 
belonging to a different subviral family (Rimsky et al., 1989; Sakai et al., 1990).  Rex binds 
specifically to the Rev response element (RRE) or Rex response element (RXRE) sequence in 
viral RNA (Cochrane et al., 1990; Malim et al., 1990).   
 
Cross-linking experiments and Bio-specific Interaction Analysis (BIA) have shown that 
eIF5A binds to the HIV-1 Rev activation domain (Ruhl et al., 1993).  The HIV-1 Rev RNA 
transport factor requires eIF5A as an essential cofactor, suggesting that eIF5A may play a role 
in a specific nuclear export pathway.  However, Rev in yeast cells does not appear to be 
exported in an eIF5A-dependent manner, but is rather dependent on the presence of Crm1 
(Valentini et al., 2002).  Immunofluorescence studies show that while eIF5A exists 
predominantly in the cytoplasm, a significant proportion of eIF5A localises to the nucleus in 
mammalian cells (Rosorius et al., 1999). Microinjection studies of somatic cells have 
demonstrated that eIF5A acts as a nucleocytoplasmic shuttle protein, the action of which can 
be inhibited by the addition of the cytotoxin Leptomycin B that blocks the nucleocytoplasmic 
translocation of HIV-1 Rev (Wolff et al., 1997; Wolff & Park, 1999).  In addition, binding 
studies using recombinant GST-eIF5A and nuclear envelope proteins from Xenopus oocytes 
have shown that eIF5A interacts with nucleoporins and nuclear actin (Hoffmann et al., 2001). 
eIF5A has also been indicated as being an indispensable cofactor for Rex function and 
associates with Rex to form an oligomer (Katahira et al., 1995).  Taken together, these results 
support the suggestion that eIF5A plays a role as a nucleocytoplasmic shuttle protein that is 
utilised by HIV-1 in its replication cycle.  However, the archaeal homologue aIF5A has no 
nucleoocytoplasmic shuffling function, and so this cannot by inference be eIF5A’s primary 
and conserved function (Zanelli & Valentini, 2007). 
  
Inhibition of DOHH activity in mammalian cells results in the suppression of HIV-1 Rev 
replication (Andrus et al., 1998).  Treatment of HIV-1-infected cell lines with mimosine, a 
natural compound and deferiprone, an experimental drug, results in the inhibition of DOHH 
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and suppresses virus replication by restricting HIV-1 to the early, non-degenerative phase of 
its reproductive cycle (Andrus et al., 1998).  In addition, in the HIV-1 infected T-cell line, 
ACH2, extensive apopototic activity, particularly in cells actively producing HIV-1 following 
treatment with these drugs  has been observed (Andrus et al., 1998).  Similarly, inhibition of 
DHS by the novel inhibitor guanylhydrazone CNI-1493 or by RNA interference, results in the 
suppression of retroviral replication cycle in cell culture and primary cells (Hauber et al., 
2005).  The absence of measurable adverse effects on the general cytotoxicity, cell cycle 
transition and apoptosis of the inhibited cell lines suggest that the DHS and DOHH enzymes 
could be suitable targets for antiretroviral therapies (Andrus et al., 1998; Hauber et al., 2005). 
 
Polyamine biosynthesis in most mammalian cells is regulated by four enzymes, 
predominantly ornithine decarboxylase (ODC) and S-adenosylmethionine decarboxylase 
(SAMDC) (Tabor & Tabor, 1984, 1985; McCann & Pegg., 1992; Pegg & McCann., 1992; 
Schafer et al., 2006).  The well-established, potent low-molecular weight inhibitor of 
SAMDC, SAM486A, was used to efficiently suppress HIV-1 replication, including the 
replication of viruses previously resistant to multiple protease inhibitors and reverse 
transcriptase inhibitors (Regenass et al., 1994; Schafer et al., 2006).  These studies provide a 
novel drug-design approach in the suppression of multiple-drug resistant viruses by inhibiting 
enzymes in the hypusine pathway. 
 
1.3.3  eIF5A as an anti-cancer target 
Most anti-cancer therapies are designed to induce cell death or inhibit cellular proliferation 
(Caraglia et al., 2001; Marra et al., 2007).  Since eIF5A is involved in regulating the cell 
cycle, the protein has become a target for the development of novel anti-neoplastic agents.  
The polyamines, spermine and spermidine and putrescine (the diamine precursor for 
spermidine synthesis) are thought to be responsible for a number of cellular processes 
including cell growth, cell-cycle regulation, apopotosis and carcinogenesis.  Polyamine 
synthesis results in the formation of hypusine and hence the hypusination process has also 
been targeted in the development of anti-cancer drugs.  The following discussion focuses on 
the development of inhibitors of the active eIF5A modifying enzymes, DHS and DOHH and 
other tumour-suppressing agents that involve hypusinated eIF5A  The anti-neoplastic agents, 
with their observed effects on cellular proliferation, are also discussed in this section and are 
summarised in Table 1.1.    
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Suppression of spermidine synthesis by D, L-α-difluoromethylornithine (DFMO) and 
subsequent inhibition of hypusine synthesis results in the thwarting of the G1-S boundary in 
Chinese hamster ovary cells.  Arrest in late G1 and inhibition of DOHH activity occurs 
simultaneously (Park, 1987).  Inhibition of hypusination using another compound, 2-(4-
hydroxy-toluene-3-yl)-4,5-dihydro-5-carboxythiazole (Carboxythiazole), results in reversible 
cell cycle arrest in late G1, in Human T lymphocyes as well as the suppression of human T 
lymphocytes in vitro at the G1-S boundary, thus reducing cell proliferation (Lalande & 
Hanauske-Abel., 1990). 
     
Table 1.1: Potential anti-cancer agents which synergistically affect the modulation of   
cellular proliferation.  
 
Agent Abbreviation Cell line Effects observed Reference 
Interferon α  IFN-α human 
epidermoid 
cancer KB 
cells 
Reduces hypusine 
synthesis 
Caraglia et al., 
1999 
D,L-α-difluoro-
methylornithine 
DFMO Chinese 
hamster ovary 
cells 
Depresses spermidine 
levels; Suppresses 
hypusine formation; 
Arrests cells at the G1-S 
transition 
Park, 1987 
2-(4-hydroxy-toluene-3-
yl)-4,5-dihydro-5-
carboxythiazole 
Carboxythiazole Human T 
lymphocytes 
Arrests cells at G1-S 
phase, Reduces cellular 
proliferation 
Lalande & 
Hanauske-Abel, 
1990 
Diaminoheptane DAH DH23A cells Strong inducer of 
apopotosis; Blocks 
hypusine synthesis 
Tome & Gerner, 
1997 
Cytosine arabinoside 
combined with 
desferioxamine 
Ara-C and DSF Human acute 
myeloid 
leukaemic 
blasts 
Induces apoptosis;  
Growth inhibition; Iron 
depletion; Inhibitor of 
deoxyhypusine 
hydroxylase  
Leardi et al., 1998 
N1-guanyl-1,7-
diaminoheptane; 
α-
difluoromethylornithine; 
N1-(3-aminopropyl)-
cyclohexamine 
GC7 
 
DFMO 
APCHA  
Mouse 
mammary 
carcinoma 
FM3A cells 
Decrease in eIF5A; 
Decrease in polyamines; 
Inhibition of cell growth 
Nishimura et al., 
2005 
N1-guanyl-1,7-
diaminoheptane 
GC7 
 
Malan-a-
murine 
melanocytes; 
Tm5 murine 
melanomal 
cells 
Inhibitor of DHS; 
Decrease in cell viability; 
impaired melanomal 
growth in mice 
Jasiulionis et al.,  
2007 
Hypusine inhibitors 
 
HIs 
 
Leukemia 
K562 cells 
Anti-proliferative effect  Balabanov et al., 
2007 
 
In HeLa cells, the association of eIF5A with transglutaminases (TGases) is promoted by the 
addition of Ca2+, Mg2+ and retinoic acid (Singh et al., 1998).  TGase activity is found to 
promote apoptosis (Fesus, 1998) and tumour cell proliferation (Nakaoka et al., 1994; Johnson, 
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1994).  Beninati et al.,1995, 1998).  When Balb C-3T3 cells are transfected with the gene for 
the human TGase, a 50 % retardation of cell proliferation, accompanied by a 50 % increase in 
apoptosis is observed, presumably through the inactivation of hypusinated eIF5A (Beninati et 
al. 1998).  Similarly, the proapoptotic agent Interferon α (IFNα), induces a strong reduction 
in hypusine synthesis along with apoptotic events in human epidermoid KB cancer cells 
(Caraglia et al., 1999).  However, this reduction in hypusine synthesis can be restored by 
exposing the IFNα-treated cells to the epidermal growth factor (EGF).   
 
The triggering of apoptosis in tumour cells is enhanced by the excess accumulation of 
polyamines, specifically spermidine (Tome & Gerner, 1997).  This cytostasis or cytoxicity has 
been attributed to excess putrescine or polyamines in a number of mammalian cell lines 
(Brunton et al., 1991; Mitchell et al., 1992; Packham & Cleveland, 1994; McCloskey et al., 
1995; Tobias & Kahana, 1995).  However, in hepatoma DH23A/b cells which express high 
levels of ornithine decarboxylase, there is an accumulation of putrescence resulting in the 
inhibition of hypusination and results in the induction of apoptosis (Tome & Gerner, 1997).  
Diaminoheptane (Table 1.1), a strong inducer of apoptosis, also blocks post-translational 
modification of eIF5A (Tome et al., 1997).  The addition of cytosine arabinoside (Ara-C) 
combined with desferioxamine (DSF), a powerful iron-depleting agent, result in growth 
inhibition and an increase in the induction of apoptosis (Leardi et al., 1998).  The precise 
mechanism by which the accumulation of putrescine and polyamine effect the inhibition of 
hypusination, and induce apoptosis is yet to be determined.   
 
More recently, three other potential chemotherapeutic agents, namely N1-guanyl-1,7-
diaminoheptane (GC7), α-difluoromethylornithine (DMFO) and a combination of N1-(3-
aminopropyl)-cyclohexamine (APCHA) with DMFO (Table 1.1), were investigated for their 
ability to inhibit cell growth by reducing polyamine (and more specifically spermidine) 
synthesis, and thus decreasing levels of active eIF5A (Nishimura et al., 2005).  Treatment of 
mouse mammary carcinoma cells with GC7 resulted in the inhibition of hypusine synthesis 
without a decrease in total polyamines, while DFMO resulted in a decrease in both 
polyamines and hypusine synthesis (Nishimura et al., 2005).  This suggests that polyamines 
and eIF5A can independently affect cell proliferation.  DMFO plus APCHA-treated cells 
showed a reduction of total polyamines with little to no reduction of hypusine synthesis 
(Nishimura et al., 2005).  GC7 also has been reported to impair melanomal growth in 
melanomal mice (Jasiulionis et al., 2006).   
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The expression of hypusinated eIF5A is down-regulated by the tyrosine kinase inhibitor, 
Imatinib (Table 1.1) (O’Dwyer & Druker, 2001; Balabanov et al., 2007).  Imatinib treatment 
has been used extensively in the inhibition of BCR-ABL tyrosine kinase in patients with 
chronic myeloid leukemia.  The use of hypusine inhibitors (HIs) alone has been shown to 
result in a reduction in cellular proliferation in BCR-ABL-positive and –negative leukemia 
K562 cell lines.  However, when HIs were combined with Imatinib, the anti-proliferative 
effect was confined to BCR-ABL-positive cells (Balabanov et al., 2007).   
 
Hypusinated eIF5A partners with syntenin, a protein that binds to the cytoplasmic domains of 
the syndecans (transmembrane proteoglycans) to collaborately regulate p53 activity 
(Grootjans et al., 1997; Li et al., 2004).  The transcription factor p53 is a tumour suppressor 
scaffolding protein understood to be the major component of the DNA damage response 
pathway (Lane, 1992; Rahman-Roblick et al., 2007).  In 50 % of human cancers, the p53 gene 
is mutated (Bourdon, 2007).  Li et al., (2004) have recently shown that the eIF5A-syntenin 
complex functions to regulate p53 and p53-dependent apoptosis.  While over-expression of 
eIF5A alone leads to the up-regulation of p53 activity and thus p53-dependent apoptosis, or 
sensitises cells to apoptotic events by anti-neoplastic agents, administration of eIF5A together 
with syntenin results in significantly lowered p53 protein levels (Li et al., 2004).  
Furthermore, induction of apoptosis in colon carcinoma cells by the over-expression of either 
active eIF5A or unmodified mutant eIF5A protein reveals that unhypusinated eIF5A may be 
sufficient to induce programmed cell death (Taylor et al., 2006; Taylor et al., 2007).    
 
The expression of p53 relies on the presence of eIF5A following the apoptotic induction by 
treatment with Actinomycin D (Taylor et al., 2006; Taylor et al., 2007).  Subcellular 
localisation experiments show that following induction of apoptosis (by either death receptor 
activation or treatment with Actinomycin D), eIF5A is rapidly translocated from the 
cytoplasm to the nucleus.  These results suggest that eIF5A may have pro-apoptotic functions 
when translocated to the nucleus and that this function may not be dependent on the presence 
of the hypusine modification (Taylor et al., 2006; Taylor et al., 2007).     
 
1.3.4  eIF5A is an mRNA binding  protein 
eIF5A has been proposed to act as a bimodular protein, interacting with both nucleic acid and 
protein (Liu et al., 1997).  Motif analysis showed that eIF5A has a cluster of basic amino 
acids at the N-terminus, and a region rich in leucine at the C-terminus.  This, together with the 
observation that eIF5A closely resembles the structure of Cold shock protein A (CspA), an 
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RNA chaperone with a distinct oligonucleotide binding (OB) fold, has led to the hypothesis 
that eIF5A could itself bind RNA (Jiang et al., 1997; Liu et al., 1997).  This was confirmed by 
gel mobility shift assays, which demonstrated that eIF5A binds RNA in a hypusine-dependent 
manner (Liu et al., 1997).  Another interesting observation is that protein synthesis is reduced 
by about 30 % when compared with wild-type rate in eIF5A-depleted cells, with a slight 
change in total polysomal profiles (Kang & Hershey, 1994; Zanelli et al., 2006).  This 
suggests that eIF5A is not required for general protein synthesis, but is rather involved in the 
translation of certain mRNAs (Kang & Hershey, 1994).   
 
GST-pulldown experiments have shown that eIF5A associates with translationally active 
ribosomal components in a hypusine-dependent manner, specifically the eukaryotic 
translation elongation factor (eEF2), 60S ribosomal protein P0 and the 40S ribosomal protein 
S5 (Zanelli et al., 2006). Because eIF5A co-fractionates with monosomes in a translation-
dependent manner and non-functional mutants of eIF5A are also sensitive to translation 
inhibitors, a role for this factor in translation elongation, rather than translation initiation was 
proposed (Zanelli et al., 2006).  eIF5A is dissociated from ribosomes upon treatment with 
EDTA or RNase A (Zanelli et al., 2006).  Since eIF5A associates with EF2, it is proposed that 
eIF5A associates specifically with translationally active (elongating) ribosomes (Zanelli et al., 
2006). 
 
Systemic evolution of ligands by exponential enrichment (SELEX) was used to identify the 
consensus RNA binding sequence recognised by eIF5A.  The Post-SELEX RNAs obtained 
after 16 rounds of enrichment all shared a high sequence homology, typified by the conserved 
motifs, UAACCA and AAUGUCACAC (Xu & Chen, 2001).  Further refinement determined 
the consensus sequence as being AAAUGUCAC with  the RNA bound to eIF5A being 
sensitive to ribonuclease attack.  Most importantly, hypusine was again identified as a critical 
factor in the sequence-specific binding of eIF5A to the RNA (Xu & Chen, 2001).  Additional 
research demonstrated the direct binding of cloned RNA species to eIF5A by electromobility 
assays, and the species were identified by affinity co-purification and PCR differential display 
(Xu et al., 2004).  Many RNA-binding proteins do not target defined RNA sequences, but 
rather structural elements such as hairpins, bulges and stem-loops.  The cloned RNAs all had 
the potential to form extensive secondary structural elements, particularly stem-loops (Xu et 
al., 2004). 
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In a separate study in S. cerevisiae, the turnover rates of mRNA were thought to have 
significant effects on the expression of certain genes and would allow for flexible protein 
levels in the cell. During experiments to determine factors involved in increased levels of 
unstable pre mRNAs, a mutant form of TIF51A was identified (Zuk & Jacobson, 1998).  This 
mutant tif51A was shown to encode a change of Ser 149 to Pro 149 (S149P) at the C-terminus 
of eIF5A.  The substitution resulted in decreased mRNA decay, and a 30 % decrease in 
overall protein synthesis.  An additional observation was that the cells bearing the tif51A 
allele also accumulated uncapped mRNAs (Zuk & Jacobson, 1998).  These results implied 
that eIF5A was involved in the regulation of 5’-> 3’ exonucleolytic decay.  Another tif51A 
mutant was analysed in a yeast knockout system, this time with a point mutation at Val 81 to 
Gly (V81G) (Schrader et al., 2006).  Not only was strong temperature sensitivity observed, 
but also an accumulation of nonsense-containing RNAs.  These RNAs are known to be 
degraded by the polyadenylation-independent 5’-> 3’ mRNA decay pathway, also known as 
nonsense-mediated decay (NMD).  Other effects included reduced telomere silencing and 
telomere shortening (Schrader et al., 2006). Together, these observations reinforced the 
proposal that eIF5A influences essential cellular functions such as cell viability and 
senescence through its role in RNA processing, particularly the translation of the suite of 
mRNAs required for programmed cell death (Wang et al., 2001; Schrader et al., 2006). 
 
Veress et al., (2000) showed that polyamine depletion resulted from the addition of the α-
difluoromethylornithine (DFMO) inhibitor in Rat-2 cells.  This depletion was coupled with 
the blocking of cell growth, and also resulted in the stabilisation of mRNAs.  It was deduced 
that the lack of spermidine for the hypusination of eIF5A influenced the mRNA turnover, and 
provided an efficient means for cells to resume growth after the recovery from polyamine 
starvation (Veress et al., 2000). 
 
The human cancer-promoting gene, cyclooxygenase-2 (COX-2) has been determined to have 
consensus eIF5A response elements (EREs) in its 3’-untranslated region (3'-UTR) (Parker & 
Gerner, 2002).  The depletion of polyamines by DL-α-difluoromethylornithine (DFMO) 
treatment results in the induction of COX-2 mRNA steady-state levels in various human 
cancer cell lines (Parker & Gerner, 2002), suggesting that polyamines negatively regulate 
COX-2 levels by a post-transcriptional mechanism, mediated by eIF5A. 
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Tandem affinity purification (TAP) along with mass spectroscopy (MS), has been employed 
to search for and identify potential eIF5A-interacting proteins (Jao & Chen, 2006).  
Deoxyhypusine synthase was identified as the sole protein partner of hypusinated eIF5A at 
high (150 mM) salt concentrations.  Upon the lowering of salt concentrations to 125 mM or 
less, a new set of eIF5A-bound proteins were identified, which were identified as the 
components of the 80S ribosome complex.  Treatment with both RNase and EDTA resulted in 
the disassociation of the eIF5A-RNA complex into its components and the 40S and 60S 
ribosomal subunits (Jao & Chen, 2006).  Mutation of the hypusine (lysine) to arginine, 
resulted in the abolishment of the eIF5A-ribosome interaction.  These results show that eIF5A 
requires hypusine to form a molecular complex with actively translating ribosome in order to 
perform its essential role in the cell (Jao & Chen, 2006).  
 
Finally, an archaeal protein (aIF5A) isolated from Halobacterium sp. NRC-1 with strong 
homology to yeast and human eIF5A showed RNA-degrading activity whether it was 
hypusinated or not (Wagner & Klug, 2007).  However, there is also some evidence that 
human eIF5A shows hypusinated ribonucleolytic activity (Xu & Chen, 2004; Wagner & 
Klug, 2007).  In addition, RNA binding with aIF5A was observed, but only from protein 
purified from the native host, i.e. hypusinated protein.  These results indicate RNA binding is 
hypusine-dependent, while RNA cleavage activity is hypusine-independent.  Also, both 
domains of aIF5A, the N-terminal domain with its charged amino acids, and the C-terminal 
domain are required for RNA cleavage activity.  Interestingly, the ribonucleolytic activity of 
aIF5A also seemed to depend on its oligomeric state (Wagner & Klug, 2007).  The human 
eIF5A protein has also been found to exist in a number of oligomeric states (Chung et al., 
1991).  Using exclusion chromatography and analytical ultracentrifugation, the study 
demonstrated that hypusinated eIF5A exists as a dimer in solution and is capable of 
undergoing reversible self-association to form higher oligomers (Chung et al., 1991). 
 
1.3.5 Function of eIF5A in protein synthesis   
 
eIF5A was originally identified as a general translation initiation factor as it stimulated the 
synthesis of methionyl-puromycin in vitro (Benne & Hershey,1978; Kang & Hershey, 1994).  
Following this, eIF5A was thought to be involved in the translation of a specific subset of 
mRNAs rather than in general protein synthesis (Kang & Hershey, 1994).  This was 
demonstrated by work showing that hypusinatedeIF5A interacts with the structural 
components of the 80S ribosome and translation elongation factor 2 (Zanelli et al., 2006; Jao 
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& Chen, 2006), suggesting a role for eIF5A in translation elongation.  More recently, 
mutational analysis of eIF5A showed that the region around hypusination site, specifically 
residues K47D and K50R (human eIF5A) and K56A and Q22H/L93F (in yeast eIF5A) and 
not only the highly conserved lysine (K51 in yeast), played a role in protein synthesis (Cano 
et al., 2008; Dias et al., 2008).  Although a specific mechanism for eIF5A in protein synthesis 
is not available, it is worth reviewing eIF5A’s role in translation initiation or elongation based 
on this new evidence.  
 
1.4  Structure of eIF5A  
When eIF5A was first purified from rabbit reticulocytes and the resulting cDNA was cloned 
and analysed for the product, the prediction was that eIF5A possessed little secondary 
structure at the amino terminal region of the protein and that the carboxy terminal region was 
rich in alpha helices (Smit-McBride et al., 1989).  This has subsequently been shown not to be 
the case, at least for archaeal homologues of eIF5A.  The crystal structures of the eIF5A 
homologues (aIF5A) from Methanococcus jannaschii, Pyrobaculum aerophilum and 
Pyrococcus horikoshii have been solved using multiple isomorphous replacement (MIR) or 
multiwavelength anomalous diffraction (MAD) (Kim et al., 1998; Peat et al., 1998; Yao et 
al., 2003).  MIR and MAD techniques make use of the addition of a reducing agent such as 
dithiothreotol (DTT) or β-mercaptoethanol to keep the substituting heavy atoms (Hg, Se, Ir) 
in a reduced form.  All the structures to date were derived from purified protein expressed in 
E. coli and were thus not hypusinated (Kim et al., 1998; Peat et al., 1998; Yao et al., 2003).  
Although the crystal structure is not currently available, attempts have been made to produce 
homology models of the human eIF5A based on aIF5A and unpublished protozoan eIF5A 
structures (Facchiano et al., 2001; Costa-Neto et al., 2006).   
 
The aIF5A protein consists of two distinct anti-parallel β-sheet folding domains separated by 
a flexible hinge (Figure 1.4).  Each of the domains has a well-defined hydrophobic core inside 
the β-barrels (Peat et al., 1998).  The conserved lysine residue, that is the site of hypusination, 
is in all cases, located in the middle of a highly-conserved stretch of residues on a long, 
protruding hairpin loop of domain I (Figure 1.4).  Most of the amino acid residues conserved 
between the three aIF5A proteins are found to be within domain I (N-terminus) while domain 
II (C-terminus) is less conserved (Yao et al., 2003).  Both domains have the capacity to bind 
nucleic acids.  Domain I contains an SH3-like barrel motif that is found in the DNA binding 
domains of a number of proteins, including HIV-integrase (Lodi et al., 1995, Eijkelenboom et 
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al., 1995).  Domain II, forming a barrel structure between the sheets and loops, resembles the 
oligonucleotide-binding fold (OB Fold) of several proteins, but is most similar to the E. coli 
cold shock protein A (CspA), which has a recognised RNA-binding fold (Schindelin et al., 
1994; Murzin, 1993).  There is only a 10 % sequence identity between the E coli CspA and 
the M. jannaschii aIF5A, attributed mainly to the differences in size of the proteins.  
 
A comparison of the three currently available archael crystal structures is represented in 
Figure 1.4, displaying the relative position of the lysine that is hypusinated in each (as sticks).  
All three models share the same backbone structure of β-sheet arrangement and variations are 
observed in the presence of partial α-helical turns in the C-terminal domain.  
 
 
 
Figure 1.4: Models of the crystal structures of three archaebacterial initiation factor 5As 
(aIF5As).  From left to right:  Models of the crystal structures of Methanococcus jannaschii 
(PDB code 2EIF), Pyrococcus horikoshii (PDB code 1IZ6; monomeric unit) and 
Pyrobaculum aerophilum (PDB code 1BKB).  Marked in sticks on each model is the highly-
conserved lysine residue (equivalent to Lys 51 in yeast) on the N-terminal region of the 
protein.  Partial α-helical turns are present on the latter two crystal structures near the C-
terminus (Kim et al., 1998; Peat et al., 1998; Yao et al., 2003).  The figures were generated 
using Pymol (DeLano, 2002).  
 
1.5  The evolution and conservation of eIF5A  
Yeast contains two clusters of eight genes each on chromosomes V and X, namely ARC and 
COR regions, which include TIF51A and TIF51B respectively (Melnick & Sherman, 1993).  
Comparisons and alignments of the two regions show a possible ancestral relationship, arising 
due to duplication, transposition and single rearrangement events, followed by extensive 
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divergence, another explanation for the interchangeability of the two genes under aerobic or 
anaerobic growth conditions (Melnick & Sherman, 1993).    
 
Although hypusine, its precursor deoxyhypusine, eIF5A, DHS and DOHH occur in all 
eukaryotes, only eIF5A, hypusine and DHS have been detected in archaeal proteomes (Park 
2006).  The presence of deoxyhypusine and hypusine has been reported in archaeal species 
(Bartig et al., 1992), but it is unclear how hypusine can be produced without the presence of 
DOHH.  The stretch of amino acids surrounding the highly-conserved lysine residue (Lys 51 
in yeast) is highly conserved amongst the eukaryotic and archaeal initiation factor 5As (Park 
et al., 1986, 1993; Bartig et al., 1992).  The yeast and human eIF5A proteins share 64 % 
sequence identity while  yeast eIF5A shares about 35 % sequence identity with 
archaebacterial translation initiation factor 5A (aIF5A), (Schnier et al., 1991; Magdolen et al., 
1994). 
   
Although no evidence for the existence of deoxyhypusine in eubacteria, elongation factor P 
(EF-P), an orthologue of eIF5A has been identified as being essential in bacteria as it 
stimulates the peptidyl transferase activity of ribosomes (Glick & Ganoza, 1975; Kyrpides & 
Woese, 1998; Brochier et al., 2004).  Phylogenetic analysis has resulted in the identification 
of several bacterial species that contain DHS cognate genes.  These are presumed to have 
been transferred by horizontal gene transfer from the archaea.  DHS does not ordinarily occur 
in bacteria so it is unlikely that EF-P undergoes deoxyhypusine modification (Brochier et al., 
2004).  This suggests that eIF5A and the hypusination machinery (DHS and DOHH) have 
evolved sequentially, but in an independent manner (Brochier et al., 2004).  The crystal 
structure of EFP from Thermus thermophilus HB8 shows that EFP consists of three domains, 
arranged in an “L” shape: domain I sharing topological similarities to the N-terminal portion 
of eIF5A (Figure 1.5A), and domains II and III sharing a topology with the C-terminal region 
of eIF5A (Figure 1.5B) (Hanawa-Suetsugu et al., 2004).  To some extent, eIF5A shares a 
remarkable functional similarity with EFP, in that both are affected by peptidyl-transferase 
inhibitors in vitro (Aoki et al., 1997a; Hanawa-Suetsugu et al., 2004); both are essential for 
cell viability and bind to elongating ribosomes (Aoki et al., 1997b; Ganoza et al., 2002) and 
both may affect protein synthesis (Kang & Hershey, 1994).   
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Figure 1.5:  Comparison of the crystal structures of aIF5A with EFP.  (A):  Domain I of 
T. thermophilus EFP (right) structurally resembles the N-terminal region of the M. jannaschii 
aIF5A (left), while the crystal structure of domains II and II of EFP are similar to the C-
terminal portion of aIF5A (B).  The cartoon representations were generated using Pymol 
(DeLano, 2002) from M. jannaschii aIF5A (PDB code 2EIF) and T. thermophilus EFP (PDB 
code 1UEB) (Kim et al., 1998; Hanawa-Suetsugu et al., 2004). 
  
Cold shock protein A (CspA), another orthologue of eIF5A, has also been suggested to be 
evolutionarily linked to eIF5A, mainly because this 7.4 kDa protein structurally resembles the 
C-terminal portion of eIF5A (Figure 1.6) (Jiang et al., 1997; Kim et al., 1998).  Although no 
specific RNA targets have been found to bind to CspA, it is thought that it has a broad 
sequence specificity for binding, reinforcing its role as an RNA chaperone.  CspA functions 
by either destabilizing RNA secondary structures making them more susceptible to 
ribonuclease attack, or by preventing the formation of secondary structures in RNA molecules 
at low temperatures (Jiang et al., 1997).  Thus it can be extrapolated that the observed RNA-
binding capacity and mRNA turnover of eIF5A could be mediated by the OB-fold. 
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Figure 1.6:  Structural comparison of CspA and aIF5A.  Cartoon depiction of the E. coli 
RNA-chaperone, CspA (right; PDB code 1MJC) (Schindelin et al., 1994; Feng et al., 1998), 
that bears a strong resemblance to the C-terminal domain of M. jannaschii aIF5A (left; PDB 
code 2EIF) (Kim et al., 1998; Jiang et al., 1997).  Models were generated using Pymol 
(DeLano, 2002).   
 
HEX-1, the major self-assembly protein component of Woronin body function (septal pore 
sealing) in Neurospora crassa, has a potential ancestral link to eIF5A (Yuan et al., 2003).    
HEX-1 fails to complement an eIF5A mutant in yeast, presumably because it lacks the ability 
to undergo hypusination, so although a structurally-related analogue, it displays a high degree 
of functional divergence (Holm & Sander, 1999; Jedd & Chua, 2000; Yuan et al., 2003). The 
structural similarities between the HEX-1 monomer and aIF5A are depicted in Figure 1.7. 
 
The structural comparisons of the eIF5A homologue, aIF5A, with the orthologues CspA and 
EFP and the analogue, HEX-1 are summarised in Table 1.2.  All of the above have in 
common an OB-fold, and with the exception of CspA, all have an SH-3-type β-barrel 
architecture.  These proteins, along with a more detailed eIF5A structural analysis, will be 
discussed extensively in Chapter 2.   
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Figure 1.7:  Crystal structure comparison of aIF5A and HEX-1.  On the left is a cartoon 
representation of the M. jannaschii aIF5A (PDB code 2EIF; Kim et al., 1998), depicting the 
lysine residue that is modified (Lys 51 in yeast) as sticks.  On the right is a comparative 
crystal model of the N. crassa HEX-1 protein (PDB code: 1KHI; Yuan et al., 2003).  
Although HEX-1 contains a C-terminal region α-helix, the monomer show remarkable 
structural similarity.  Models were generated using Pymol (DeLano, 2002).   
 
Table 1.2:   Structural comparison of the eIF5A homologue, aIF5A, orthologues, CspA 
and   EFP and analogue HEX-1.  
 
Relation to 
eIF5A 
Homologue Orthologues Analogue 
 aIF5A CspA EFP HEX-1 
Host Organism M. jannaschii E. coli T. thermophilus N. crassa 
PDB Code 2EIF 1MJC 1UEB 1KHI 
Topological 
features 
SH3-type barrels; 
Lacks OB-Fold 
OB-Fold SH3-type barrels; 
OB-fold 
SH3-type barrels; 
Predicted OB-Fold 
Predicted 
Functions 
Translation 
initiation; binding 
of nucleic acid 
RNA-Chaperone; 
Binding of nucleic 
acid 
Translation 
elongation; binding 
of nucleic acid 
Self-assembly protein; 
septal pore sealing; 
nucleic acid binding  
Size (monomer) 16 kDa 7.4 kDa 20.2 kDa 19 kDa 
Structural 
similarity to 
eIF5A 
aIF5A similar to 
both N- and C-
terminal regions of 
eIF5A 
CspA similar to 
the C-terminal 
domain of eIF5A 
Domain I similar to 
N-terminal region of 
eIF5A; Domains II 
and III similar to C-
terminal region of 
eIF5A 
N- and C-terminal 
domains similar to 
eIF5A 
Sequence 
identity to aIF5A  
100 %  24 % to the C-
terminal portion of 
aIF5A 
27 % 20 % 
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1.6  Knowledge Gap 
The biological functions of eIF5A are not well understood, although several roles have been 
proposed, including cell-cycle regulation, HIV-replication, carcinogenesis, apoptosis and 
nucleocytoplasmic transport of mRNA during the translation process, all of which are 
dependent on the presence of hypusine.  Hypusine is also required for eIF5A to bind specific 
RNA sequences and to form associations with translationally active ribosomal components.   
 
The biochemical synthesis of hypusine has also been extensively studied, with an emphasis on 
the structure of the eIF5A modification enzymes DHS and DOHH.  Recently, the focus has 
shifted to developing an understanding of the biological interactions of these enzymes with 
eIF5A, as well as ligands interacting with eIF5A in vivo.  Exactly how hypusine relates to the 
function of eIF5A in vivo is as yet not clear, because structural information has been 
predominantly derived from X-ray crystallographic studies on several aIF5As (Kim et al., 
1998, Peat et al., 1998; Yao et al., 2003) and two protozoan (unpublished) eIF5A which were 
crystallised in their unhypusinated form.   
 
In contrast to eIF5A, there has not been substantial biochemical characterisation of aIF5As.  
There is now evidence which suggests that there might be significant differences the 
biological function of the archaeal and eukaryotic homologues.  For example,  hypusine is 
required for RNA binding in aIF5A and eIF5A, while RNA cleavage activity is hypusine-
dependent only in aIF5A (Wagner & Klug, 2007).  This raises the question of how relevant 
the structural information derived from archaeal homologues of eIF5A are in providing 
insights into how the protein functions in vivo.   Finally, there is no structural data available 
for eIF5A in its modified (hypusinated) form and it remains to be seen whether the presence 
of hypusine results in conformational changes of the protein which are required for its 
functions in vivo, including the binding of specific RNAs. 
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1.7  Research Aim 
The overall aim of the research described in this thesis is to produce an homology model of 
the yeast eIF5A and to conduct biochemical and functional analyses to validate the model.  
 
1.8  Research objectives 
1. To generate an homology model of yeast eIF5A using available structures of 
homologues and analogues. 
2. To develop an experimental system and to conduct a biochemical and functional 
characterisation of native yeast eIF5A. 
3. To relate the biochemical and functional data to the predicted structure of eIF5A. 
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Chapter 2:  In silico analysis of eIF5A 
 
2.1 Introduction 
A number of crystal structures of eIF5A homologues have been published, including the 
archaeal translation initiation factor (aIF5Aa) from Methanococcus jannaschii (Kim et al., 
1998), Pyrobaculum aerophilum (Peat et al., 1998) and Pyrococcus horikoshii (Yao et al., 
2003).  In addition, human eIF5A has been crystallised, but the structure has not been solved 
(Sun et al., 2005; Facchianao et al., 2001).  In each case, the crystal structures were derived 
from recombinant protein produced in E. coli.  The information derived from this structural 
data is thus limited to the archaeal homologue of eIF5A, in its monomeric form, and lacks the 
post-translational modification of hypusine.   
 
Molecular models of the human eIF5A protein have been produced based on the crystal 
structure of the eIF5A from Leishmania brasiliensis (Costa-Neto et al., 2006).  In addition, 
circular dichroism (CD) data was obtained with a synthetic peptide of the loop region bearing 
the hypusination site, which showed that this critical region may adopt an ordered 
conformation that might contribute to functionality of human eIF5A with Dexoyhypusine 
synthase (DHS) or with nucleic acids.  Since there is no structural data available for yeast 
eIF5A, an homology model could provide insights into bridging the structure-function 
relationship gap.    
 
The main objective of the research discussed in this chapter was to make use of in silico tools 
to predict the structure of yeast eIF5A.  It is hypothesised that the yeast eIF5A protein is 
similar enough to the archaeal homologues to produce a homology model.  This model could 
then be used to identify regions important for the structural integrity and/or function of yeast 
eIF5A.   Since it is postulated that human eIF5A exists mainly in a dimeric form in solution, 
and since aIF5A from Halobacterium sp. depends on its oligomeric state to be active, it was 
not unreasonable to assume that yeast eIF5A may also exist as a dimer or even in higher 
oligomeric states (Chung et al., 1991; Wagner & Klug, 2007).  Furthermore, the eIF5A 
structural analogue, HEX-1 from Neurospora crassa, exists as a crystal lattice, formed by 
three types of dimer interactions (Yuan et al., 2003).  Thus it is also hypothesised that the 
yeast eIF5A mimics the dimer configurations employed by the evolutionary-related structural 
analogue, HEX-1.     
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2.2 Materials and Methods 
2.2.1 Alignment of eIF5A sequences 
The non-redundant GenBank nucleotide database (NCBI) and Swiss Prot protein sequence 
database (SwissProt) were searched using the amino acid sequence of S. cerevisiae (yeast) 
eIF5A (Accession code NP010880) employing the BLASTP algorithm (Altschul et al., 1997).  
The results were then restricted to those with the highest scores for proteins with known three 
dimensional structures in the Protein Data Bank (PDB).  The search results included the 
identification of the Methanococcus jannaschii aIF5A (PDB entry 2EIF), Pyrococcus 
horikoshii aIF5A (PDB entry 1IZ6), Pyrobaculum aerophilum aIF5A (PDB entry 1BKB), 
Leishmania mexicana eIF5A (PDB entry 1XTD), L. brasiliensis eIF5A (PDB entry 1X6O) 
and the Neurosporra crassa HEX-1 proteins (PDB entry 1KHI). The S. cerevisiae (yeast) 
eIF5A (Accession code NP010880), Homo sapiens eIF5A (Accession code NP001961) and L. 
mexicana eIF5A (Accession code 1XTDA) protein sequences were aligned using the 
CLUSTALW algorithm (Chenna et al., 2003).  The sequences of M. jannaschii aIF5A 
(Accession code 2EIFA), P. horikoshii aIF5A (Accession code 050089) and P. aerophilum 
aIF5A (Accession code P56635) were also aligned using CLUSTALW (Chenna et al., 2003).   
 
2.2.2 Structural prediction and homology modeling 
Secondary structure prediction of α-helices and β-sheets was performed using JPred (Cuff & 
Barton, 1999).  Three-dimensional molecular models of yeast eIF5A were generated using the 
Swiss Model first-approach mode tool (Guex & Pietsch, 1997; Schwede et al., 2003), using 
the three-dimensional structure of the eIF5A from L. mexicana (Protein Data Bank (PDB) 
entry 1XTD) or the aIF5A from M. jannaschii (PDB entry 2EIF).  Yeast eIF5A homology 
models were also generated using WHAT IF (Vriend, 1990) and MODELLER (Sali et al., 
1995) and outputs were verified using WHAT_CHECK (Hooft et al., 1996) and PROCHECK 
(Laskowski et al., 1993).  Pymol was used to view and manipulate monomeric structural 
representations of eIF5A, its homologues and analogues (DeLano, 2002). Oligomeric 
structures were derived from the template protein by identifying symmetry mates within a unit 
cell, within a distance of 4 Angstroms (Å).  
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2.3 Results and Discussion 
Since the structure of eIF5A could be used to derive a possible mechanism by which the 
protein functions, an in silico analysis of the yeast eIF5A was performed.  This involved 
drawing inferences, using homology modeling and secondary structure predictions, from 
current crystal structure data derived from the well-studied archaeal homologues M. 
jannaschii (Kim et al., 1998), P. horikoshii (Yao et al., 2003) and P. aerophilum (Peat et al., 
1998).  Structural information on eukaryotic homologues of yeast eIF5A is limited, but 
databases such as the Protein Data Bank were useful in retrieving structural information from 
other homologues and analogues of eIF5A.  The homologue of particular interest was the 
eIF5A from L. mexicana because although not published, the three-dimensional structure is 
available on the database. The analogue of interest was the distantly related, functionally 
diverse, but structurally related Neurospora crassa protein HEX-1 (Yuan et al., 2003).  HEX-
1 is known to dimerise by three distinct configurations to ultimately form a crystal lattice.  
Although eIF5A is not known to form such a lattice, it was useful to make use of these 
configurations to predict oligomeric models of eIF5A.  
 
2.3.1 Protein alignments and secondary structure predictions 
Firstly, yeast eIF5A was analysed in comparison with other eIF5A proteins for regions of 
conservation. Yeast eIF5A shares a 60 % and 43 % sequence identity with human eIF5A and 
L. mexicana eIF5A respectively. As expected, alignment of these proteins shows a high 
degree of conservation of the area flanking the highly conserved (hypusinated) lysine (Figure 
2.1A, highlighted in blue).  Although only three of the eIF5A proteins are represented, 
extensive alignments with other eIF5A show similar degrees of conservation in the areas 
highlighted in Figure 2.1A (and data not shown).  In addition either an “RPCK” or a “PCK” 
motif was observed when aligning the various eIF5A proteins (Figure 2.1A, highlighted in 
yellow).  Also notable was that there were at least 2 cysteine residues in eIF5A proteins (data 
not shown). 
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In contrast, when aligning the archaeal translation initiation factor 5Aa (aIF5Aa) proteins 
(Figure 2.1B), only a “PC” motif was conserved.  Moreover, only 1 cysteine residue was 
observed for each aIF5Aa analysed (data not shown).  Three of the aIF5Aa proteins were 
aligned to represent the areas of conservation obtained in all aIF5Aas analysed (Figure 2.1B 
and data not shown).  These included the M. jannaschii, P. horikoshii and P. aerophilum 
aIF5Aa proteins.  M. jannaschii shares a 44 % and 49 % sequence identity with P. horikoshii 
and P. aerophilum respectively.  The region flanking the hypusinated lysine residue in aIF5Aa 
was highly conserved, but not to the same extent as in eukaryotes.  There were also a greater 
number of aromatic residues observed in eIF5A proteins when compared with aIF5Aa 
proteins (Figure 2.1A and B, highlighted in green). 
 
Next, predictions were performed to determine the secondary structure of yeast eIF5A.  An α-
helical region was predicted near the C-terminus of the protein (sequence ELGDSLQTAF) 
and eleven anti-parallel beta sheet regions were identified (Figure 2.2).  The β-sheet 
arrangement compared favourably with the current crystal structure data available for archaeal 
homologues (Kim et al., 1998, Peat et al., 1998, Yao et al., 2003).  This α-helical region 
seems to be exclusive to eukaryotes as was not observed in any of the aIF5Aa crystal 
structures.  Interestingly, the predicted secondary structures appeared to lie within less-
conserved regions of the eIF5A proteins.   
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Figure 2.1:  Sequence alignment of eIF5A proteins and aIF5Aa proteins.  (A)  CLUSTAL 
W multiple sequence alignment of yeast eIF5A (Sc) (Accession code NP010880), human 
eIF5A (Hs) (Accession code NP001961) and eIF5A from L. mexicana (Lm) (Accession code 
1XTDA).  (B) CLUSTAL W multiple sequence alignment of aIF5Aa proteins M. jannaschii 
(Mj) (2EIFA), P. horikoshii (Ph) (050089 and P. aerophilum (Pa) (P56635). Blocks of 
identity are boxed in grey and the lysine residue that is hypusinated is marked by a downward 
arrow. The “RPCK” or “PC” motifs are highlighted in yellow and the highly conserved 
stretches of residues surrounding the lysine are highlighted in blue.  Conserved aromatic 
residues are boxed in green.  The arrow pointing up represents Phe 128 residue in yeast 
eIF5A.  Identical residues are marked by an asterisk and semi-conserved and conserved 
residues are indicated by either a full-stop or a colon, respectively.   
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Figure 2.2:  Secondary structure prediction of yeast eIF5A.  Annotated above on the 
sequence of yeast eIF5A (Sc) (Accession code NP010880) aligned with human eIF5A (Hs) 
(Accession code NP001961) and L. mexicana eIF5A (Lm) (Accession code 1XTDA), are the 
predicted β-strands (red) or α-helical region (blue) as determined by JPred.  Below the 
aligned sequences are the known secondary structures (β-sheets in grey block arrows and α-
helix in black) for L. mexicana.   
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2.3.2 Homology modeling of the yeast eIF5A monomer 
A comparison of the crystal structures of aIF5Aa from M. jannaschii (PDB entry 2EIF) and 
eIF5A from L. mexicana (PDB entry 1XTD) showed similar β-sheet arrangement at the N-
terminus but the archaeal homologue lacked an α-helix at the C-terminus that was present in 
L. mexicana eIF5A (Figure 2.3 A and C).  This α-helix was also predicted in the human 
homology model produced by Costa-Neto et al., (2006).  Molecular modeling of the yeast 
eIF5A was performed using the Swiss Model first approach mode (Guex & Pietsch, 1997; 
Schwede et al., 2003) using either M. jannaschii aIF5Aa or L. mexicana eIF5A with sequence 
identities of 25 % and 48 % to yeast eIF5A respectively, as templates.   
 
There was greater confidence in the model generated using L. mexicana eIF5A as a template, 
due to the stronger degree of sequence identity and better alignment between the two proteins 
as compared with the archaeal protein.  The yeast eIF5A model, using L. mexicana eIF5A as 
the template indicated the presence of an α-helix in a similar position to that of the template 
(Figure 2.3 C and D).  The model generated using M. jannaschii as a template was 
significantly different in that it did not show this α-helix and (Figure 2.3 A and B).  The poor 
sequence identity between yeast eIF5A and aIF5A, and hence limited confidence in the 
model, was reflected in the resulting three-dimensional molecular model.  Thus it was 
concluded that the yeast eIF5A structure, produced using M. jannaschii aIF5A as a template, 
was not inclusive enough to support major extrapolations of potential functionally important 
regions.   
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Figure 2.3:  Homology modeling of eIF5A.  Cartoons depicting the structures of (A) aIF5Aa 
from M. jannaschii (PDB entry 2EIF), (B) yeast eIF5A modeled on M. jannaschii, (C) eIF5A 
from L. mexicana (PDB entry 1XTD) and (D) yeast eIF5A modeled on L. mexicana.  Swiss 
Model was used to generate the homology models (Guex & Pietsch, 1997; Schwede et al., 
2003). Shown as sticks on the N-terminal domain in each case, is the lysine residue that is 
hypusinated. 
 
To assess the validity of the highly automated approach used in the Swiss Model algorithm, 
the WHAT IF modeling tool was employed and model quality was determined using 
WHAT_CHECK to produce yeast eIF5A models (Guex & Pietsch, 1997; Schwede et al., 
2003; Vriend, 1990; Hooft et al., 1996).  When superposed, the WHAT IF model (Figure 
2.4A) based on the L. mexicana eIF5A structure (Figure 2.4A and 2.4B Red), compared 
favourably with the model produced using Swiss Model (Figure 2.4B Blue).  Differences 
were apparent in the loop structures, which are highly conserved.  Costa-Neto et al., (2006) 
reported in their human eIF5A homology model based on L. brasiliensis eIF5A, that the 
conformation of the loop structure bearing the hypusination site was variable, which 
suggested an increased flexibility in this region.  The variability of the yeast eIF5A models in 
the same region was also apparent in the superposed structures of the models generated using 
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different modeling tools (Figure 2.4B Boxed).  In the case of human eIF5A, it was proposed 
this loop region may assume a regular structure in a more hydrophobic environment, such as 
that provided by the hydrophobic surface pocket of DHS (Costa-Neto et al., 2006).  This 
proposal is plausible in that the DHS enzyme has been shown to complex with eIF5A 
precursor (Lee et al., 1999; Wolff et al., 2000).  More recently, Gly 49 and Lys 47 in human 
eIF5A were identified as being critical for eIF5A function in yeast, presumably because the 
G49A and K47A mutant proteins act as suitable substrates for DHS (Cano et al., 2008).  The 
equivalent residues in yeast (Gly 50 and Lys 48 respectively) also occur in the loop of 
conformational variability. 
 
The human eIF5A homology model was based on the L. brasiliensis eIF5A (Costa-Neto et 
al., 2006) using the MODELLER (Sali et al., 1995) algorithm and validated with 
PROCHECK (Laskowski et al., 1993).  For this reason, a similar yeast eIF5A homology 
model, using MODELLER (Sali et al., 1995) and PROCHECK (Laskowski et al., 1993) was 
produced using the L. brasiliensis eIF5A as a template (Figure 2.4C).  The sequence identity 
between yeast eIF5A and L. brasiliensis eIF5A is 48 % (alignment not shown), comparable to 
the 48 % sequence identity between yeast eIF5A and L. mexicana eIF5A.  The yeast eIF5A 
structure produced compared favourably with the human eIF5A homology model generated 
by Costa-Neto et al. (2006).  Even when using the Swiss Model algorithm (Guex & Pietsch, 
1997; Schwede et al., 2003) to model yeast eIF5A on the eIF5A from L. brasiliensis (Figure 
2.4D blue) and superposing it with the MODELLER (Sali et al., 1995) version (FIGURE 
2.4D red), it became apparent that variation in the models occurred only in the unstructured 
regions (particularly the loop region surrounding the site of hypusination).  Given that the 
yeast eIF5A models based on either L. mexicana or L. brasiliensis eIF5A, using all of the 
three modelling programs, produced a similar output, the L. mexicana eIF5A model was 
chosen for further study. 
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Figure 2.4:  Comparison of homology models of eIF5A generated using different 
modeling tools.  (A) Yeast eIF5A homology model generated using WHAT IF (Vriend, 
1990) with L. mexicana eIF5A (PDB entry 1XTD) as the template.  (B) Superposition of yeast 
eIF5A homology models generated using Swiss Model (Guex & Pietsch, 1997; Schwede et 
al., 2003) in blue and using WHAT IF (Vriend, 1990) in red.  (C)  Yeast eIF5A homology 
model generated using MODELLER (Sali et al., 1995) using L. brasiliensis eIF5A (PDB 
entry 1X6O) as the template.  (D) Superposition of yeast eIF5A homology models using 
Swiss Model (Guex & Pietsch, 1997; Schwede et al., 2003) in blue and using MODELLER 
(Sali et al., 1995) in red.  The conserved lysine that becomes hypusinated is represented as 
sticks and the boxed region indicates the loop of conformational variability. 
 
2.3.3 The eIF5A oligonucleotide binding fold 
Since RNA is known to bind hypusinated eIF5A (Xu & Chen, 2001), the presence of an 
oligonucleotide binding fold (OB-fold) in yeast eIF5A was investigated.  Murzin (1993) 
defined this novel folding motif as a five-stranded β-sheet folding in a coil to form a closed β-
barrel, which is capped by an α-helix between the third and fourth strands.  Features of the 
barrel-helix interface include the helix packing perpendicular to the barrel axis and the 
presence of a large hydrophobic residue in the cavity formed by the barrel (Murzin, 1993).   
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When the yeast eIF5A C-terminal domain was analysed, it was clear that the five anti-parallel 
β-strands formed a barrel conforming to the OB-fold criteria (Figure 2.5A).  In addition, a 
phenylalanine residue was present in the cavity.  This Phe 128 (or at least another aromatic 
residue) is highly conserved between eIF5As in the same position (Figure 2.1A, highlighted in 
green, upward arrow), indicating that eIF5A houses a structural feature to allow for nucleic 
acid binding.  The aIF5A proteins from M. jannaschii, P. horikoshii, P. aerophilum and 
Halobacterium sp. lack the α-helix and the conserved aromatic residue and thus do not 
contain a true OB-fold (Figure 2.5B) (Kim et al., 1998; Peat et al., 1998; Yao et al., 2003; 
Wagner & Klug, 2007).  However, aIF5A from Halobacterium sp. has been shown to bind 
RNA, suggesting an alternate mode of RNA-binding in archaeal homologues of eIF5A. 
 
 
 
Figure 2.5:  Defining the yeast OB-fold.  Cartoon depicting the C-terminal domain of: yeast 
eIF5A (A) yeast eIF5A (modeled on the L. mexicana eIF5A template), and (B) aIF5Aa from 
M. jannaschii (PDB entry 2EIF).  The five β-strands and the α-helix are labeled.  The 
hydrophobic phenylalanine (Phe 128) is shown as sticks in the oligonucleotide binding cavity 
(A only).  The oligonucleotide binding site is shown by an arrow.  
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2.3.4 Structural analogues of eIF5A 
Since HEX-1 protein from N. crassa was found to be structurally analogous to yeast eIF5A in 
the initial homology modeling analysis, it was thought that this structural analogue may help 
to refine the homology model, particularly in terms of quaternary structure.  HEX-1 is known 
to dimerise in three distinct conformations (Group I, II and II) to ultimately form a functional 
lattice, and because HEX-1 is structurally analogous to eIF5A (Yuan et al., 2003), it was 
rationalised that the dimerisation mechanisms employed by HEX-1 could be mirrored in yeast 
eIF5A.  It has previously been proposed that human eIF5A exists in a number of oligomeric 
states, with a preference for a dimeric form in solution (Chung et al., 1991).  In addition, the 
activity of Halobacterium sp. aIF5A depends on its oligomeric state (Klug & Wagner, 2007).  
 
The 26 % sequence identity between HEX-1 and yeast eIF5A was not sufficient to produce a 
homology model of yeast eIF5A using either Swiss Model or WHAT IF (despite the stringent 
energy minimisation algorithm employed by the latter).  Instead an alternative approach was 
used to model the dimer configurations of yeast eIF5A, using the HEX-1 dimer configurations 
as a starting point.  This in silico approach could be used to identify potential structurally 
critical residues, or regions within eIF5A that are involved in dimerisation. 
   
The HEX-1 protein was aligned with the yeast and L. mexicana eIF5A (identical residues 
indicated with asterisks in Figure 2.6).  Next, residues corresponding to those involved in 
contacts in each of the HEX-1 three dimer configurations were identified and compared with 
conserved residues in the yeast and L. mexicana eIF5A proteins (Figure 2.6 yellow, green and 
orange shading).  Only Ser 61 in HEX-1, corresponding to Ser 47 in yeast, was identified as 
being identical in all three sequences.  Ser 61 is important as a stabilising residue in the Group 
II dimer configuration of HEX-1 (Yuan et al., 2003).  Residues of similar charge in all three 
sequences were also considered as potential candidates at inter- and intra-subunit interfaces.  
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Figure 2.6:  Protein alignment of eIF5A and HEX-1 indicating potential residues 
involved in dimeric interaction.  CLUSTALW alignment of eIF5A from yeast (Sc) and L. 
mexicana (Lm) with HEX-1.  Identical residues are marked by an asterisk, while the yellow, 
orange and green bars represent contact residues involved in the dimerisation of HEX-1 
Group I, II and III configurations, respectively. The position of serine 61 (HEX-1) or the 
corresponding serine 47 (yeast) is marked by a downward arrow. 
  
Next, monomeric models of both HEX-1 and yeast eIF5A were structurally compared.  The 
serine residue identified as being conserved in both eIF5A and in HEX-1, while also being a 
stabilising residue in the dimerisation of HEX-1 Group II interactions is identified on the 
models (Figure 2.7 A and B).  In addition, the Lys 51 residue that becomes hypusinated on 
eIF5A is marked (Figure 2.7 B).  The residue corresponding to Lys 51 in HEX-1 was 
identified by alignment as Gln 66 (Figure 2.7A).   
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Figure 2.7:  Monomeric models of the HEX-1 and yeast eIF5A proteins.  (A) Crystal 
structures of the monomer of HEX-1 (PDB entry 1KHI).  (B) Homology model of yeast 
eIF5A (modeled on L. mexicana eIF5A, PDB entry 1XTD).  Marked as sticks on the models 
are the relevant positions of the conserved lysine residue (yeast eIF5A) corresponding to 
glutamine 66 (HEX-1) and the serine residue that is conserved at the same position of both 
proteins (Ser 47 in yeast eIF5A or Ser 61 in HEX-1). 
     
2.3.5 Dimerisation of analogues and homologues of eIF5A 
The three HEX-1 dimeric configurations (Groups I, II and III) with their relevant contacting 
residues were reproduced.  In HEX-1, these dimer configurations alternate to ultimately form 
a vast crystal lattice to allow for Woronin body function in N. crassa.  Yuan et al. (2003) 
identified critical residues for the function and/or structure of the crystal lattice.   The residues 
involved in each of the dimer configurations are summarised in Table 2.1.  The Group I dimer 
configuration is achieved by salt bridging of Arg 41 and Asp 44, stabilised by His 39, as well 
as additional hydrogen bonding involving Ser 92, Glu 121 and Gln 105 (Figure 2.8 A).  The 
Group II dimer also involves salt bridges, but between Arg 68 and Glu 81, with additional 
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hydrogen bonding and stabilisation between Ser 84 and Gln 49 and Ser 61 and Glu 81 (Yuan 
et al., 2003) (Figure 2.8 B and C).  The dimer, held together by a series of hydrogen bonds 
(Group III configuration), involves interaction of Gln 127 and Ile 56, as well as between Val 
125 and Gln 134 (Figure 2.8 D).  In addition to these interactions, a number of water-
mediated hydrogen bonds stabilise the dimers (Yuan et al., 2003). 
 
Table 2.1:  Contact residues involved in dimerisation of the archaeal eIF5A homologue 
M. jannaschii aIF5A and the N. crassa HEX-1 protein.   
 
Homologue/Analogue 
of eIF5A 
Type of bond Residues 
involved 
Equivalent aligned 
residues in yeast 
eIF5A 
 
 
N. crassa HEX-1 
(Yuan et al., 2003) 
Group I: 
 
Salt bridges 
and hydrogen 
bonding  
Arg 41 
Asp 44 
His 39 
Ser 92 
Glu 121 
Gln 105 
Arg 27 
Gly 30 
Ala 25 
Thr 76 
Met 105 
Glu 89 
 
 
N. crassa HEX-1 
(Yuan et al., 2003)  
Group II: 
 
Salt bridges 
and hydrogen 
bonds 
Arg 68 
Glu 81 
Ser 84 
Gln 49 
Ser 61 
Gly 53 
Thr 66 
Lys 69 
Lys 35 
Ser 47 
 
N. crassa HEX-1  
(Yuan et al., 2003) 
Group III: 
 
Hydrogen 
bonds 
Gln 127 
Ile 56 
Val 125 
Gln 134 
Asp 111 
Val 42 
Thr 109 
Glu 117 
 
M. jannaschii aIF5Aa 
(Kim et al., 1998) 
 
Hydrogen 
bonds 
Lys 38 
Pro 39 
Gln 96 
Ser 35 
Lys 48 
Thr 49 
Asp 106 
Ser 45 
Note: Residues in bold are conserved at similar positions. 
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Figure 2.8:  Models of the HEX-1 dimer configurations.  Cartoons depicting the overall 
view of the interacting molecules in each of the three dimer configurations of the HEX-1 
(PDB entry 1KHI; Yuan et al., 2003) protein that ultimately form a crystal lattice, namely the 
Group I (A), Group II (B) and Group III (D) interactions.  The Group II dimer is also shown 
by a view down the crystallographic axis to reveal the 65 screw symmetry (C). 
 
 
Crystals produced in solving the structures of aIF5As and eIF5A (Kim et al., 1998; Peat et al., 
1998; Yao et al., 2003; Sun et al., 2005)  routinely involved the addition of reducing agents, 
presumably to stabilise the protein and thus aid the crystallisation process.   Kim et al. (1998) 
reported that M. jannaschii aIF5A may form a dimer connected by intermolecular hydrogen 
bond interactions, summarised in Table 2.1, involving Lys 38, Pro 39 and Gln 96 (equivalent 
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to Lys 48, Thr 49 and Asp 106 in yeast eIF5A, respectively).  The three-dimensional aIF5Aa 
dimer structure observed by Kim et al. (1998) in some crystals was therefore reproduced 
(Figure 2.9).  Although less ordered than crystal form II (PDB entry 2EIF), the structure 
solved from crystal form I (PDB entry 1EIF) was used, since it was the crystal that displayed 
a dimeric configuration.  The two aIF5A molecules are connected by intermolecular 
hydrogen-bond interactions, involving Ser 35 (equivalent to Ser 45 in yeast eIF5A) and 
additional water mediated hydrogen bonding.    
 
 
 
Figure 2.9:  M. jannaschii aIF5A dimer model.  Cartoon representation of the overall view 
of the aIF5A dimer model, with the conserved lysine residue near the disordered part of the 
loop structure.  A close-up view of the dimer interaction site (boxed) is shown on the right.  
The interaction site involves a highly conserved serine residue (Ser 35) on each monomer, 
further facilitated by hydrogen bonding mediated by the presence of water (Kim et al., 1998). 
 
2.3.6 Putative yeast eIF5A dimer models 
Potential eIF5A dimer models were constructed by producing within one unit cell, the 
symmetry mates associated with the monomeric form, to within 4 Å.  Although functionally 
divergent from eIF5A, HEX-1 dimer configurations could be used to derive inferences as 
HEX-1 bears such remarkable structural similarity to eIF5A.  The M. jannaschii aIF5A 
protein has a greater degree of functional equivalence and identity to eIF5A, although it is 
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structurally more divergent.  The aIF5A dimer was also compared to potential eIF5A dimer 
configurations.   Residues thought to be involved in each of the proposed dimer interactions 
were also analysed for the degree of conservation, particularly if the residues occurred in 
highly conserved motifs, such as the “PCK”, “DIFT”, “PSTHN” or the “LSL” motifs (from 
the alignment in Figure 2.1A).  
 
Three putative dimer models, named Type I, II and III, were generated.  The Type I dimer 
model (Figure 2.10A), bearing similarities to the Group I HEX-1 dimer (Figure 2.10A) as 
well as to the M. jannaschii aIF5A dimer (Figure 2.9), was plausible in that there was 
potential for salt bridges to be formed between Asp 43 and Lys 48, as well as water-mediated 
hydrogen bonding involving Ser 45 (Figure 2.10B).  The space-fill model of this potential 
dimer configuration also indicated that the conserved Lys 51 residue was exposed.  Following 
hypusination (and thus extension), this residue could be in contact with the C-terminal domain 
of the protein near the α-helical region (Figure 2.10C). 
 
 
 
Figure 2.10:  Predicted Type I eIF5A dimer.  Cartoon representation of a putative eIF5A 
dimer configuration bearing similarity to the Group I dimer of HEX-1 and the M. jannaschii 
aIF5A dimer.  (A) Overall view of the dimer model showing putative contact points. (B) 
Close-up view of putative salt bridging of Asp 43 and Lys 48, as well as water-mediated 
hydrogen bonding involving Ser 45.  (C) Space-fill model of this dimer configuration.  
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The Type II dimer model (Figure 2.11A) was similar to the dimer belonging to Group II 
configuration of HEX-1 (Figure 2.8B). This configuration was the most plausible in that 
numerous predicted contact points between the monomeric units were observed.  Salt-
bridging involving Asp 61, Glu 69 and Asp 70 with His 54, His 52 and Lys 51, respectively 
(Figure 2.11B), could occur in this configuration.  The space-fill (Figure 2.11C) shows this 
putative dimer model as having numerous contact points that would result in a highly stable 
configuration.  Alternative views of the overall dimer model down the crystallographic axis 
(Figure 2.11D) show the extent to which the N-terminal domains of the two molecules would 
interact.  The extensive N-terminal domain linkages are reiterated in the space model from the 
same crystallographic axis (Figure 2.11E). 
 
 
 
Figure 2.11:  Putative Type II  eIF5A dimer.  Cartoons of a possible yeast eIF5A dimer 
configuration displaying similarities to the Group II dimer of HEX-1.  (A) Overall dimer 
configuration with putative contact points marked as sticks.  (B) Close-up view of possible 
eIF5A dimer contact region involving salt bridging between the residues indicated in the 
colour key.  (C) Space-fill model of the overall putative dimer configuration.  (D)  View of 
the dimer down the crystallographic axis.  (E) Space-fill model of the dimer down the 
crystallographic axis. 
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The Type III dimer model the least plausible in that so few potential contact points exist in 
this configuration, bore similarity to the Group III HEX-1dimer.  This putative dimer (Figure 
2.12A) seemed to be mediated by a single salt bridge between Asp 106 and Lys 67, with 
potential co-ordination of Thr 64 (Figure 2.12B).  Since this dimer configuration in HEX-1 
was required for the completion of the crystal lattice, something not observed in yeast eIF5A, 
it is unlikely that eIF5A dimerises in this configuration.  The space-fill model (Figure 2.12C) 
echoes the weak feasibility of this dimer, showing a loose contact zone. 
 
 
Figure 2.12:  Putative Type III eIF5A dimer. Cartoon representations of the putative yeast 
eIF5A dimer model Type III.  (A)  Overall view of this dimer configuration with the putative 
contact points boxed.  (B) Close-up view of the potential salt-bridging between the residues 
indicated in the colour key.  (C)  Space-fill model of this dimer configuration.  
 
Summarised in Table 2.2 are the residues in yeast eIF5A postulated to play a role in structure 
of yeast eIF5A should it occur as a dimer. Interestingly, eight of these residues (Table 2.2, 
bold) occur within highly conserved eIF5A motifs and reinforce the sentiment that these 
residues are of structural importance.  The most unstructured regions of eIF5A appear to be 
highly conserved, and the structured regions appear to have evolved to present the 
unstructured region (presumably so that they can take part in function and/or inter-subunit 
interactions). 
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 Table 2.2:  Summary of the residues thought to be important for the structural integrity 
of the yeast eIF5A dimer.  
 
Type I 
Dimer 
Type II 
Dimer 
Type III 
Dimer 
OB-Fold Highly conserved eIF5A motifs 
 
Ser 45 
Asp 43 
Lys 48 
 
Asp 61 
Glu 69 
Asp 70 
His 54 
His 52 
Lys 51 
 
Thr 64 
Asp 106 
Lys 67 
 
Phe 128 
 
PCK (38-40) 
STSKTGKHGHAKV (45-57) 
DIFT (61-64) 
ED (71-72) 
PSTHN (74-78) 
FD (128-129) 
Note:  In bold are the putative dimer-contact residues that occur within highly conserved 
motifs. 
 
2.4 Conclusions 
The main objective of the research discussed in this Chapter was to produce a suitable model 
of yeast eIF5A using currently available structural data.  This objective was achieved by using 
the eIF5A homologue from L. mexicana as a template.  The new model, along with secondary 
structure predictions revealed that yeast eIF5A contains an α-helix on the C-terminal domain.  
This finding was in accordance with the homology model of human eIF5A (Costa-Neto et al., 
2006).  Low confidence molecular models were produced using aIF5A as the template, 
echoing the sentiment that there may be too many structural and hence functional differences 
that one cannot extrapolate information across the major domains of living organisms.  All 
crystallographic data involving homologues of eIF5A have been solved using heterologously-
produced (unhypusinated) protein.  To accurately determine the functional and higher order 
structural effects (such as the potential for oligomerisation and hypusination), it will be 
necessary to solve the structure of hypusinated protein.  Also, since it is known that the 
presence of hypusine is required to bind RNA, the data generated to date is further restricted 
by the absence of RNA in solving the structure of activated eIF5A (Xu & Chen, 2001).   
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The presence of both hypusine and RNA may result in substantial conformational changes in 
the protein, which could provide clues about its functional mechanism.  The credibility of the 
yeast eIF5A dimer models can only be confirmed once such crystal structure data is 
generated.  It must be stressed that inferences drawn from the HEX-1 and aIF5Aa dimer 
models, are purely conjectural at this stage.  The following chapters include the 
characterisation of yeast eIF5A using biochemical analyses and functional studies.  It is 
expected that these analyses could be used to validate the models proposed in this Chapter.  
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Chapter 3:  Development of an experimental system for studying the 
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Chapter 3:  Development of an experimental system for studying 
the biological activity of eIF5A  
 
3.1 Introduction 
Substantial information on eIF5A has been generated through studies conducted in S. 
cerevisiae (yeast). The primary reason is that this simple eukaryote has the best characterised 
genome that unlike higher eukaryotes, is easy to manipulate.  In addition, yeast experimental 
systems allow for robust functional gene analysis because unlike E. coli, yeast cells support in 
vivo post-translational modification of eIF5A such as hypusination and phosphorylation 
(discussed in Chapter 1, Section 1.1.2).    
 
As discussed earlier (Chapter1, Section 1.1.1) the yeast genome encodes two eIF5A 
homologues, Tif51a and Tif51b.  TIF51A (HYP2/YEL034W) is situated on Chromosome V 
and has been the best characterised, while less is known about TIF51B (ANB1/YJR047C), 
which is situated on Chromosome X (Mehta et al., 1990; Schnier et al., 1991).  The TIF51A 
and TIF51B genes share over 90 % nucleotide sequence identity (Schwelberger et al., 1993).  
Expression of Tif51a and Tif51b results in two isoelectric variants, the more acidic eIF5A (20 
kDa) and more basic eIF5Ab (18 kDa), expressed under aerobic or anaerobic conditions, 
respectively (Mehta et al., 1990; Scwelberger et al., 1993).  Although both variants undergo 
hypusination, eIF5A is also phosphorylated on one or more serine residues, accounting for the 
difference in MR of these two highly homologous proteins (Kang et al., 1993).  
 
The hypusinated gene products of either TIF51A or TIF51B are able to support growth 
interchangeably under aerobic and anaerobic conditions in yeast strains lacking TIF51B or 
TIF51A, respectively (Schwelberger et al., 1993).  When cell free lysates from wild-type yeast 
cells grown aerobically were analysed, it was found that eIF5A is more abundant than eIF5Ab 
and that a natural proteolytic breakdown of eIF5A, but not of eIF5Ab, occurred following cell 
lysis (Kang et al., 1993).  Human eIF5A, which shares about 63 % amino acid sequence 
identity with the yeast eIF5A, can substitute for either of the yeast homologues, eIF5A or 
eIF5Ab (Schwelberger et al., 1993).   
 
The overall aim of the experiments described in this chapter was to develop an experimental 
system for the functional and biochemical characterisation of yeast eIF5A.  Important 
components of this system include: (1) the availability of anti-eIF5A antibodies that can be 
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used to track the presence of the protein in cells and during purification procedures; (2) the 
ability to over-express and efficiently purify native eIF5A from both E. coli and yeast cells; 
(3) an in vivo assay system for testing biological activity of mutant eIF5As. This chapter 
describes the over-expression and affinity purification of 6 x His-tagged eIF5A and the use of 
this protein to raise anti-eIF5A rabbit polyclonal antibodies.  Also included is the design and 
construction of the yeast experimental system for in vivo assays.  This involved the insertion 
of a chromosomal copy of TIF51A under the control of the GAL1 promoter (PGAL1TIF51A), 
followed by successive disruption of the TIF51B and TIF51A genes by integrative 
transformation, resulting in a strain that was viable in media containing galactose, but unable 
to grow with glucose as a carbon source.    
 
3.2 Materials and Methods 
3.2.1 Strains and culture conditions 
The parent yeast strain, INVScI (Table 3.1), was grown in YPD (complete) medium 
(Appendix A) and competent cells were prepared using the Frozen-EZ Yeast Transformation 
II™ Kit (Zymo Research). Knockout yeast strains (Table 3.1) were grown at 28oC in selective 
minimal medium (SMM) broth containing galactose as a carbon source, supplemented with 
the required amino acids for each strain as well as uracil where required (Appendix A, Kaiser 
et al., 1994).  Recombinant plasmids were hosted in E. coli DH5α cells while heterologous 
expression of eIF5A was carried out in E. coli BL21 (DE3) (Table 3.2).  All E. coli cultures 
were grown in Luria Bertani (LB) medium and competent cells were prepared using the 
method of Hanahan (1985) (Appendix B). 
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Table 3.1:  Genotypes of yeast strains used in this study.  
Strain Genotype Source 
INVScI MATa his3∆ leu2 trp1-289 ura3-52/ 
Matα his3∆ leu2 trp1-289 ura3-52  
Invitrogen 
PGY1 MATa his3∆1 trp1-289 ura3-52 PGAL1TIF51A::LEU2/ 
Matα his3∆1 trp1-289  ura3-52 PGAL1TIF51A::LEU2 
This study 
PGY7 MATa his3∆1 trp1-289 PGAL1TIF51A::LEU2 TIF51B::hisG-URA3-hisG / 
Matα his3∆1 trp1-289 PGAL1TIF51A::LEU2 TIF51B::hisG-URA3-hisG 
This study 
PGY8 MATa his3∆1 trp1-289 ura3-52 PGAL1TIF51A::LEU2 TIF51B::hisG/ 
Matα his3∆1 trp1-289 ura3-52 PGAL1TIF51A::LEU2 TIF51B::hisG 
This study 
PGY9 MATa his3∆1 trp1-289 PGAL1TIF51A::LEU2 TIF51B::hisG TIF51A::hisG-URA3-
hisG/  
Matα his3∆1 trp1-289 PGAL1TIF51A::LEU2 TIF51B::hisG TIF51A::hisG-URA3-hisG 
This study 
PGY10 MATa his3∆1 trp1-289 ura3-52 PGAL1TIF51A::LEU2 TIF51B::hisG TIF51A::hisG/  
Matα his3∆1 trp1-289 ura3-52 PGAL1TIF51A::LEU2 TIF51B::hisG TIF51A::hisG 
This study 
 
Table 3.2:  Genotypes of E. coli strains used in this study. 
Strain Genotype Reference 
E. coli DH5α F- Φ80lacZ∆M15 ∆(lacZYA-argF)U169 deoR recA1 
endA1 hsdR17(rk-, mk+) phoA supE44 thi-1 gyrA96 relA1 λ- 
Hanahan, 1983 
E. coli BL21 (DE3) F- omptT hsdSB (rB-;  mB-) gal(DE3) dcm plyS Cmr Studier & Moffat, 1986  
 
3.2.2 Recombinant DNA techniques 
Recombinant plasmid DNA was isolated from E. coli DH5α cells either using the method of 
Berghammer and Auer (1993) for initial diagnostic purposes, or the High Pure Plasmid 
Isolation Kit (Roche).  The integrity of all PCR products and recombinant plasmids resulting 
from the cloning of oligonucleotides or site-directed mutagenesis was routinely determined by 
DNA sequencing using the ABI Prism® Big Dye™ Terminator v 3.1 Cycle Sequencing Kit 
(Applied Biosciences) with the specified sequencing primers (Appendix C) and analysed 
using the ABI Prism 3100 Genetic Analyser (Applied Biosystems).  Chromatograms of 
sequences were visualised using the Chromas v. 2 (Technelysium Pty Ltd.) and analysed 
using Vector NTI DeLuxe v. 4.0 or v. 5.0 (Informax Inc.) software packages.  The sequences 
of all DNA primers used in this and following chapters can be found in Appendix C.    
 
3.2.3 INVScI genomic DNA isolation and PCR amplification of TIF51A 
INVScI cells were inoculated into YPD broth (Appendix A) and grown at 28oC to mid-log 
phase (OD600 nm = 0.8) before being harvested by centrifugation at 1000xg.  Genomic DNA 
was extracted using the phenol/chloroform method described by Kaiser et al. (1994) 
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(Appendix D). Primer pair PG5F and PG2R (Appendix C), which exclude the UAG (stop) 
codon and introduce flanking 5’ Nde I and 3’ Bam HI and Sma I sites, were used to amplify 
the TIF51A coding sequence from genomic DNA.  The PCR product was gel purified using 
Glassmilk® (GeneClean® II kit, QBiogene) and ligated into the pGEM® T Easy vector 
(Promega) and transformants screened by restriction analysis.  The recombinant plasmid, 
pPG5, containing the correct insert was sequenced using the pUCF and pUCR primers 
(corresponding to flanking pGEM®-T-Easy vector sequences) to verify the integrity of the 
PCR amplification product.   
  
3.2.4 Construction of the E. coli TIF51A –His expression vector, pPG6 
Ten micrograms each of oligonucleotides PG3F and PG4R (Appendix C) were annealed in 
200 mM Tris-HCl pH 7.6, 100 mM MgCl2 (final volume 20 µl) and incubated at 100oC for 5 
minutes and then cooled at room temperature.  The double-stranded oligonucleotide, PG3, 
(Figure 3.1) encoding a 6 x polyhistidine (6 x His) tag followed by an UAG (stop) codon, 
flanked by Bam HI and Sma I sites on its 5’ end and an Eco RI site on the 3’ end, was used to 
fuse a 6 x His tag to the 3’ end of TIF51A coding sequence in pPG5.  A Nde I - Eco RI 
restriction fragment carrying the TIF51A-His coding sequence was then ligated into pT7-7 
(Tabor, 1990) resulting in the TIF51A-His expression vector, pPG6 (Figure 3.1). 
 
3.2.5 Heterologous expression of eIF5A-His in E. coli  
E. coli BL21 (DE3) cells transformed with pPG6 or pT7-7, were inoculated into LB broth 
(supplemented with 200 µg/ml ampicillin) and grown at 37oC until the OD600 nm reached 0.4 
after which expression was induced by the addition of IPTG to a final concentration of 1 mM.  
Aliquots of cells were collected at hourly intervals and analysed by sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) using a 15 % polyacrylamide gel (Appendix 
E) followed by staining with Coomassie.  To determine solubility, samples containing 2 
OD600 nm units of cells were disrupted by sonication at a frequency of 400 mHz at 10 second 
intervals (10 seconds sonication followed by 10 seconds on ice) for a total of 2 minutes.  
Lysates were centrifuged at 1000xg for 10 minutes at 4oC.  The resulting supernatant and 
pellet fractions were analysed by SDS-PAGE. 
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Figure 3.1:  Schematic map of the E. coli eIF5A-His expression vector pPG6.  Annealed 
oligonucleotides PG3F and PG4R, encoding a 6 x His tag flanked by the overhanging Bam HI 
and Sma I sites on the 5’ end and an Eco RI site at the 3’ end, preceded by a UAG (stop) 
codon (*).  The annealed oligonucleotides were ligated into the pT7-7 derived plasmid, pPG5, 
bearing the TIF51A gene excluding the UAG (stop) codon, such that the TIF51A would 
encode eIF5A-His (C-terminal 6 x His tag) resulting in the expression vector, pPG6.  The 
pT7-7 vector makes use of the T7 promoter system in E. coli (Studier & Moffat, 1986) and 
bears an E. coli origin of replication (oriV) and β-lactamse gene encoding ampicillin 
resistance (AmpR).   
 
3.2.6 Nickel affinity purification of eIF5A-His  
E. coli BL21 (DE3) cells expressing eIF5A-His (pPG6) were harvested at 2000xg and 
resuspended in Lysis Buffer (50 mM Tris-HCl, pH 8.0, 300 mM NaCl, 10 mM imidazole).  
The cell suspension was sonicated as described above, followed by a clearing centrifugation 
step at 1500xg for 10 minutes at 4oC.  The supernatant was loaded onto equilibrated Qiagen 
Ni-NTA Spin columns and the manufacturer’s native purification protocol was followed with 
changes in the wash buffer (50 mM Tris-HCl, pH 8, 300 mM NaCl, 20 mM imidazole) and 
elution buffer (50 mM Tris-HCl, pH 8, 300 mM NaCl, 250 mM imidazole).  The flow-
through, washes and elutions collected during the purification procedure were analysed by 
SDS-PAGE and Coomassie staining to detect the presence of eIF5A.  
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3.2.7 Western analysis 
One milligram of purified eIF5A-His protein was used to raise rabbit polyclonal antibodies 
(Prof D.U. Bellstedt, Department of Biochemistry, Stellenbosch University).  Serum was 
collected from the rabbit before inoculation of the protein (“Day 0” Pre-bleed) and on Day 39, 
following a series of booster inoculations on Days 28, 30 and 32 post-inoculation.   
 
Antibody concentrations were optimised for Western analysis as follows.  Crude protein 
extracts from E. coli BL21 (DE3) cells transformed with pPG6 or pT7-7 were resolved using 
a 15 % SDS-polyacrylamide gel and transferred to Hybond C+ (Amersham Biosciences) 
nitrocellulose membranes using the standard Western blotting procedure (Appendix F).  
Varying dilutions of antiserum (“Day 0” Pre-bleed, or "Day 39” serum) were used as primary 
antibodies while the secondary antibody used was the recommended 1:12 500 dilution of the 
Roche BM Chemiluminescence Western Blotting Kit secondary antibody. Antibodies were 
diluted in TBS-Tween 20 solution containing 1 % BSA (Appendix F).   
 
To test the specificity of the “Day 39” serum whole cell protein extracts derived from E. coli 
BL21 (DE3) cells transformed with pPG6 or pT7-7 were resolved by SDS-PAGE, followed 
by Western analysis. Sensitivity of the antiserum was tested by probing known concentrations 
of purified eIF5A-His with the optimised serum dilution.  After the appropriate dilutions of 
antiserum were determined, a pre-adsorption procedure was followed to remove non-specific 
antibodies (method adapted from Harlow and Lane (1988), Appendix G).  This was done by 
incubating serum with lysates of cells transformed with pT7-7, in a ratio of 1:3 at 4oC for 12 
hours at 50 rpm, followed by a clearing spin at 2000xg for 20 minutes.  The supernatant (pre-
adsorbed antiserum) was analysed using lysates of cells harbouring either pPG6 or pT7-7 to 
determine the specificity to eIF5A.   
 
Finally, the sensitivity of the pre-adsorbed antiserum was determined by Western analysis of 
dilutions of known concentrations of purified eIF5A-His.  In the case of detection of eIF5A 
expressed in yeast strains, cells were grown at 28oC in SMM broth, supplemented with the 
required amino acids for each strain as well as uracil (Appendix A, Kaiser et al., 1994) 
containing galactose as a carbon source until the OD600 nm reached 0.8.  Two OD600 nm units of 
cells were harvested and protein was extracted using the method of Kaiser et al. (1994) 
(Appendix H).  Protein extracts were resolved by SDS-PAGE followed by Western analysis 
using anti-eIF5A pre-adsorbed antiserum.    
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3.2.8 Construction of yeast strain with PGAL1-dependent eIF5A expression 
TIF51A was amplified from INVScI genomic DNA (as in Section 3.2.3) using primers PG1F 
(introducing a 5’ Hind III site) and PG6R (introducing a 3’ Bam HI site) (Appendix C) and 
the product inserted between the GAL1 promoter and CYC1 terminator in the YipLac128-
derived plasmid, YipLacVCAPB320 (Venter, 2001).  YipLac128 carries a LEU2 selectable 
marker and is used to insert recombinant genes into the leu2 locus on chromosome III in 
INVScI by homologous recombination (Gietz and Sugino, 1988).  The resulting plasmid, 
pPG13, was linearised with Cla I, and used to transform INVScI cells.  Leu+ transformants 
were selected after incubation for 4 days at 28 oC on SMM agar plates supplemented with 
uracil, tryptophan, histidine and glucose as the carbon source (Appendix A, Kaiser et al., 
1994).  Genomic DNA was extracted from potential recombinants and the presence of the 
PGAL-eIF5A expression cassette confirmed by PCR using primers sets:  PG1F (specific to 5’ 
TIF51A) and AI1R (specific to 3’ TCYC1); AI2F (specific to 5’ PGAL1) and PG6R (specific to 3’ 
TIF51A); and AI2F and AI1R.   
 
3.2.9 Construction of the TIF51A-disruption plasmid (pPG14) 
The TIF51A gene (including its endogenous promoter) was amplified from INVScI genomic 
DNA using primers PG8F and PG6R (Appendix C), which introduce flanking Age I and Bam 
HI sites at the 5' and 3' ends of the gene, respectively.  The PCR product was inserted into 
pGEM®T-Easy (pPG9) and the integrity of the PCR product was confirmed by DNA 
sequencing.  Site-directed mutagenesis (QuikChange SDM Kit, Stratagene) was used to 
introduce a Bgl II site in the middle of the TIF51A gene of pPG9 (into the Asp 63 codon), 
using primers PG17F and PG18R (Appendix C).  The resulting plasmid, pPG18 (Figure 
3.2A), was confirmed by restriction analysis and DNA sequencing.   Next, pNKY51 (Alani et 
al., 1987, Figure 3.2B) was digested with Bam HI and Bgl II, releasing a 3.8 kbp fragment 
carrying the URA3 gene flanked by hisG repeats, which was ligated into pPG18 linearised 
with Bgl II in the middle of the TIF51A gene producing the TIF51A-disruption vector, pPG14 
(Figure 3.2C).  
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Figure 3.2:  Schematic representation of the construction of the TIF51A-disruption 
vector, pPG14.  (A) pPG18 with an engineered Bgl II site at the Asp63 codon of the TIF51A 
gene was digested with Bgl II and ligated with a 3.8 kbp fragment obtained by the digestion of 
pNKY51 digested with Bgl II and Bam HI (B).  The resulting plasmid, pPG14 (C), bearing a 
β-lactamase gene encoding ampicillin resistance and a phage f1 origin of replication (F1 ori), 
was used for the disruption of TIF51A. 
 
3.2.10 Construction of the TIF51B-disruption plasmid (pPG16) 
The TIF51B gene and its endogenous promoter were amplified from INVScI genomic DNA 
using primers PG13F and PG14R (Appendix C) and the PCR product cloned into pGEM®T-
Easy (pPG15).  Site-directed mutagenesis was used to introduce a Bam HI site into the middle 
of the TIF51B gene (into the Pro 75 codon), using primers PG15F and PG16R (Appendix C).  
This resulting plasmid, pPG19 (Figure 3.3A), was selected by restriction analysis and the 
introduction of the Bam HI site further confirmed by DNA sequencing.  Next, a 3.8 kbp    
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Bam HI-Bgl II fragment carrying the hisG-URA3-hisG cassette from pNKY51 (Figure 3.3B), 
was ligated into the pPG19 Bam HI site.  The resulting TIF51B-disruption vector, pPG16 
(Figure 3.3C), was confirmed by restriction analysis and the disruption region was sequenced 
using primers PG13F, URA1, HISG and PG14R (Appendix C). 
  
 
 
Figure 3.3:  Schematic representation of the construction of the TIF51B-disruption 
vector, pPG16.  (A) pPG19, with an engineered Bam HI site at Pro75 of the TIF51B cassette 
was digested with Bam HI and ligated with a 3.8 kbp fragment obtained by the digestion of 
pNKY51 digested with Bgl II and Bam HI (B).  The resulting plasmid, pPG16 (C), housing a 
phage f1 origin of replication (F1 ori) and a β-lactamase gene encoding ampicillin resistance 
(AmpR), was used for the disruption of TIF51B.     
 
3.2.11 Construction of yeast knockout strains 
Construction of the TIF51B-disruption strain, PGY8.  The 4.6 kb Eco R1 fragment from 
pPG16, carrying the hisG-URA3-hisG cassette flaked by the 5' and 3' regions of TIF51B gene, 
(Figure 3.3C) was used for the transformation of PGY1 competent cells.  Ura+ transformants 
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were selected on SMM agar plates (supplemented with each histidine and tryptophan and 
glucose as carbon source) after growth at 28oC for 4 days.  Genomic DNA was extracted and 
analysed for the integration of the TIF51B disruption cassette by PCR amplification with 
primer sets PG13F (specific to 5’ TIF51B) and PG14R (specific to 3’ TIF51B) or PG13F and 
URA1 (specific to 5’ URA3) (Appendix C).  Since yeast strains INvSc1 and thus PGY1 are 
diploid strains, transformants in which both copies of TIF51B had been disrupted were 
selected (PGY7, Table 3.1).  This was done by plating transformants onto SMM agar plates, 
supplemented with histidine, tryptophan, uracil and 0.001 % 5-fluoroorotic acid (5-FOA) 
together with glucose as a carbon source.  The cells were incubated at 28oC for 4 days, to 
allow for the deletion of the hisG repeat together with the URA3 marker by homologous 
recombination, resulting in reversion to the Ura- phenotype.  Genomic DNA was extracted 
from Ura- colonies and analysed for curing of the Ura+ phenotype together with the disruption 
of both copies of TIF51B using PCR amplification with primers PG13F and PG14R 
(Appendix C).  The resulting strain, PGY8 (Table 3.1) contained a copy of TIF51A under 
control of the GAL1 promoter with both copies of the TIF51B disrupted by insertion of the 
hisG coding sequence.   
 
Construction of the TIF51B-TIF51A-disruption strain, PGY10.  The 4.6 kb Eco RI restriction 
fragment from pPG14 (Figure 3.2C), carrying the hisG-URA3-hisG cassette inserted into the 
TIF51A gene sequence, was transformed into PGY8 competent cells.  Ura+ transformants 
were selected on SMM agar plates (supplemented with histidine and tryptophan and galactose 
as a carbon source) as described above.  Genomic DNA was extracted and analysed for 
homologous integration of the disruption cassette into the two TIF51A genes using PCR 
amplification with primers PG8F (specific to 5’ TIF51B) and URA1 (specific to 5’ URA3) 
(Appendix C). Transformants in which both copies of TIF51A had been disrupted (PGY9), 
were plated onto SMM agar plates, supplemented with histidine, tryptophan, uracil and 5-
FOA together with galactose as a carbon source.  The plates incubated, at 28oC for 4 days, to 
allow for the removal of the hisG repeat by homologous recombination and reversion to a 
Ura- phenotype.   
 
Genomic DNA was extracted and analysed to confirm the removal of the URA3 marker and 
disruption of TIF51A using PCR amplification with primers PG8F and PG6R, which are 
specific to 3’ TIF51A (Appendix C).  The resulting strain, PGY10 contained a copy of 
TIF51A under control of the GAL1 promoter with two copies each of TIF51B and TIF51A 
disrupted by the insertion of the hisG coding sequence. 
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3.2.12 Southern Blot analysis  
Genomic DNA was extracted from strains INVScI, PGY1, PGY8 and PGY10 digested with    
Eco RV and resolved using a 1 % agarose gel.  The DNA was transferred to a Hybond N+ 
(Amersham Biosciences) nylon membrane using the method described in Appendix I 
(Sambrook et al., 1989).  A pGEM®T-Easy construct, carrying the TIF51A coding sequence 
(pPG30, Appendix J), was linearised using Hind III and used to generate a negative sense  
[32P]-dCTP-labelled RNA probe with T7 RNA polymerase according to the manufacturer’s 
recommendations (MBI Fermentas).  Since TIF51A and TIF51B coding sequences share over 
90% nucleotide sequence identity, this probe would hybridise to both genes.  Hybridisation 
was performed at 42oC (with formamide) and stringent washes were carried out to remove 
unbound and non-specifically bound probe (Ausubel et al., 1983; Appendix I).   
 
3.2.13 Construction of the TIF51A complementation vectors 
The coding region of TIF51A, as well as its endogenous promoter was amplified from INVScI 
genomic DNA using primer pair PG8F and PG6R (Appendix C), which introduced a 5’ Age I 
and a 3’ Bam HI site.  The product was inserted into the pGEM® T Easy vector and the 
recombinant plasmid selected by restriction analysis and DNA sequencing using the pUCF 
and pUCR primers (Appendix C).  Digestion with Age I and Bam HI released a 738 bp 
fragment carrying the TIF51A coding region preceded by its native promoter, which was 
ligated into Age I/Bam HI-digested pYES2 (Invitrogen).  The integrity of the resulting 
construct, pPG10, was confirmed by restriction analysis and DNA sequencing using primers 
AI2F and AI1R (Appendix C).  Plasmid pPG10, (Figure 3.4) was used for complementation 
assays in the TIF51A-TIF51B-disrupted strain, PGY10.  
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Figure 3.4:  The TIF51A complementation vector pPG10. Schematic representation of the 
pYES2-derived vector, pPG10, which bears the URA3 auxotrophic marker, and has, in place 
of the GAL1 promoter, the TIF51A coding region preceded by the endogenous promoter.   In 
addition, pPG10 bears the yeast 2 micron origin of replication (2 µ ori), the β-lactamase gene 
encoding ampicillin resistance (AmpR) and a Tcyc1 transcriptional terminator.  
 
An N-terminal 6 x His tag was then introduced upstream of the TIF51A AUG start codon in 
the vector pPG10.  This was achieved by PCR amplification using the overlapping primers 
PG30 and PG31 (Appendix C), which introduce a Pvu II site followed by the 6 x His tag 
immediately upstream from the eIF5A ORF.  The PCR product was digested with Pvu II and 
ligated with T4 DNA ligase.  The resulting His-eIF5A complementation plasmid, pPG20 
(Figure 3.5), bearing the His-TIF51A sequence was confirmed by restriction analysis and the 
integrity of the DNA sequence confirmed using primers AI2F and AI1R (Appendix C) that 
bind to the 5’ PGAL1 and 3’ TCYC1 regions respectively.  Plasmid pPG20, (Figure 3.5) was used 
for complementation assays in the TIF51A-TIF51B-disrupted strain, PGY10.  
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Figure 3.5:  Construction of His-eIF5A complementation plasmid, pPG20. Schematic 
representation of primers PG30 (sense) and PG31 (anti-sense) that were used in the inverse 
PCR of pPG10, digested with Pvu II and ligated to produce pPG20, the His-eIF5A 
complementation vector for strain PGY10.  The construct bears a β-lactamase gene encoding 
ampicillin resistance and a URA3 auxotrophic marker. 
 
Furthermore, a C-terminal 6 x His tag version of the complementation vector was generated.  
This was achieved by removing a 400 bp fragment following digestion with Sal I/Eco RI from 
pPG6 (Section 3.2.4) and replacing the 3’ portion of TIF51A from pPG10 with the same 3’ 
region, but containing the coding sequence for the 6 x His tag at the C-terminus.  Plasmid 
pPG10-His (Appendix J) was also used for complementation assays in the TIF51A-TIF51B-
disrupted strain, PGY10.  
  
3.2.14 Complementation of the TIF51A-TIF51B-disruption strain, PGY10 
Strain PGY10 was transformed with either pYES2 (Invitrogen) or with pPG10 and grown on 
SMM agar plates supplemented with histidine, tryptophan and galactose but no uracil, at 28oC 
for 4 to 6 days.  Following patching, 4 OD600 nm units of cells were scraped from the agar 
plates, washed in sterile distilled water and inoculated into either YPD or YPGal broth. After 
24-36 hours of growth with shaking at 28oC, cells were harvested by centrifugation at 1000xg 
and resuspended to an OD600 nm of 1.0 in water.  Five-fold serial dilutions were performed and 
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5 µl of each dilution were spotted onto either YPD or YPGal agar plates.  These plates were 
incubated for a further two days at 28oC.  
 
3.3 Results and Discussion 
The two most important requirements of an experimental system for studying eIF5A were: (1) 
to track the presence of the protein during purification and biochemical characterisation and 
(2) to assay for eIF5A function in vivo.  Thus the focus in this chapter was to produce good 
quality anti-eIF5A antibodies and to construct a knockout yeast strain for complementation 
assays to detect eIF5A function. 
 
3.3.1 Over-expression and purification of eIF5A-His from E. coli 
The construct, pPG6, which carries a copy of the TIF51A coding sequence downstream of the 
T7 promoter, was used for over-expression of eIF5A in E. coli.  Cells expressing eIF5A were 
induced and analysed for the presence of the protein by SDS-PAGE.  A protein migrating at 
approximately 21 kDa was observed in cells transformed with pPG6, with maximum levels of 
this protein produced after 2 hours of induction (Figure 3.6, lanes 3-6).  This is consistent with 
the MR of eIF5A-His (20 kDa plus the 6 x His tag).  Since no equivalent protein was detected 
in extracts from cells transformed with the vector, pT7-7 (Figure 3.6, compare lane 1 with 
lane 6), the 21 kDa protein was attributed to the presence of eIF5A-His.  Nearly all of eIF5A-
His was present in the soluble fraction, with a significantly lower amount visible in the 
insoluble fraction (Figure 3.6, lanes 7 and 8), indicating that the recombinant protein was 
soluble. 
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Figure 3.6: Expression and solubility of recombinant eIF5A-His in E. coli. Coomassie-
stained 15 % SDS-polyacrylamide gel with the following resolved proteins.  Lane 1:  protein 
extract from cells transformed with pT7-7 (-) sampled 4 hours post-induction; Lanes 2–6:  
protein extracts from cells transformed with pPG6 (eIF5A-His) at hourly intervals from 0 to 4 
hours after induction; Lane 7:  insoluble fraction (pellet) and Lane 8:  soluble fraction 
(supernatant) of cell free extract derived from cells expressing eIF5A-His after four hours of 
induction. The position of the eIF5A-His protein is shown on the right (arrow), while the 
relative molecular weights are indicated on the left in kDa.   
 
Since the majority of recombinant eIF5A-His appeared to be soluble, it was decided to 
proceed with native purification of the protein.  Cell-free extracts derived from 10 OD600 nm 
units of E. coli cells expressing eIF5A-His (pPG6) were used for nickel-affinity purification 
of eIF5A-His.  Analysis of eluted fractions using SDS-PAGE revealed little eIF5A-His in the 
flow-through fraction, indicating that the protein had bound to the column (Figure 3.7, lane 
2).  Similarly, no eIF5A-His could be detected in the wash fractions (Figure 3.7, lanes 3-5), 
which contained an increase in the imidazole concentration when compared with the binding 
buffer (from 10 mM to 20 mM, respectively).  A buffer containing 250 mM imidazole was 
used to elute the eIF5A-His.  The elution fractions comprised mainly of purified eIF5A 
protein (migrating at approximately 21 kDa), with the presence of a small amount of higher 
molecular weight proteins, at about 70 kDa in size, (Figure 3.7, lanes 6-8).  Since the 
contaminating proteins represented a minor fraction of the total protein, the sample was used 
to raise polyclonal antibodies. 
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Figure 3.7:  Nickel affinity purification of eIF5A-His. Coomassie-stained 15 % SDS-
polyacrylamide gel with the following resolved protein samples: Lane 1:  Cell-free lysates 
(CL) of cells transformed with pPG6 following induction for 4 hours; Lane 2:  Flow-through 
(FT) obtained after binding of CL to the column; Lanes 3-5:  Wash fractions (W1-3) collected 
using 20 mM imidazole buffer; Lanes 6-8:  Elutions of purified eIF5A-His (E1-3) collected 
using 250 mM imidazole buffer. eIF5A-His is indicated by the arrow (right) and the size of 
the molecular weight markers are indicated on the left in kDa. 
 
3.3.2 Optimisation of Western analysis with anti-eIF5A polyclonal antibodies 
Western analysis was used to confirm the absence of anti-eIF5A antibodies in the rabbit 
serum prior to immunisation with purified eIF5A-His.  Protein extracts from E. coli cells 
expressing eIF5A-His (pPG6) and whole cells transformed with pT7-7 were probed with 
“Day 0” serum. At a dilution of 1:250 000, neither eIF5A nor other cellular proteins could be 
detected (Figure 3.7A, lanes 1 and 2).  To confirm that antibodies present in the antiserum had 
been raised against eIF5A, the “Day 39” anti-eIF5A-His serum was used to detect eIF5A in 
cell-free extracts at dilutions of either 1:250 000, 1:500 000 or 1:1 000 000.  eIF5A was 
detected in cell-free extracts derived from cells transformed with pPG6, but not with pT7-7 
(Figure 3.8A, lane 4 vs. lane 3) indicating the presence of anti-eIF5A antibodies in the serum.   
 
Some cross-reaction with other E. coli proteins was observed, especially with a protein 
migrating at 14 kDa.  Dilution of the antiserum to 1:500 000 or 1:1 000 000 resulted in 
reduction, but not elimination of cross-reaction with E. coli cellular proteins, (Figure 3.8A, 
lanes 5 to 8).  To reduce the degree of cross-reaction with E. coli proteins, it was decided to 
immunoprecipitate these non-eIF5A-specific antibodies by pre-adsorbing the antiserum with 
cell-free protein extracts derived from E. coli cells harbouring the vector pT7-7.  Western 
analysis of whole cells transformed with either pPG6 (+) at or pT7-7 (-), using the pre-
absorbed antiserum resulted in substantially reduced levels of cross-reactivity with E. coli 
cellular proteins (Figure 3.8B lanes 1 and 2).  Finally, the sensitivity of the anti-eIF5A 
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antiserum was determined using dilutions of purified eIF5A-His showing that the antibodies 
could detect 7.5 ng of purified eIF5A-His (Figure 3.8C, lane 4). 
 
 
 
Figure 3.8:  Optimisation of anti-eIF5A antiserum for Western analysis.  (A) Western 
analysis of whole cells transformed with pPG6 (+) or pT7-7 (-) using “Day 0” antiserum at a 
dilution of 1:250 000 (lanes 1 and 2) or using the “Day 39” antiserum at dilutions of 1:250 
000 (lanes 3 and 4), 1:500 000 (lanes 5 and 6) and 1: 1 000 000 (lanes 7 and 8).  (B) Western 
analysis of protein extracts from cells harbouring either pT7-7 (-) or pPG6 (+) using the “Day 
39” anti-eIF5A serum at a dilution of 1:1 000 000 after pre-adsorption.  (C) Western analysis 
of purified eIF5A-His proteins at concentrations of 150 ng, 75 ng, 38 ng and 7.5 ng (lanes 1 to 
4 respectively), using the pre-adsorbed “Day 39” anti-eIF5A serum at a dilution of 1:1 000 
000.   The autorad exposure time in each case was 1 minute.  Sizes of the relative protein 
molecular weight markers are indicated on the left of the blots in kDa, and the relative size of 
eIF5A-His is indicated on the right (arrow).   
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3.3.3 Construction of the TIF51A-TIF51B knockout yeast strain, PGY10 
The strategy for assaying for eIF5A function by complementation was to construct a knockout 
yeast strain in which the endogenous TIF51A and TIF51B genes had been disrupted, with a 
functional copy of TIF51A under control of the GAL1 promoter inserted into the leu2 gene.  
Thus expression of LEU2::TIF51A ("endogenous eIF5A") could thus be induced by growth in 
galactose and repressed in medium containing glucose, allowing for the ability to assay for 
biological function of "exogenous eIF5A" (expressed from a plasmid under control of the 
native TIF51A promoter). 
 
3.3.3a  The LEU2::PGAL1-TIF51A strain, PGY1 
In the first step, a copy of TIF51A under the control of the GAL1 promoter (PGAL1TIF51A), 
was inserted into the leu2 locus of INVScI by homologous recombination.  This was achieved 
by transforming pPG13, linearised using a single Cla I site within the LEU2 coding sequence 
(Figure 3.9A and B) and selecting for Leu+ transformants.  Confirmation of integration of the 
LEU2::PGAL1-TIF51A fragment was obtained by PCR analysis of genomic DNA extracted 
from recombinants using three primer pairs designed to recognise only the LEU2::PGAL1-
TIF51A sequence.  The PCR analysis of five recombinants with the correct genotype is 
represented in Figure 3.8C. Recombinant 2 (Figure 3.9C, lanes 2, 7 and 12, marked by 
asterisks) was selected for further strain construction (PGY1).  The sizes of all three PCR 
products from strain PGY1 corresponded with the expected sizes based upon the sequence 
(Figure 3.9B). It is unknown whether the homologous recombination event occurred in both 
copies of leu2 in the diploid INVScI cells but it was certain that at least one copy of 
PGAL1TIF51A had been inserted onto the chromosome at the leu2 locus. It was expected that a 
single copy would be able to drive the production of sufficient TIF51A in the subsequent 
disruption strains in medium containing galactose as the sole carbon source, to ensure 
viability. 
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Figure 3.9:  Construction and confirmation of the yeast strain, PGY1.  (A)  Schematic 
depicting the result of insertion of pPG13 into the leu2 locus of yeast strain INVSc1. (B) 
Schematic of the integrated PGAL1TIF51A with the functional LEU2 and the non-functional 
leu2 auxotrophic markers.  The positions of primers, AI2F, PG1F, PG6R and AI1R are 
indicated.  Sizes of amplified products with primer pairs PG1F and AI1R, AI2F and PG6R, as 
well as AI2F and AI1R are indicated as dotted lines below the map.  (C)  Analysis of PCR 
products by agarose gel electrophoresis: Lanes 1-5:  Amplification products obtained using 
primers PG1F and AI1R; Lane 6-10:  Amplification products obtained using primers AI2F 
and PG6R and Lanes 11-15: Amplification products obtained using primers AI2F and AI1R.  
Of the five samples, the second was chosen as the representative sample (marked *).  Lane 
16-18:  Amplification products obtained using primers AI2F and AI1R of the representative 
sample (*) (lane 16), of the original plasmid, pPG13 (+) (lane 17) and of INVScI DNA (-) 
(lane 18). The relative sizes of the molecular markers are indicated on the left of the gel in 
base pairs and the positions of the bands corresponding to the expected sizes of the DNA 
fragments are indicated on the right (arrows).   
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3.3.3b  The TIF51B-disrupted strain, PGY8 
The integration of PGAL1TIF51A into the leu2 locus on chromosome III enabled the successive 
disruption of TIF51A and TIF51B by the integrative transformation process developed by 
Alani et al., (1987).  This process involved the transformation of PGY1 cells with a linear 
DNA fragment carrying the TIF51B gene disrupted by a copy of URA3, flanked on either side 
by a hisG repeat (Figure 3.10A).  Next, cells in which the URA3 marker had been deleted via 
homologous recombination between the hisG repeats, were isolated by selecting for the Ura- 
phenotype by growth on agar containing 5-FOA (Figure 3.10B).  PCR analysis was used to 
confirm the initial disruption of the two copies of TIF51B and subsequent deletion of the 
URA3 marker (Figure 3.10C).  Of the 200 transformants screened, only 2 appeared to contain 
the TIF51B disruption cassette.  A 4.5 kbp PCR amplification product representing the 
disrupted TIF51B gene, was obtained from one transformant  as well as a 0.7 kbp fragment 
representing a wild-type TIF51B gene (Figure 3.10C, lane 1), suggesting that only one of the 
TIF51B genes were disrupted.   
 
PCR analysis of a second transformant (PGY7), resulted in only the 4.5 kbp fragment 
(represented in Figure 3.10C, lane 4) suggesting that both TIF51B genes had been disrupted. 
Further PCR analysis of this transformant (PGY7) confirmed that only the 4.5 kbp fragment 
was amplified with primers PG13F and PG14R (Figure 3.10D, lane 1), Amplification with 
PG13F and URA1 resulted in the production of an expected 2.8 kbp fragment (Figure 3.10D, 
lane 2).  These sizes corresponded with the control reactions using the pPG16 plasmid (Figure 
3.10D, lanes 4 and 5, respectively). 
 
The strain containing the double knockout of TIF51B, PGY7, was used to select for Ura- 
revertants by selecting for 5-FOA resistance.  Cells with a Ura- phenotype are resistant to 5-
FOA, while Ura+ cells are 5-FOA sensitive (Boeke et al., 1984; Umezu et al., 1971).  
Genomic DNA from 5-FOA resistant cells was subjected to PCR analysis to confirm the 
deletion of the URA3 marker as a result of homologous recombination between the hisG 
repeats (Figure 3.9D, lane 3).  The presence of a 1.8 kbp PCR product (representing a single 
copy of hisG) in Ura- cells as compared with the 4.5 kbp fragment corresponding to the hisG-
URA3-hisG fragment, confirmed the correct genotype (Figure 3.10D, lane 1) in strain PGY8, 
which was used to create the TIF51B-TIF51A knockout strain.   
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Figure 3.10:  Construction and confirmation of the disrupted TIF51B yeast strain, 
PGY8.  (A) Schematic of the TIF51B disruption fragment bearing URA3 flanked by hisG 
repeats.  Below the map (dotted lines) are the expected fragment sizes expected upon 
amplification with the indicated primer sets.  (B)  Schematic of the disrupted TIF51B 
following homologous recombination of the hisG repeats and subsequent reversal to Ura- 
phenotype.  (C)  1 % agarose gel with the amplified products of four potential transformants 
selected for the Ura+ phenotype using primers PG13F and PG14R (lanes 1-4).  (D) 1 % 
agarose gel with the amplified products using the primer sets indicated to confirm integration 
prior to 5-FOA treatment (PGY7) (Lanes 1 and 2): and post-5-FOA treatment (PGY8) (Lane 
3) of the selected transformant.  Lanes 4 and 5 represent the control reactions performed using 
the disruption vector pPG16.  The sizes of the molecular weight markers are shown on the left 
of the gels in kbp and the positions of the bands corresponding to the expected sizes of the 
DNA fragments are indicated on the right (arrows).  Primers used for the PCR amplifications 
are indicated above the lanes. 
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3.3.3c  The TIF51B-TIF51A-disrupted strain, PGY10 
To disrupt TIF51A, strain PGY8 was transformed with an Eco RI-digested DNA fragment 
from pPG14 carrying the TIF51A 5’ coding sequence disrupted by URA3, flanked on either 
side by a copy of hisG (Figure 3.11A).  As with the disruption of TIF51B, the hisG-URA3-
hisG cassette was inserted into TIF51A by homologous recombination between the 5' and 3' 
TIF51A flanking sequences.  Since disruption of both TIF51A loci results in loss of viability, 
Ura+ transformants were grown on agar plates containing galactose to induce expression of 
PGAL1-TIF51A inserted into the leu2 locus in this strain. Transformants were screened by PCR 
analysis to determine whether or not the hisG-URA3-hisG cassette had been inserted into the 
two TIF51A loci.  Of the 500 transformants screened, only 2 had at least one of the two 
TIF51A loci disrupted (Figure 3.11C, lanes 1 and 7).  These two transformants, were 
subjected to selection for reversion of the Ura+ phenotype by selecting for 5-FOA resistance.  
The Ura- colonies were analysed for the TIF51A disruption using PCR primers PG8F and 
PG6R.  It was discovered that only one of the two strains initially selected had  both copies of 
TIF51A disrupted, while the other still carried one wild-type copy of the gene (Figure 3.11D, 
lanes 1 and 2, respectively).   
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Figure 3.11:  Construction of the disrupted TIF51A yeast strain, PGY10.  (A) Schematic 
representation of the TIF51A disruption fragment bearing URA3 flanked by hisG repeats.  
Below the map (dotted lines) are the expected fragment sizes expected upon amplification 
with the indicated primer sets.  (B)  Schematic representation of the disrupted TIF51A 
following homologous recombination of the hisG repeats and subsequent reversal to Ura- 
phenotype.  (C)  1 % agarose gel with the amplified products of seven potential transformants 
selected for the Ura+ phenotype using the primer set indicated (lanes 1-7).  (D) 1 % agarose 
gel with the amplified products of two potential integrants, following reversion of the Ura+ 
phenotype.  The sizes of the molecular weight markers are shown on the left of the gels in 
kbp, the positions of the bands corresponding to the expected sizes of the DNA fragments are 
indicated on the right (arrows) and the primers used in the amplification are indicated above 
the lanes.  
 
Finally, a series of PCR amplifications were conducted to confirm the genotypes of the 
TIF51B-TIF51A knockout yeast strain.  To verify the presence of the LEU2::PGAL1-TIF51A 
fragment, DNA primers AI2F and AI1R, which correspond to sequences in PGAL1 and TCYC1 
were used to amplify a 1.2 kbp product containing the TIF51A coding sequence, from 
genomic DNA.  The PCR fragment was obtained from all strains excepting the wild type 
parental strain, INVSc1 (Figure 3.12A, lanes 2-4 vs. lane 1).  To confirm the disruption of 
TIF51B, a 1.8 kbp fragment, corresponding to the sequence flanked by primers PG13F and 
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PG14R, was amplified.  The PCR product was detected in strains PGY8 and PGY10, but not 
in strain INVSc1 or PGY5.  (Figure 3.12B, lanes 3 and 4).  The wild-type TIF51B gene 
(present in strains INVScI and PGY1) was represented by a 0.7 kbp fragment (Figure 3.12B, 
lanes 1 and 2).  Lastly, to verify the disruption of TIF51A, primers PG8F and PG6R, 
corresponding to the 5’ and 3’ regions of TIF51A, respectively, were used to amplify a 1.8 
kbp fragment indicating disruption of TIF51A by hisG from genomic DNA extracted from 
strain PGY10 (Figure 3.12C, lane 4).  As expected, a 0.7 kbp fragment, indicating the wild-
type sequence, was amplified from genomic DNA isolated from strains INVScI, PGY1 and 
PGY8 (Figure 3.12C, lanes 1-3). 
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Figure 3.12: Genotypic confirmation of the yeast strains used in this study using PCR.  
Genotypic confirmation of strains PGY1 (A), PGY8 (B) and PGY10 (C) by PCR analysis 
(left) using primers AI2F and AI1R, PG8F and PG6R, and PG13F and PG14R, respectively. 
On the right in each case is a corresponding representation of the wild-type strain (INVScI) 
and the integrated strains PGY1 (A), PGY8 (B) and PGY10 (C).  Indicated below each 
schematic (dotted lines) are the expected fragment sizes upon amplification with the indicated 
primers above the lanes. The sizes of the molecular weight markers are indicated on the left of 
the gels (in kbp) and the positions of the bands corresponding to the expected sizes of the 
DNA fragments are indicated on the right (arrows).   
 
3.3.4  Southern blot analysis of yeast genomic DNA 
Genomic DNA extracted from all the strains, including the wild-type, INVScI, was digested 
with Eco RV and probed with a radio-labelled RNA transcript that would recognise the 
coding sequences of both TIF51A and TIF51B.  The LEU2::PGAL1-TIF51A sequence, detected 
as a 1.6 kbp RE fragment, was present in strains PGY6, PGY8 and PGY10 (Figure 3.13A, 
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lanes 1-3, fragment “a”), but not in the parental strain, INVScI (Figure 3.13A, lane 4).  The 
disrupted TIF51B sequence was confirmed by the shifting of a 0.6 kbp fragment in strains 
INVSc1 and PGY6 (Figure 3.13A, lanes 3 and 4, fragment “b”) to a 0.8 kbp fragment in 
strains PGY8 and PGY10 (Figure 3.13A, lanes 1 and 2, fragment “c”).  The fragment 
indicated by the asterisk (*) is produced by the digestion of the 5’ TIF51B region, that is not 
as readily recognised by the probe, since the regions upstream of TIF51B and TIF51A are not 
well conserved.  Finally, the TIF51A knockout was confirmed by a shift from a band of 2.1 
kbp in strain INVSc1, PGY6 and PGY8 (Figure 3.13A, lanes 2-4, “d”) to 3 kbp in strain 
PGY10 (Figure 3.13A, lane 1, fragment “e”).  The restriction fragment sizes observed on the 
Southern blot corresponded with the sizes expected as indicated for each strain by the 
schematic maps in Figure 3.13B (“a”–“e”). 
 
 
 
Figure 3.13: Genotypic confirmation of yeast strains by Southern blot analysis.  (A) 
Southern Blot of Eco RV-digested genomic DNA extracted from all yeast strains probed with 
an RNA transcript binding the CDS of both TIF51A and TIF51B. The relative sizes of the 
molecular weight markers are indicated on the left of the blot, and the positions of the DNA 
fragments of interest (“a” – “e”) are indicated on the right (arrows).  (B) Schematic maps of 
the wild-type (INVScI), PGAL1TIF51A integrated (PGY1), TIF51B-disrupted (PGY8) and 
TIF51A-disrupted (PGY10) strains, indicating the expected sizes of the DNA fragments to 
which the RNA probe would bind below (dotted lines).   
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3.3.5  Phenotypic confirmation of knockout yeast strains 
With the genotypes of the yeast strains confirmed by both PCR and Southern blot analysis, it 
was necessary to determine the phenotypes of the yeast strains.  This was achieved by the 
growing the strains in complete medium containing galactose as the sole carbon source 
(YPGal), followed by growth on YP agar containing either galactose or glucose.  All the yeast 
strains grew on medium containing galactose as the carbon source due to the integration of 
PGAL1-TIF51A.  In contrast to the other strains, PGY10 did not grow on medium containing 
glucose, (Figure 3.14).  The loss of viability in the absence of galactose indicated both 
TIF51A and TIF51B loci were successfully disrupted, resulting in a strong phenotype in this 
diploid knockout, which corresponds to the phenotypes observed by Schnier et al., (1991) and 
Schwelberger et al., (1993). 
 
 
 
Figure 3.14:  Phenotypic analysis of the yeast strains used in this study.  Phenotypic 
analysis of the strains INVScI, PGY1, PGY8 and PGY10 (positioned on the top, left, bottom 
and right of the plates, respectively, as indicated) on complete medium containing either 
galactose (left) or glucose (right) as the sole carbon source.     
 
3.3.6  Protein profile analysis of the yeast strains using Western analysis 
Western analysis was conducted to examine the expression of eIF5A and eIF5Ab in all the 
yeast strains, using the anti-eIF5A antibodies (Section 3.3.2).  eIF5A (approximate MR of 20 
kDa) and eIF5Ab (approximate MR of 18 kDa) were present in the wild-type strain, INVScI 
(Figure 3.15 lane 1).  Although equivalent amounts of total protein were loaded in each lane 
(determined using Bradford’s assay and Coomassie staining), there appeared to be more 
eIF5A as compared with eIF5Ab in strain PGY6, consistent with the increase in expression as 
a result of the presence of LEU2::PGAL1-TIF51A (Figure 3.15, lane 2).   
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Figure 3.15: Protein profile analysis of strains used in this study.  Western analysis of 
eIF5A and eIF5Ab present in the total protein extracts of strains INVScI (lane 1), PGY1 (lane 
2), PGY8 (lane 3) and PGY10 (lane 4), grown in complete medium containing galactose as 
the carbon source.  The relative positions of eIF5A and eIF5Ab are indicated by arrows on the 
right, and the relative molecular weight markers are indicated on the left of the blot in kDa. 
 
As expected, the disruption of TIF51B (strain PGY8), resulted in the loss of eIF5Ab in protein 
extracts (Figure 3.15, lane 3). Upon further disruption of TIF51A (strain PGY10), a reduction 
in the levels of eIF5A suggested that only the eIF5A expressed from PGAL1 was detected 
(Figure 3.15, lane 4).   
 
3.3.7  Complementation of PGY10   
To test the functionality of the knockout strain PGY10, serial dilutions of washed cells 
transformed with either pYES2 (vector) or pPG10 (bearing TIF51A under the control of its 
endogenous promoter) were plated onto SMM (supplemented with histidine and tryptophan) 
agar plates containing either galactose or glucose as the carbon source.  Cells transformed 
with either pYES2 (-) or pPG10 (+) grew on medium containing galactose as the sole carbon 
source, due to the presence of the LEU2::PGAL1-TIF51A on the chromosome (Figure 3.16 
left).  Cells transformed with pYES2 (empty vector) exhibited a lethal phenotype on plates 
containing glucose, but complementation of growth was observed for cells transformed with 
pPG10 (Figure 3.16 right). 
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Figure 3.16:  Complementation of PGY10 growth by exogenously-supplied eIF5A. Serial 
dilutions of strain PGY10 transformed with either pYES2 (-) or with pPG10 (+) plated onto 
SMM containing galactose (left) or glucose (right).  A non-lethal phenotype of PGY10 is 
observed on galactose while a lethal phenotype is observed on glucose (-) which is reversed 
upon the addition of plasmid borne eIF5A (+) from the pPG10 plasmid.   
 
3.3.8 Assay for biological function of His-eIF5A and eIF5A-His 
Next, yeast strain PGY10 was used for complementation assays to determine whether an 
amino or carboxyl terminal 6 x His tag affected the biological function of eIF5A.  Plasmids 
pPG10 (expressing wild-type TIF51A under the control of its endogenous promoter), pPG20 
(His-TIF51A preceded by the endogenous promoter), pPG10-His (TIF51A-His preceded by 
the endogenous promoter) and pYES2 (no TIF51A) were transformed into PGY10 cells.  
Following growth in galactose, the transformants were diluted and plated onto medium 
containing either glucose or galactose.  Cells expressing the wild type TIF51A were able to 
grow on glucose medium while those containing the vector, pYES2 were not viable (Figure 
5.3).  Cells expressing His-eIF5A  or eIF5A-His were equally able to grow on glucose 
medium, indicating that the presence of the 6 x His tag on either terminus of eIF5A was not 
interfering with the function of the protein.  Thus any biochemical data derived from the 
following studies using His-eIF5A or eIF5A-His will be derived from functional protein. 
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Figure 3.17:  Functional complementation assays to determine the biological activity of 
His-eIF5A.  Five-fold serial dilutions of PGY10 cells transformed with either pPG10 
(eIF5A), pPG20 (His-eIF5A), pPG10-His (eIF5A-His) or with pYES2 (-) and plated on 
medium containing either galactose (left) or glucose (right) as the sole carbon source. 
 
3.4 Conclusions 
The first of the objectives for this chapter was to raise eIF5A-specific polyclonal antibodies 
which could be used for detecting eIF5A and eIF5Ab.  Following pre-absorption to remove 
non-specific antibodies, the substantially diluted antiserum was able to detect as little as 7.5ng 
of purified eIF5A-His, which indicates that the antiserum would be useful in detecting low 
quantities of eIF5A and eIF5Ab. The second objective was to develop a yeast experimental 
system that would enable the functional and biochemical characterisation of eIF5A.  This 
objective was partially accomplished by constructing a yeast strain, PGY10 through the 
successive disruption of TIF51A and TIF51B and insertion of PGAL1TIF51A onto the 
chromosome, such that cells grown in medium containing galactose as the carbon source 
would remain viable.   However, a lethal phenotype was observed for PGY10 cells grown in 
medium containing glucose which could be rescued by exogenously-supplied eIF5A. This 
experimental system was used in subsequent experiments to explore functional and 
biochemical characterisation of eIF5A.   
 
Although it might have been easier and probably a more practical genetic approach to have 
used a haploid yeast strain for the construction of a TIF51A/TIF51B-knockout with a 
phenotype in glucose, the diploid strain PGY10 does potentially offer advantages in that the 
starting INVScI strain was originally designed as a fast-growing expression strain to be used 
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in conjunction with the pYES2 plasmid system (Invitrogen). This allows for the expression of 
wild-type and mutant proteins from pYES2-derived plasmids (to be discussed in Chapter 4).  
And lastly, although it proved to be an inefficient system to develop, with an integrative 
transformation frequency as low as 0.2 %, it was still possible to construct a homozygous 
diploid yeast strain with a lethal disruption in both copies of the TIF51A and TIF51B genes 
that displays a lethal phenotype in glucose. 
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Chapter 4:  Biochemical characterisation of recombinant eIF5A   
 
4.1 Introduction 
The main aim of the experiments described in this chapter was to characterise recombinant 
eIF5A.  Since current information about the structure of eIF5A has been derived from the 
recombinant protein purified from E. coli cells (Kim et al., 1998; Peat et al., 1998; Yao et al., 
2003; Sun et al., 2005), it was decided to use this experimental system developed to produce 
His-tagged eIF5A (Chapter 3, Section 3.2.6).  Gel filtration, native PAGE and cross-linking 
studies were then conducted to determine the oligomeric status of the native, purified protein.  
 
4.2 Materials and Methods 
4.2.1 Strains, culture conditions and recombinant techniques 
As in Section 3.2.1, recombinant plasmids were hosted in E. coli DH5α while heterologous 
expression of eIF5A was carried out in E. coli BL21 (DE3) cells.  E. coli cells were grown in 
LB medium and competent cells were prepared using the method of Hanahan (1985) 
(Appendix B).  Recombinant plasmid DNA was isolated from E. coli DH5α cells either using 
the methods described in Section 3.2.2.  The integrity of all PCR products and recombinant 
plasmids resulting from the cloning of oligonucleotides or site-directed mutagenesis was 
routinely determined by DNA sequencing as in Section 3.2.2. The sequences of all primers 
used in this chapter are listed in Appendix C.  
 
4.2.2 Construction of E. coli expression vector pPG8 
Primers PG5F and PG6R, introducing flanking Nde I and Bam HI sites, were used to amplify 
the TIF51A ORF from INVScI genomic DNA (as isolated in Section 3.2.3).  The PCR 
product was ligated into the pGEM T-Easy vector (pPG7) The TIF51A gene was then excised 
from pPG7 by digestion with Nde I and Bam HI and inserted into the Nde I and Bam HI sites 
of expression vector pIVEX2.4b (Roche), which encodes an N-terminal His-tag preceded by 
an AUG (start) codon followed by a Nde I site.  The expression vector, pPG8 (Figure 4.1), 
which contained a copy of TIF51A fused to a His-tag at its amino terminal end, was used in 
the over-expression of His-eIF5A. 
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Figure 4.1:  E. coli His-eIF5A expression vector, pPG8.  Schematic representation of the 
T7-based expression vector pPG8, encoding an N-terminal His-tagged eIF5A.  The vector 
bears the β-lactamase gene encoding ampicillin resistance (AmpR) and an E. coli origin of 
replication (ori).  The binding sites for sequencing primers T7F and T7T, flanking the 5’ 
region of the T7 RNA polymerase and the 3’ end of the TIF51A ORF, respectively, are also 
indicated. 
 
4.2.3 Expression and purification of His-eIF5A 
Expression of His-eIF5A in E. coli was performed as described in Section 3.2.5.  Cell lysates 
were prepared by sonication (Section 3.2.5) before being subjected to nickel affinity 
chromatography using the ÄKTA 900 FPLC series (Amersham Biosciences) system (His-
Trap columns). The native purification procedure (according to the Qiagen 5 ml His-Trap 
recommended protocol, Appendix K) was followed for the purification of His-eIF5A with an 
increase in the imidazole concentration from 0-500 mM.  The eluted fractions (500 µl) were 
analysed by reading the absorbance at OD280 nm and then by SDS-PAGE.  Fractions containing 
His-eIF5A protein were pooled and dialysed against a buffer containing 100 mM Tris-HCl pH 
7.5, 100 mM NaCl and concentrated using Amicon® Ultr-15 centrifugal filter units 
(Millipore) to the desired concentration.  Finally, protein concentrations were determined 
using the Bradford’s Assay (Bradford, 1976) and Abs 28 0nm readings.  
 
4.2.4 Site directed mutagenesis of His-eIF5A 
Primer pair PG36 and PG37 (Appendix C) was used to generate mutant pPG8-C39S using 
site-directed mutagenesis (QuikChange Site-directed Mutagenesis kit, Stratagene).  The bases 
encoding the Cys 39 residue within the TIF51A gene were altered to encode serine (C39S), 
while also removing a Hinc II site.  Similarly, primer pair PG34 and PG35 (Appendix C) was 
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used to generate pPG8-C23S that encodes a serine residue at Cys 23 (C23S) in eIF5A.  
Primers PG1F and PG6R (Appendix C) were used to determine the DNA sequence of mutated 
TIF51A genes to confirm the presence of the appropriate C39S or C23S mutation.  Expression 
and purification of the mutant His-eIF5A proteins was performed as in Section 4.2.3. 
 
4.2.5 Gel filtration and native PAGE 
Gel filtration was performed using a Tricorn 10/30 column (Amersham Biosciences) packed 
with Superdex 200 pg matrix according to the manufacturer’s recommendations.  The volume 
of the packed column was determined to be 27.5 ml with a 14 900 theoretical plate number 
per metre and a peak symmetry of 0.95 as determined from the manufacturer’s recommended 
acetone test. The column was calibrated using 2 mg/ml each of Myoglobin, Carbonic 
anhydrase, Ovalbumin and Bovine serum albumin proteins (Sigma). Gel filtration of all 
protein samples was performed with 100 mM Tris-HCl, pH 7.5, 100 mM NaCl buffer (except 
for high salt testing that made use of a buffer containing 100 mM Tris-HCl, pH 7.5, 500 mM 
NaCl).    
 
Either 100 µl or 200 µl loops were used for the injection of protein and eluted protein 
fractions were analysed by readings at OD280 nm.  Native PAGE (Appendix E) analysis 
involved the electrophoresis of protein samples, resuspended in non-reducing tracking buffer 
(Appendix E), using a 10 % continuous polyacrylamide gel and resolving at 150 V for a 
period of 50 minutes, followed by staining with Coomassie stain.   
  
4.2.6 Chemical treatment of His-eIF5A with glutaraldehyde and dithiothreitol (DTT) 
Chemical cross-linking of His-eIF5A was performed by adding glutaraldehyde (0-2 % final 
concentration in 0.5 % increments) (Sigma) to purified protein (2 mg/ml) in a final volume of 
30 µl buffer containing 50 mM Tris-HCl, pH 7.5, 50 mM NaCl and 1 mM EDTA.  The 
mixture was incubated at room temperature for 2 minutes before adding 10 µl of 1 M Tris-
HCl, pH 8.0, to stop the reaction.  Glutaraldehyde-treated protein was then resolved by SDS-
PAGE and stained with Coomassie stain.  Reducing conditions were obtained by adding DTT 
(Sigma) to a final concentration of 1 mM to approximately 2 mg/ml purified His-eIF5A (in a 
final volume of 100 µl) for a period of 15 minutes at room temperature, and then analysed by 
gel filtration and native PAGE. 
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4.3 Results and Discussion 
4.3.1 Purification of native His-eIF5A  
In reports in the literature, structural characterisation of eIF5A has been largely performed on 
recombinant protein with an engineered fusion tag (predominantly His-tags) on the N-
terminus (Kim et al., 1998; Peat et al., 1998; Yao et al., 2003; Sun et al., 2005).  Accordingly 
the vector, pPG8, was constructed to facilitate the expression of His-eIF5A (as opposed to 
eIF5A-His in the previous chapter).  His-eIF5A was over-expressed in E. coli BL21 (DE3) 
cells and the protein was then purified from cell lysates using a 5 ml His-Trap column.  The 
cell-free lysates (CL), the flow-through (FT) following binding to the column as well as the 
eluting fractions (E) absorbing in the 280 nm range were then analysed by SDS-PAGE.  His-
eIF5A protein present in the CL fraction (Figure 4.2 lane 1), was not observed in the FT 
fraction (Figure 4.2 lane 2) following the binding step, indicating that complete binding to the 
column of the His-tagged proteins had occurred.  Eluted fractions, E40-E65 (Figure 4.2 lanes 
4-9), corresponding to a 250-300 mM imidazole concentration, contained relatively pure 
quantities of His-eIF5A, with an apparent molecular weight of about 19 kDa.  Co-eluting with 
His-eIF5A were small amounts of a protein approximately 43 kDa in size (Figure 4.2 lanes 7-
9). The elution fractions containing His-eIF5A were pooled, resulting in a total of   20 ml of 
purified protein that was dialysed against 100 mM Tris-HCl (pH 7.5), 50 mM NaCl and 
concentrated to 22 mg/ml (Figure 4.2 lane 10).  The co-eluted 43 kDa protein represented a 
minor portion of the total yield of His-eIF5A.  
  
 
 
Figure 4.2:  Purification of His-eIF5A from E. coli.  PAGE analysis of the fractions 
collected during the purification of His-eIF5A from E. coli.  Lane 1: The cell-free lysate (CL) 
obtained by the over-expression of His-eIF5A; Lane 2: The flow-through (FT) obtained 
following binding of the tagged protein to the His-Trap column; Lanes 3-9:     The elution 
fractions collected with increasing levels of imidazole; and Lane 10: Purified His-eIF5A 
following dialysis and concentration.  The sizes of the molecular weight markers are indicated 
in kDa and the position of His-eIF5A is shown.   
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4.3.2 Oligomeric analysis of His-eIF5A  
Gel filtration (size-exclusion chromatography) and native (non-reducing) PAGE were used to 
determine the oligomeric state of the purified His-eIF5A. An integrated elution volume of 
16.9 ml, corresponding to a protein of approximately 37 kDa in size, was obtained following 
gel filtration (Figure 4.3).  Since the apparent molecular weight of the reduced form of His-
eIF5A was determined to be about 19 kDa, (Figure 4.2), the gel filtration data suggested that 
the protein exists as a dimer under non-reducing conditions.  Native PAGE analysis showed 
that His-eIF5A resolved as two species; the protein at higher mobility was attributed to the 
dimeric form of eIF5A, while the lower order species probably represents the monomeric 
form (Figure 4.3 inset).  
 
 
 
Figure 4.3:  Oligomeric state of His-eIF5A as determined by size exclusion 
chromatography and native PAGE.  Chromatogram obtained following gel filtration or 
native PAGE analysis (inset) of purified His-eIF5A.  The sizes of the protein standards are 
represented by triangles, corresponding to Myoglobin (18 kDa), Carbonic anhydrase (29 
kDa), Ovalbumin (43 kDa) and Bovine serum albumin (67 kDa). 
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4.3.3 Capturing the oligomers of eIF5A 
To confirm that the higher order species observed in the previous experiment could be a 
dimer, chemical cross-linking of His-eIF5A with glutaraldehyde, which is commonly used as 
a small inter- and intra-molecular cross-linker, was employed.  The process of this cross-
linking is induced by an initial reaction of glutaraldehyde with amine groups within close 
molecular contacts (Cheung & Nimni, 1982; van der Spuy et al., 2001).  Varying 
concentrations of glutaraldehyde (from 0 – 2 % in increments of 0.5 %) were used to capture 
the oligomeric states of His-eIF5A.  SDS-PAGE analysis of the cross-linked protein samples 
at each of the glutaraldehyde concentrations indicated that His-eIF5A has the ability to exist 
in a monomeric (approximately 20 kDa), dimeric (approximately 40 kDa) or in a higher order 
state (approximately 55 kDa) (Figure 4.4).  This result provided evidence that the species 
migrating at a higher mobility following native PAGE analysis (Figure 4.3 inset), and the 
protein eluting at approximately 37 kDa eluted by gel filtration analysis was a dimeric form of 
His-eIF5A.  
  
 
 
Figure 4.4:  Cross-linking of His-eIF5A with glutaraldehyde.  Purified His-eIF5A from E. 
coli was subjected to varying concentrations of glutaraldehyde (from 0 to 2 %) and cross-
linked products were analysed by SDS-PAGE.  The relative positions of the monomeric, 
dimeric and higher order states of the protein are indicated on the right, while the sizes of the 
molecular weight marker are shown on the left. 
 
4.3.4 Determination of His-eIF5A ionic interactions 
To determine whether the various oligomeric states of the His-eIF5A protein are as a result of 
ionic interactions, high salt concentrations (500 mM NaCl) were used during gel filtration of 
His-eIF5A.  The reasoning was that if ionic interactions were responsible for oligomerisation, 
then these interactions would be disrupted by an elution buffer with high ionic strength. No 
visible disruption of the His-eIF5A dimeric species was observed following gel filtration of 
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His-eIF5A under high salt conditions (Figure 4.5), with the original integrated elution volume 
of 16.9 ml being retained.  This result suggested that stronger molecular force was at play in 
holding the dimeric and potential higher conformations of His-eIF5A together.  
      
 
 
Figure 4.5: Effect of ionic strength on the dimeric state of His-eIF5A.  Chromatogram 
obtained from the gel filtration of His-eIF5A using a high salt buffer or a low salt buffer.  
Calibration of the column was achieved using Myoglobin (18 kDa), Carbonic anhydrase (29 
kDa), Ovalbumin (43 kDa) and Bovine serum albumin (67 kDa) (indicated by triangles). 
  
4.3.5 Independence of dimerisation on protein concentration  
To address the possibility that the dimeric state of His-eIF5A was the result of concentration-
dependent aggregation, high (greater than 2 mg/ml) and low (less that 500 µg/ml) 
concentrations of His-eIF5A were analysed by gel filtration. The results revealed that dilution 
of His-eIF5A did not affect the presence of the dimeric state (Figure 4.6) with an integrated 
elution volume of 16.9 ml, corresponding to a protein of about 37 kDa in size.  The possibility 
of aggregation in a concentration-dependent manner was thus excluded as no apparent shift 
from the dimeric state was observed.  Also observed was a small protein peak in the low salt 
sample eluting near the void volume of 27 ml (approximately smaller than 14 kDa in size) 
which was attributed to a common His-eIF5A proteolytic product present in the protein 
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sample prior to gel filtration.  This proteolytic product has also observed by Schwelberger et 
al. (1993), Kang et al. (1993) and Valentini et al. (2002).   
 
 
 
Figure 4.6:  The concentration-independence of the dimeric state of His-eIF5A.  Gel 
filtration profiles obtained for high and low concentrations of His-eIF5A protein.  The 
triangles indicate the relative sizes of standard proteins Myoglobin (18 kDa), Carbonic 
anhydrase (29 kDa), Ovalbumin (43 kDa) and Bovine serum albumin (67 kDa). 
 
4.3.6 Exposure of His-eIF5A to reducing agents and the role of Cys 39 
To investigate whether disulphide bridging might be responsible for the dimeric state of His-
eIF5A, protein samples were treated with the strong, specific reducing agent, DTT and 
subjected to gel filtration and native PAGE analysis.  Interestingly, the dimeric state of the 
protein was disrupted by the addition of DTT, shifting the integrated elution volume from the 
previously-observed 16.9 ml to 23.07 ml, equivalent to the monomeric size of approximately 
18 kDa (Figure 4.7).  Native PAGE analysis showed the presence of only the monomeric form 
following the addition of DTT as opposed to dimeric and monomeric forms in untreated 
protein samples (Figure 4.7 inset). A similar shift from the dimeric state was observed 
following native PAGE analysis of His-eIF5A treated with 1 mM β-mercaptoethanol (data not 
shown).  These results suggested that cysteine, methionine, serine and threonine residues in 
His-eIF5A might be important for the structural integrity of the dimer, either by forming intra- 
or inter-subunit disulphide bonds.      
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Figure 4.7:  Effect of reducing agents on the dimeric state of eIF5A. Gel filtrations 
profiles of His-eIF5A in the presence and absence of DTT-treatment.  Inset:  Native PAGE 
analysis of His-eIF5A in the presence (lane 1) and absence (lane 2) of DTT.  Proteins 
Myoglobin (18 kDa), Carbonic anhydrase (29 kDa), Ovalbumin (43 kDa) and Bovine serum 
albumin (67 kDa) were used to calibrate the column (represented by triangles).  
 
Since the yeast TIF51A gene encodes only two cysteine residues (present at positions Cys 23 
and Cys 39 near the N-terminus of the eIF5A protein), it was decided to investigate whether 
these residues were important for dimerisation of eIF5A, perhaps by the formation of 
disulphide bridges.  With this in mind, the cysteine 39 residue was chosen as the most likely 
candidate because it is highly conserved among the eukaryotic and archaeal homologues of 
eIF5A.  To test this hypothesis, plasmid pPG8-C39S, in which Cys 39 has been substituted 
with a serine residue, was used for the expression of mutant protein His-eIF5A-C39S.  The 
mutant protein showed a similar Ni-affinity purification profile to that obtained for native His-
eIF5A (in Section 4.3.1, Figure 4.2) and was dialysed and concentrated to 2 mg/ml.   
 
Analysis by gel filtration revealed that the His-eIF5A-C39S protein (C39S) eluted 
predominantly as the monomeric form (Figure 4.8), which contrasted to the predominant 
dimeric form observed for His-eIF5A (WT).  This was supported by the data obtained from 
native PAGE analysis (Figure 4.8 inset).  The results showed that the Cys 39 residue is critical 
for stabilising the eIF5A dimer formed by protein purified from E. coli.  The appearance of 
minor, indistinct higher molecular weight protein peaks (greater than 67 kDa in size) 
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indicated that the destabilisation of His-eIF5A may also have led to some aggregation.  The 
expression of His-eIF5A-C23S, with Cys 23 substituted by a serine residue, was too poor to 
collect enough protein to continue with a similar investigation. 
 
     
 
Figure 4.8:  Effect of the C39S mutation on the dimeric state of His-eIF5A.  Gel filtration 
of His-eIF5A (WT) and His-eIF5A-C39S (C39S) mutant proteins produced in E. coli.  Inset: 
Migration of His-eIF5A (WT, lane 1) and His-eIF5A-C39S (C39S, lane 2) as resolved by 
native PAGE.  The positions of the calibration proteins, Myoglobin (18 kDa), Carbonic 
anhydrase (29 kDa), Ovalbumin (43 kDa) and Bovine serum albumin (67 kDa) are indicated 
by triangles. 
 
4.4 Conclusions 
Although not shown, the same experiments were conducted on eIF5A with an engineered C-
terminal His-tag to eliminate the possibility of involvement in the N-terminal His tag in 
dimerisation of eIF5A.  In all cases, the results of these experiments with eIF5A-His were 
consistent with those obtained for eIF5A with the N-terminal His tag.  This indicated that the 
His-tag, whether engineered upstream or downstream of the TIF51A ORF, was unlikely to be 
interfering with the folding of the protein during these analyses. 
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The biochemical analyses of heterologously-expressed eIF5A described in this chapter reveals 
that native eIF5A exists predominantly as a dimer in solution.  This is in agreement with the 
finding by Chung et al., (1991) who proposed that mammalian eIF5A can exist in a 
monomeric, dimeric and trimeric form.  The dimeric form or His-eIF5A was retained under 
high salt conditions, indicating that stabilisation of the dimer was not due to ionic interactions.  
The observation that addition of DTT and that mutant His-eIF5A-C39S exists as a monomer 
indicates that eIF5A probably undergoes a redox-controlled structural transition, involving 
Cys 39.  The crystallisation procedures of heterologously-produced eIF5A and aIF5A 
involved the addition of a reducing agent, and this explains why the crystal structures of 
eIF5A and its homologues were solved in the monomeric form (Kim et al., 1998; Peat et al., 
1998; Yao et al., 2003; Sun et al., 2005).  The possibility that the dimer is stabilised by intra- 
or inter-subunit disulphide bridging was reinforced by the observation that His-eIF5A, under 
reducing conditions, was monomerised.  Thus dimerisation of eIF5A expressed in E. coli is 
dependent on the oxidative state and the presence of the highly conserved cysteine residue.  
Whether or not this highly conserved residue is also important in the function of eIF5A in its 
native host, yeast, is one of the topics covered in the following chapters.   
 
Although E. coli is the most widely used heterologous expression host, it has limitations in 
that no post-translational modification can take place.  The biological function of eIF5A 
requires the presence of hypusine (Park et al., 1989) raising the question of whether or not 
hypusine plays a role in determining the oligomeric state of eIF5A.  The next chapter 
describes the results of a similar investigation into the oligomeric state of hypusinated eIF5A 
produced via a homologous (yeast) expression system.  
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Chapter 5:  Functional and biochemical analysis of native eIF5A 
 
5.1 Introduction 
All the currently available structural information on eIF5A and its archaeal homologues has 
been derived from recombinant protein produced in E. coli.  Since eIF5A produced in E. coli 
is not hypusinated, these structures cannot account for how hypusine relates to the structure of 
the protein.  While HEX-1 is structurally related to eIF5A, it is not hypusinated, so the data 
derived from crystallographic studies on this protein provide no further clues as to the 
structural implications of the presence of hypusine.   
 
The in silico study described in Chapter 2 resulted in an homology model of yeast eIF5A 
based upon available data derived from the crystal structures of the L. mexicana and archaeal 
homologues.  Further modeling informed by the structure of the HEX-1 analogue predicted 
that eIF5A could exist in solution as one of three potential dimers (Section 2.3.6).  To test this 
hypothesis, His-tagged eIF5A was purified from E. coli and the oligomeric state of the native 
protein was characterised by gel filtration and native PAGE.  The results confirmed the 
presence of a dimer which was disrupted under reducing conditions, leading to the 
identification of Cys 39 as being important for the formation of the dimeric species (Section 
4.3.6).    
 
The aim of the research described in this chapter was to determine whether hypusinated 
eIF5A also exists as a dimer and if so, whether as in E. coli, dimerisation was dependent upon 
Cys 39.  The results revealed that hypusinated eIF5A (expressed in yeast) also exists as a 
dimer in solution but that dimerisation is dependent upon hypusination and RNA binding and 
not Cys 39. 
 
 
5.2 Materials and Methods 
5.2.1  Strains, culture conditions and recombinant DNA techniques 
Recombinant plasmids were hosted in E. coli DH5α cells (as in Section 3.2.1) while 
heterologous expression of eIF5A was carried out in E. coli BL21 (DE3) cells.  E. coli cells 
were grown in LB medium and competent cells were prepared using the method of Hanahan 
(1985) (Appendix B).  The methods described in Section 3.2.2 were used to isolate 
recombinant plasmid DNA from E. coli DH5α cells and the integrity of all PCR products and 
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recombinant plasmids resulting from the cloning of oligonucleotides or site-directed 
mutagenesis was routinely determined by DNA sequencing. 
 
5.2.2  Construction of yeast expression vector    
The hybrid alcohol dehydrogenase 2-glyceraldehyde-3-phosphate dehydrogenase 
(ADH2/GAPDH) promoter was amplified from plasmid pMT9 (Tomasicchio et al., 2007) 
using primers PG32F and PG33R (Appendix C) which introduce flanking Age I and Pvu II 
sites at the 5' and 3' ends of the promoter, respectively.  The PADH2/GAPDH fragment was then 
used to replace the GAL1 promoter in pPG20, using the same enzymes.  The resulting 
plasmid, pPG39 (Figure 5.1), was used for the over-expression of His-eIF5A in yeast cells.  
Primers AI2F and AI1R were used to confirm the correct sequence of the ADH2/GAPDH 
promoter and the TIF51A ORF in pPG39.  
 
 
 
Figure 5.1: The vector, pPG39, used for over-expression of His-eIF5A in yeast.  The 2µ-
based multicopy expression vector contains a TCYC1 transcriptional terminator, a β-lactamase 
gene encoding ampicillin resistance and a uracil auxotrophic marker.  The highly efficient 
dual-promoter system, PADH2/GAPDH is fused to the 5’ coding region of His-TIF51A (from 
pPG20).  Primers AI2F and AI1R were used to were used to confirm the correct sequence of 
the ADH2/GAPDH promoter and the TIF51A ORF.    
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5.2.3  Site-directed mutagenesis of His-eIF5A  
The procedure outlined in Chapter 4 (Section 4.2.4) was used to generate mutant eIF5A 
plasmids by site-directed mutagenesis. Tabulated below (Table 5.1) are the primer pairs used 
to introduce base substitutions into the TIF51A coding sequence to produce variants of pPG20 
(used in complementation assays), pPG39 (used for native eIF5A over-expression) and pPG8 
(used for heterologous expression in E. coli, from Section 4.2.2).   
 
Table 5.1:  Primers used to introduce base substitutions in TIF51A ORF.  Primer 
sequences are listed in Appendix C. 
 
Primers 
(sense & 
antisense 
respectively) 
Substitution Restriction 
site 
introduced 
Name of plasmid 
variant produced 
PG10a & PG10b Lysine 51 to Arginine 
(K51R) 
None pPG20-K51R 
pPG39-K51R 
pPG8-K51R 
PG36 & PG37 Cysteine 39 to Serine 
(C39S) 
Hinc II pPG20-C39S 
pPG39-C39S 
PG34 & PG35 Cysteine 23 to Serine 
(C23S) 
None pPG20-C23S 
pPG39-C23S 
 
5.2.4  His-eIF5A expression in yeast  
INVScI cells were transformed with the relevant plasmids and plated onto selective agar 
plates (SMM supplemented with leucine, tryptophan and histidine, Appendix A) containing    
2 % glucose.  Following patching onto fresh selective plates,, cells were inoculated into SMM 
broth (supplemented with leucine, tryptophan and histidine) and 0.01 % glucose at an     
OD600 nm of 0.05 and incubated with shaking at 28 oC for 36 hours.  The depletion of glucose 
results in the activation of PADH2/GAPDH (Cousens et al., 1987), resulting in the expression of 
His-eIF5A or the His-eIF5A mutants.  Cells were harvested at 500xg for 10 minutes and 
washed in sterile distilled water before being resuspended in lysis buffer (Section 3.2.6).  
Cells were then lysed using 0.1 g of glass beads per 2 OD600 nm units using a bead beater 
(bursts of 30 seconds on ice) for a total of 5 minutes.  Lysed cells were centrifuged at 500xg 
for 10 minutes and the supernatants were used for nickel affinity purification of His-eIF5A. 
 
5.2.5  Analysis of His-eIF5A and His-eIF5A mutants 
Expression and purification of His-eIF5A and His-eIF5A mutants in E. coli, was performed as 
described in Section 4.2.3.  Homologously-expressed His-eIF5A and mutant His-eIF5A  were 
purified using the native purification procedure outlined in Section 4.2.3. The same methods 
from Sections 4.2.5 were used for analysis of proteins by gel filtration and native PAGE.  
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Proteins were subjected to glutaraldehyde and DTT treatment of protein as in Section 4.2.6.  
RNase (1 µM final concentration) (Merck) was added to 100 µl of purified proteins   (2 
mg/ml) and digested at 37 oC for a period of either 10 or 20 minutes, before analyzing by gel 
filtration and native PAGE.  Proteins were re-purified following RNase digestion as above, 
using Qiagen Ni-NTA spin columns (as in Section 3.2.6).  The protein extraction protocol and 
Western analysis of His-eIF5A was performed as in Section 3.2.7.  
 
5.3 Results and Discussion 
5.3.1  Purification of native His-eIF5A from yeast 
To produce sufficient quantities of purified hypusinated His-eIF5A to allow for further 
biochemical analyses, His-eIF5A was over-expressed in INVScI cells transformed with 
pPG39 in which the GAL1 promoter has been replaced with the hybrid ADH2-GAPDH 
promoter which supports several orders of magnitude higher levels of expression than PGAL1.  
The His-eIF5A was then purified from the cell lysates using a 5 ml His-Trap column 
(Amersham Biosciences) under native purification conditions.  The cell-free lysates (CL), the 
flow-through (FT) following binding to the column as well as the eluting fractions (E) 
absorbing in the 280 nm range were analysed by SDS-PAGE.  His-eIF5A protein visible in 
the CL fraction (Figure 5.2 lane 1) was not observed in the FT fraction (Figure 5.2 lane 2) 
following the binding step, indicating that complete binding to the column of the His-tagged 
proteins had occurred.  Eluted fractions E40-E60 (Figure 5.2 lanes 8-12), corresponding to a 
200-250 mM imidazole concentration, all contained relatively pure quantities of His-eIF5A 
obtained from yeast (resulting in a total of 20 ml of purified protein that was dialysed against 
100 mM Tris-HCl (pH 7.5), 50 mM NaCl and concentrated to 8 mg/ml (Figure 5.2 lane 13).   
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Figure 5.2:  Ni Affinity purification of His-eIF5A from yeast.  PAGE analysis of the 
fractions collected during the purification of His-eIF5A from yeast.  Over-expression of His-
eIF5A is observed in lane 1 containing the cell-free lysates (CL), while binding of the tagged 
protein to the His-Trap column is represented by the absence of the His-eIF5A protein in the 
flow-through fraction (FL) in lane 2.  Purified protein eluted from fractions E45-E60 (lanes 9-
12) was pooled, dialysed and concentrated.  Lane 13 contains the final purified His-eIF5A.  
The sizes of the molecular weight marker are indicated on the left in kDa and the position of 
His-eIF5A on the right.  
 
5.3.2  Oligomeric analysis of hypusinated His-eIF5A  
To confirm that functional (hypusinated) His-eIF5A existed in the same oligomeric state as 
the protein produced in E. coli (non-hypusinated) in Chapter 4 (Section 4.3.2), similar 
biochemical analyses of His-eIF5A obtained from yeast were conducted.  Gel filtration of 
His-eIF5A from yeast resulted in an integrated elution volume of 16.85 ml, which 
corresponded to a protein of approximately 40 kDa in size (Figure 5.3).  This suggested that 
His-eIF5A from yeast may exist as a dimer.  Native PAGE results (Figure 5.3 inset) showed 
that the protein migrated as a higher order and lower order species.  The protein at higher 
mobility was assumed to be the dimeric form of eIF5A, while the lower order species may 
represent the monomeric form.  
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Figure 5.3:  Oligomeric state of native, hypusinated His-eIF5A.  Chromatogram obtained 
following gel filtration and native PAGE (inset) of purified His-eIF5A obtained from yeast.  
The sizes of the protein standards are represented by triangles, corresponding to Myoglobin 
(18 kDa), Carbonic anhydrase (29 kDa), Ovalbumin (43 kDa) and Bovine serum albumin (67 
kDa).  
 
To confirm that the higher order species, migrating at approximately 40 kDa could be a dimer, 
chemical cross-linking using glutaraldehyde was performed to capture the various oligomeric 
states of His-eIF5A from yeast.  SDS-PAGE analysis of the cross-linked protein (Figure 5.4) 
indicated that hypusinated His-eIF5A has the ability to exist in a monomeric (approximately 
20 kDa), dimeric (approximately 40 kDa) or in a higher order state (approximately 58 kDa).  
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Figure 5.4:  Cross-linking of His-eIF5A using varying concentrations of glutaraldehyde.  
Purified His-eIF5A from yeast was subjected to varying concentrations of glutaraldehyde 
(from 0 to 2 %) and cross-linked products were analysed by SDS-PAGE.  The relative 
positions of the monomeric, dimeric and higher order states of the protein are indicated on the 
right, while the sizes of the molecular weight marker are shown on the left. 
 
Gel filtration of His-eIF5A under the high salt (500 mM NaCl) conditions showed no visible 
disruption of the dimeric (Figure 5.5), and the original integrated elution volume of 16.85 ml 
was retained (corresponding to a protein of about 40 kDa in size).  This result suggested that 
dimerisation of hypusinated His-eIF5A, similar to unhypusinated His-eIF5A purified from E. 
coli (Section 4.3.4), was not dependent on ionic interactions. 
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Figure 5.5: Effect of ionic strength on the oligomeric state of yeast His-eIF5A.  
Chromatograms obtained from the gel filtration of His-eIF5A purified from yeast using a high 
salt (500 mM NaCl) or low salt (100 mM NaCl) buffer.  The position of standard proteins 
Myoglobin (18 kDa), Carbonic anhydrase (29 kDa), Ovalbumin (43 kDa) and Bovine serum 
albumin (67 kDa) are indicated by triangles.  
  
Finally, to confirm that dimerisation of hypusinated eIF5A was independent of the protein 
concentration, high (greater than 2 mg/ml) and low (less than 500 µg/ml) concentrations of 
the protein were separated by gel filtration.  The resulting chromatogram revealed that 
dilution of hypusinated His-eIF5A had no effect on its dimeric state (Figure 5.6), with an 
integrated elution volume of 16.85 ml corresponding to a protein of about 40 kDa in size.  The 
possibility of aggregation in a concentration-dependent manner was therefore excluded as no 
apparent shift from the dimeric state was observed.  
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Figure 5.6:  The concentration-independence on the oligomeric state of yeast His-eIF5A.  
Gel filtration profiles obtained for varying concentrations of His-eIF5A produced in yeast.  
The triangles indicate the relative sizes of standard proteins Myoglobin (18 kDa), Carbonic 
anhydrase (29 kDa), Ovalbumin (43 kDa) and Bovine serum albumin (67 kDa).  
 
5.3.3  Effect of reducing agents on hypusinated His-eIF5A and the role of Cys 39 and      
Cys 23 
To investigate whether disulphide bridging, involving Cys 39 or Cys 23 (the only two 
cysteine residues in yeast eIF5A) also played a role in the dimerisation of hypusinated His-
eIF5A, the protein was treated with DTT (as in Section 4.2.6) and then analysed by gel 
filtration and native PAGE analysis.  The His-eIF5A dimer was disrupted by the addition of 
DTT (Figure 5.7).  The integrated elution volume of 16.85 ml (corresponding to 
approximately 40 kDa) shifted to 22.5 ml (corresponding to approximately 17 kDa) in the 
presence of DTT (Figure 5.7).  This reduction or destabilisation of the dimer to a monomeric 
state following DTT treatment was also detected by native PAGE analysis (Figure 5.7 inset).  
These results suggested that, as in E. coli, dimerisation of hypusinated His-eIF5A might be 
dependent upon the formation of disulphide bridges.       
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Figure 5.7:  Effect of DTT on the oligomeric state of hypusinated His-eIF5A. Gel 
filtrations profiles of yeast His-eIF5A proteins in the presence and absence of DTT-treatment.  
Inset:  Native PAGE analysis of His-eIF5A proteins in the absence (lane 2) and presence (lane 
1) of DTT.  Proteins Myoglobin (18 kDa), Carbonic anhydrase (29 kDa), Ovalbumin (43 kDa) 
and Bovine serum albumin (67 kDa) were used to calibrate the column (represented by 
triangles).  
 
Since the yeast TIF51A protein contains two cysteine residues (present at positions Cys 23 
and Cys 39, near the N-terminus of the eIF5A protein), it was logical to investigate whether 
these residues were important in stabilising dimerisation of hypusinated His-eIF5A.  With this 
in mind, the coding sequence of His-eIF5A in plasmid pPG20 was mutated at Cys 23 and at 
Cys 39 to encode serine residues (C23S and C39S).  The resulting complementation plasmids 
(pPG20-C23S and pPG20-C39S, respectively) were used in the transformation of PGY10 
cells to determine whether the functionality of mutant proteins.  Transformants were growth 
in YPGal broth and diluted before being plated onto medium containing either galactose or 
glucose to ascertain whether the C23S or the C39 mutations affected the ability to 
complement the lethal phenotype on glucose.  Both the C23S and the C39S mutations were 
able to complement the lethal phenotype (Figure 5.8), suggesting that these cysteine residues 
were not essential for the biological function of His-eIF5A.    
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Figure 5.8: Functional analysis of His-eIF5A mutants C23S and C39S.  Five-fold serial 
dilutions of PGY10 cells transformed with either pYES2 (-), pPG20 (+), pPG20-C23S or 
pPG20-C39S, plated onto medium containing either glucose (left) or galactose (right).  
 
The results of the complementation assay suggested that that (1) Cys39 and Cys 23 were not 
required for dimerisation of hypusinated His-eIF5A, or (2) that dimerisation of the protein 
was not required for function in yeast cells.  To investigate whether these mutant proteins 
were able to dimerise, the His-eIF5A-C39S and His-eIF5A-C23S proteins were over-
expressed and purified using Ni affinity chromatography, from yeast cells.  As observed in   
E. coli, expression levels of the His-eIF5A-C23S mutant were too low to continue with the 
biochemical analyses.  Analysis of hypusinated His-eIF5A-C39S by gel filtration and native 
PAGE revealed that like the wild-type, the C39S mutant protein retained its dimeric state 
(Figure 5.9 and inset).  This was in contrast to the result obtained in a similar experiment 
using His-eIF5A-C39S protein produced in E. coli which showed that this mutant protein was 
destabilised from its dimeric state and existed in a predominantly monomeric form (Section 
4.3.6, Figure 4.7).   
 
This result suggested that either the unhypusinated His-eIF5A purified from E. coli was using 
a different mechanism to dimerise.  Alternatively, the apparent dimerisation of the protein 
may be as a result of misfolding of the recombinant protein, which does not necessarily result 
in an insoluble aggregate, since the protein was determined to be soluble in Section 3.3.1.  
Misfolding of heterologously-produced eukaryotic proteins is frequently observed, but does 
not necessarily involve the production of insoluble aggregates and inclusion bodies (Georgiou 
& Valax, 1996; Baneyx & Mujacic, 2004; González-Montalbán et al., 2007).   The E. coli 
His-eIF5A dimer, consisting as it does of unhypusinated protein, could be self-associating via 
a mechanism involving Cys 39.  Importantly, this data showed that in yeast cells, dimerisation 
of hypusinated His-eIF5A is utilising other critical residues. 
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Figure 5.9:  Effect of the C39S mutation on the oligomeric state of yeast His-eIF5A.  Gel 
filtration and native PAGE analysis (inset) of His-eIF5A and His-eIF5A-C39S mutant protein 
produced yeast. The positions of the calibration proteins, Myoglobin (18 kDa), Carbonic 
anhydrase (29 kDa), Ovalbumin (43 kDa) and Bovine serum albumin (67 kDa) are indicated 
by triangles.  
 
5.3.4  Role of hypusine in the dimerisation of His-eIF5A in yeast cells 
The results in the previous section indicated that in yeast cells, dimerisation of His-eIF5A 
appeared to be mediated via a mechanism that was not dependent upon Cys39.  The major 
difference between the two experimental systems is that heterologously-produced (E. coli) 
His-eIF5A lacks the post-translational hypusine modification while homologously-produced 
HiseIF5A (yeast) undergoes hypusination at the highly conserved lysine residue (Lys 51).  
This raised the question of whether hypusination was required for the dimerisation of His-
eIF5A in yeast cells.  Accordingly the effect of a K51R mutation was investigated.  This 
lysine residue is critical in the function of the yeast eIF5A (Park et al., 1997), but it has not 
been ascertained what effect mutation of this lysine residue would have on the structural 
characteristics of the protein.  To this end, a pPG20-K51R mutant was constructed and 
complementation assays conducted to confirm that this mutation abolished biological function 
of the protein.  Serial dilutions of pPG20-K51R-transformed PGY10 cells were plated onto 
medium containing either glucose or galactose.  As expected, complementation of the lethal 
phenotype on glucose was not obtained, confirming the importance of Lys 51 in the 
functioning of eIF5A (Figure 5.10A). 
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Figure 5.10:  Functional analysis of His-eIF5A and its mutants K51R and C39S.  (A)  
Five-fold serial dilutions of PGY10 cells transformed with pYES2 (-), pPG20-K51R (K51R), 
pPG20-C39S (C39S), pPG20 (+) on medium containing either galactose (left) or glucose 
(right).  (B)  Western analysis of His-eIF5A protein extracts obtained from PGY10 cells 
transformed with the plasmids in (A) using anti-eIF5A antibodies. 
   
To rule out the possibility that the lack of complementation of the lethal phenotype in strain 
PGY10 with pPG20-K51R was as a result of the lack of protein expression, protein extracts 
were resolved by SDS-PAGE and subjected to Western analysis using anti-eIF5A antibodies.  
His-eIF5A-K51R, His-eIF5A-C39S and (wild-type) His-eIF5A were detected (Figure 5.10B 
lanes 2-4), confirming that they were all expressed in the cells and that the lack of 
complementation was due to the critical nature of Lys 51, rather than lack of protein 
expression.  Also observed was residual "endogenous" eIF5A resulting from expression of 
eIF5A from LEU2::PGAL-TIF51A (Section 3.2.8) in medium containing galactose, but was 
distinguishable from His-eIF5A, in that His-eIF5A resolved at a higher mobility (Figure 
5.10B).  This residual protein was clearly not sufficient to maintain viability of PGY10 cells.  
In addition, a degradation product of His-eIF5A was observed (Figure 5.10B, asterisk).  In 
protein extracts obtained from cells expressing no eIF5A (Figure 5.10B, lane 1), only the 
endogenous eIF5A was detected. 
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Next, the effect of the Lys 51 mutation on the oligomeric state of the protein was investigated 
using gel filtration and native PAGE analysis.  His-eIF5A-K51R mutant proteins were 
produced in yeast and E coli, using cells transformed with pPG39-K51R or pPG8-K51R.  The 
final purified protein concentrations were 3 mg/ml (yeast) and 4 mg/ml (E. coli).  The data 
revealed that the K51R mutant protein existed as a dimer in E. coli (Figure 5.11A) but as a 
monomer in yeast (Figure 5.11B).  This result strongly suggested that Lys 51 is not only 
important in the function of His-eIF5A, but also plays a structural role in the dimerisation of 
the protein.  Conversely, the Lys 51 residue plays no role in the dimerisation of unmodified 
His-eIF5A, and this further supports the argument that the dimer observed in heterologously-
produced His-eIF5A is an artifact associated with a misfolded protein.   
 
A loose connection between structure and function of His-eIF5A has thus been developed 
from this data:  Mutation of Lys 51 that impairs dimer formation abolishes the eIF5A activity, 
whereas mutation of Cys 39 affects neither dimerisation nor the activity.  From this it can be 
deduced that the function of eIF5A is dependent on the protein forming a dimeric structure.       
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Figure 5.11:  Effect of Lys 51 substitution on the oligomeric profiles of His-eIF5A.  Gel 
filtration profiles obtained from His-eIF5A and His-eIF5A-K51R produced in E. coli (A) or in 
yeast (B).  Insets:  Native PAGE analysis of His-eIF5A (lane 1) and His-eIF5A-K51R) 
mutants (lane 2).  The positions of the calibration proteins, Myoglobin (18 kDa), Carbonic 
anhydrase (29 kDa), Ovalbumin (43 kDa) and Bovine serum albumin (67 kDa) are indicated 
by triangles.  
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5.3.5 Role of RNA in the dimerisation of His-eIF5A 
Since it is known that hypusine is required for the binding of RNA (Xu & Chen, 2001; Jao & 
Chen, 2006), and that it was demonstrated here that Lys 51 (hypusine) is required for the 
dimerisation of eIF5A (Section 5.3.4), it was next decided to determine the effect on the 
oligomeric state of eIF5A in the absence of RNA. 
 
The His-eIF5A from E. coli and yeast were digested with RNase A for 10 to 20 minutes and 
the product analysed using gel filtration and native PAGE.  No change in the dimeric state of 
E. coli-produced His-eIF5A was observed following RNase digestion (Figure 5.12A and 
inset).  In contrast, there was a shift in the dimeric state to an intermediate state consisting of 
both monomers and dimers following RNase-treatment of hypusinated His-eIF5A  purified 
from yeast (Figure 5.12B, “+RNase”).  After 20 minutes of RNase-treatment, a complete shift 
to the monomeric form was observed (Figure 5.12B, “++RNase and inset).  This result 
indicated that hypusinated His-eIF5A protein is directly involved with RNA and the His-
eIF5A dimer is stabilised by the presence of both RNA and hypusine.  Since hypusine is 
required for RNA binding (Xu & Chen, 2001; Jao & Chen, 2006) this explains why the K51R 
mutant existed as a monomer in solution, because it would be unable to interact with RNA.  
Thus unmodified His-eIF5A produced in yeast, which cannot bind RNA, is unable to 
dimerise.  Furthermore, it been shown that eIF5A expressed in E. coli (unhypusinated) does 
not bind RNA, thus the presence of bound RNA may account for the observed difference in 
the integrated elution volumes of hypusinated His-eIF5A (yeast) (16.85 ml ~ 40 kDa) and 
unhypusinated His-eIF5A (E. coli) (16.9 ml ~ 38 kDa).   
 
The data suggests that the dimeric state of protein produced in E. coli is dependent on a 
different dimerisation mechanism which possibly involves disulphide-bridging or may be an 
artifact associated with the heterologous production of eukaryotic proteins, particularly those 
requiring post-translational modifications such as hypusination (Park et al., 1993; Park, 2006) 
and phosphorylation (Kang et al., 1993).    
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Figure 5.12:  Effect of RNase on the dimeric state of His-eIF5A.  (A)  Elution profile 
obtained following the gel filtration or native PAGE analysis of His-eIF5A produced in      E. 
coli before (“WT” and inset lane 2) and after (“+RNase” and inset lane 1) a 20 minute 
RNAse-treatment.  (B) Gel filtration and native PAGE analysis obtained for His-eIF5A 
produced in yeast prior to (“WT” and inset lane 2) and following RNase-treatment for 10 
minutes (“+RNase”) or 20 minutes (“++RNase” and inset lane 1).  The positions of the 
standard proteins Myoglobin (18 kDa), Carbonic anhydrase (29 kDa), Ovalbumin (43 kDa) 
and Bovine serum albumin (67 kDa) are represented on the chromatograms as triangles. 
 
Unhypusinated His-eIF5A (E. coli) and hypusinated His-eIF5A (yeast) are both susceptible to 
monomerisation or destabilisation upon treatment with DTT.  The data in Section 4.3.6 
suggested that unhypusinated His-eIF5A (E. coli) relied on the presence of Cys 39 to form a 
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dimer, which was not the case for His-eIF5A (yeast) (Section 4.3.3).  This can be explained 
by the observations that DTT, thought to be a specific reducing agent, can act as a general 
reducing agent, influencing the redox potential to effect changes in the global structure of the 
protein.  This often involves residues other than cysteine, such as serine, threonine and 
methionine residues (Alliegro, 2000; Salvador & Klein, 1999).  As a result, both hypusinated 
His-eIF5A (yeast) and unhypusinated His-eIF5A dimers are disrupted in the presence of DTT. 
 
5.3.6 His-eIF5A exists as a homodimer 
Finally, the question remained as to eliminate the possibility that the 37 kDa dimeric species 
was not due to His-eIF5A interacting with another cellular protein of similar size as opposed 
to existing as a homodimer.  Purified hypusinated His-eIF5A was treated with RNase to 
produce the monomeric form and then subjected to nickel-affinity chromatography.  The 
reasoning was that if His-eIF5A was interacting with another protein, then that protein would 
appear in the flow-through fraction during the purification, since it would not be His-tagged.  
The procedure was followed using SDS-PAGE analysis.  Purified (dimeric) His-eIF5A treated 
with RNase (Figure 5.13, lane 1) was passed through a Ni-NTA spin column (Qiagen).  The 
flow-through fraction (Figure 5.13, lane2) contained no visible unbound protein of similar 
size to His-eIF5A.  This ruled out the possibility that His-eIF5A interacted with an untagged 
cellular protein of similar size, and confirmed that eIF5A exists as a homodimer. 
 
 
 
Figure 5.13:  His-eIF5A exists as a homodimer.  SDS-PAGE analysis of purified His-
eIF5A fractions collected during nickel affinity purification following treatment with RNase.  
Lane1: RNase-treated purified His-eIF5A (+); Lane 2:  Flow through (FT) fraction collected 
following binding to the column; Lane 3:  Wash fraction (W); Lanes 4 and 5:  Eluted His-
eIF5A protein.    
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5.4 Conclusions 
The demonstration that hypusinated eIF5A exists as a dimer in solution is in agreement with 
an early finding by Chung et al. (1991) that proposed that mammalian eIF5A exists as 
monomers, dimers and trimers.  The data presented in this chapter also demonstrate that 
dimerisation is dependent upon RNA binding and not hypusination since treatment of the His-
eIF5A dimer with RNase destabilised the dimer releasing monomeric hypusinated His-eIF5A.   
 
While initial experiments with unhypusinated His-eIF5A indicated that the protein was 
dimeric (Section 4.3.2) several lines of evidence support the argument that the mechanism for 
dimerisation of protein produced in E. coli is different to that produced in yeast:   
 
(1) While both dimers are disrupted under reducing conditions, Cys 39 was required for 
dimerisation in E. coli but not in yeast.  This was attributed to the global reducing action of 
DTT acting on residues other than Cys 39 in hypusinated His-eIF5A (yeast), rather than 
specific action affecting Cys 39 in unhypusinated His-eIF5A (E. coli). 
  
(2) A K51R mutation had no effect on the E. coli dimer, while it resulted in the disruption of 
the dimeric protein purified from yeast.  This indicated that Lys 51, or hypusine, was aiding 
the dimerisation process in native His-eIF5A. 
 
(3) In yeast, the formation of the dimer is dependent upon RNA binding while there is no 
RNA binding required for dimerisation in E. coli.  This indicated too that the presence of 
hypusine allowed for RNA binding in His-eIF5A from yeast.  
 
Thus one must conclude that the apparent solubility of His-eIF5A produced in E. coli does not 
necessarily equate to correctly folded and functional protein, which could be due to the 
cytosolic environment in the E. coli cell (slightly more reducing environment) as compared 
with yeast (slightly more oxidizing environment) (Carmel-Harel & Storz, 2000).  An 
alternative explanation could be that hypusine and thus the presence of RNA, is important in 
ensuring the correct folding of the active protein.   
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This data raises concerns about the potential implications of misfolding of His-eIF5A 
expressed in E. coli which has been routinely used for crystallographic studies.  The crystal 
structures of aIF5A from the archaea and eIF5A from the protozoans could thus represent 
alternatively-folded proteins.  If this is so, then it is expected that the less ordered regions 
(such as the loop structure around the site of hypusination) are folded in a conformation 
different to that which was previously thought.  The presence of hypusine and RNA, resulting 
in a dimer, may effect additional conformational changes in the protein, as is expected when a 
protein binds any ligand.  The following chapter addresses the possibility of such 
conformational changes upon RNA binding. 
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Chapter 6:  General discussion and conclusions 
 
While there is a wealth of information on the biological function of eIF5A and the process of 
hypusination, information on the structural aspects of eIF5A in the literature is confined to 
archaeal homologues.  The structures of two Leishmania eIF5A were recently deposited on 
the database, but these, like the aIF5A structures shed no light on the structural role of 
hypusine since the crystals were derived from protein produced in E. coli.  The principal aim 
of the research described in this thesis was to address this knowledge gap by using yeast 
eIF5A to develop insight into the structure of eIF5A, particularly with respect to the role of 
hypusine and how this relates to its biological function.   
The approach was first to use available structural information derived from the Leishmania 
and archaeal homologues to derive a homology model of the yeast eIF5A.  Structural data 
from the HEX-1 analogue of eIF5A was then used to produce dimeric structural models.  
Second, a biochemical and functional analysis was carried out which demonstrated that 
hypusinated eIF5A exists as a homodimer in solution and that dimerisation is dependent upon 
hypusination and RNA binding.   
 
6.1 Homology modeling of eIF5A  
6.1.1 Models based on Leishmania and archaeal eIF5A homologues 
The possibility that an homology model of yeast eIF5A could be produced based on currently 
available structural data of the archaeal homologues was explored.  A comparison of the 
homology models based on the archaeal vs. Leishmania structures showed clearly that the 
archaeal homologues were poor templates for eIF5A homology models, mainly because of the 
relatively low sequence identity between aIF5A and eIF5A.  The model produced using the 
Leishmania eIF5A as a template was comparable with the human eIF5A model produced by 
Facchiano et al., (2001).  These structural differences are consistent with recent evidence that 
as aIF5As are functionally different to their eukaryotic counterparts.  In particular, aIF5As 
exhibit ribonucleolytic activity rather than RNA-binding activity and lack an N-terminal 
intracellular localisation signal that is functionally restricted to eIF5As (Wagner & Klug, 
2007; Parreiras-e-Silva et al., 2007).  Although recently, Cano et al. (2008) and Dias et al. 
(2008) demonstrated that truncated mutants of this N-terminal 10 amino acid extension in 
human and yeast eIF5A (not present in aIF5A) is able to complement the yeast tif51A 
knockout strain.  This implies that the N-terminal region is not functionally required.  
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Moreover the C-terminal α-helix is proposed to be an essential structural element in yeast 
eIF5A (Dias et al., 2008).    
 
Homology models of yeast eIF5A based on unpublished eIF5A homologues (L. mexicana and 
L. brasiliensis eIF5As) deposited on the Protein Data Bank not only produced models of 
greater confidence, but also revealed the presence of an α-helix in the C-terminal domain of 
eIF5A, unique to eukaryotes.  This helix was also predicted in the homology modeling of the 
human eIF5A (Costa-Neto et al., 2006), based on the L. brasiliensis eIF5A.  The presence of 
the α-helix was also predicted to occur on the C-terminal domain using the secondary 
structure prediction program JPred (Cuff & Barton, 1999).  Forming part of an 
oligonucleotide binding fold (Murzin, 1993, this study), this helix is potentially involved in 
the binding of specific mRNAs identified by Xu and Chen (2001) by the hypusinated form of 
the protein.  However, both domains of aIF5A, as well as the flexible linker region between 
the domains have been implicated by Kim et al., 1998; Peat et al., 1998 and Wagner & Klug, 
2007 as potential RNA binding sites, and the minimal region for biological activity of eIF5A 
includes the N- and C-terminal β-sheet core structures (Cano et al., 2008).  Whether this is the 
case for yeast eIF5A remains to be seen.  
 
6.1.2 Dimeric models of eIF5A based on HEX-1 
Since eIF5A and aIF5A were proposed to exist in a number of oligomeric states (Chung et al., 
1991; Wagner & Klug, 2007), potential dimer configurations, based on the interactions 
observed in homologues and analogues of eIF5A (aIF5As and HEX-1, respectively), were 
predicted.  The potential dimeric conformations (Types I, II and III) stabilised by salt 
bridging, extensive hydrogen bonding and possible intra-subunit disulphide bridging, 
provided a means to visualise potential yeast eIF5A dimers.  Of the three types of predicted 
dimer configurations, the most likely configuration is the Type II model (Figure 6.1).  This 
stable configuration potentially involves residues Lys 35, Ser 47, Gly 53, Thr 66 and Lys 69 
as well as Lys 51 (hypusine), and could create a loose “interlocking finger” formation in the 
loop region of the N-terminal domain (Figure 6.1 marked in red).  Cano et al., 2008 showed 
that mutations in residues Lys 47 and Gly 49 in human eIF5A (equivalent to Lys 48 and Gly 
50 in yeast eIF5A) result in the abolishment of growth in a yeast eIF5A null strain.  These 
critical residues are positioned in near proximity to those predicted here to be involved in 
dimerisation.  This strongly supports the argument that the highly-conserved residues in the 
loop region, including Lys 51 may be involved in dimerisation.  Given that hypusination 
extends the Lys 51 residue, it is possible that the reach is extended at the loop region, thus 
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allowing dimerisation.  In the absence of Lys 51 (hypusine), the reach required to create the 
“interlocking finger” or loose dimer may not be achieved.  Also, this configuration would 
create an aromatic groove in the centre of the dimer interfaces that could house an RNA 
molecule.  The ssRNA molecule represented in Figure 6.1, is loosely based on the structure of 
the RNA molecules found to associate with eIF5A and identified by Xu et al., 2004. Namely 
the represented mRNA molecule consists of more than 40 nucleotides, contains secondary 
structures such as hairpins, bulges and stem-and-loops. 
 
 
 
Figure 6.1:  Type II dimer model incorporating the factors though to be involved for the 
dimerisation of yeast eIF5A.  Space-fill representation of the predicted yeast eIF5A Type II 
dimer depicting the amino acid residues thought to be involved in dimerisation.  The residues 
in red represent those in the loop structure thought to be involved in interlocking the N-
terminal domain of each hypusinated monomer.  The residues in cyan represent those thought 
to be involved at the dimer interface, creating the hydrophobic pocket where ssRNA can bind.  
The figure was generated using Pymol (DeLano, 2002) and the hypusine residue was modeled 
using ACD/ChemSketch Freeware V.8.17.  The random RNA molecule was generated using 
the M-Fold program (Zuker, 2003).    
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6.1.3 Strengths and weaknesses of the dimeric models of eIF5A  
The dimer models provide an opportunity to identify amino acid residues that might be 
involved in the correct folding of the protein.  However, these models may not necessarily 
reflect the true contact sites of eIF5A, in that it is highly possible that several conformational 
changes can take place within the protein in vivo.  In particular, the effect of hypusine on the 
folding of the protein is unknown because all structures used as templates to generate the 
eIF5A homology model were solved using protein produced in E. coli which would be 
unhypusinated.  Structured regions of the protein (α-helices and β-sheets) are unlikely to be 
affected by conformational changes, while the variable loop regions, which are typified as 
being highly conserved throughout eIF5As, are unlikely to withstand positional variation 
during conformational change.  Attempts at modelling the highly conserved, but structurally 
variable loop region bearing the site of hypusination (Costa-Neto et al., 2006), show that a 
more structured form of the loop can be achieved in a hydrophobic environment.  Perhaps the 
extension of Lys 51 to hypusine results in a conformational change in the loop region such 
that it extends into the hydrophobic pocket created by the dimer, rather than the loop 
interacting with the hydrophobic core of DHS, as suggested by Costa-Neto et al., 2006.  
 
There is substantial evidence from this work to suggest that protein produced in E. coli is 
misfolded despite being soluble (discussed below in Section 6.2.2).  A further concern in 
extrapolating information from the models of the yeast eIF5A dimers is that the templates are 
based on monomeric homologues in the unhypusinated form, and do not incorporate the 
presence of RNA.  Thus the difficulty with interpreting the homology models is three-fold: (1) 
The current structural data is produced from protein produced in E. coli and is thus not 
hypusinated; (2) Hypusine is required for the binding of RNA and thus would also not be 
reflected in the model and (3) Dimerisation of the protein would almost certainly produce 
conformational changes in the protein.  Determination of these conformational changes can 
only be achieved by obtaining structural data of hypusinated eIF5A in the presence of RNA.   
 
6.2 Factors affecting dimerisation of native, eIF5A  
6.2.1 In yeast 
To test the hypothesis that eIF5A existed as a dimer in solution, extensive biochemical and 
functional analyses were carried out on yeast eIF5A (hypusinated).  It was shown that yeast 
eIF5A exists predominantly as a dimer in solution whether in its hypusinated form.  Higher 
order oligomeric states could artificially be achieved upon cross-linking, but this was not 
observed in the native protein.  This finding is supported by an early report that mammalian 
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eIF5A exists in a number of oligomeric states (Chung et al. 1991), and that the activity of 
aIF5A depends on its oligomeric state (Wagner & Klug, 2007).  eIF5A dimers were 
destabilised by treatment with the reducing agent, DTT.  DTT has been shown to act as a 
general reducing agent, influencing the redox potential to effect changes in the structure of the 
protein, often involving not only cysteine, but also serine, threonine and methionine residues 
(Alliegro, 2000; Salvador & Klein, 1999).  Cys 23 and Cys 39 are not required for the 
biological function of eIF5A and mutation of Cys39 does not affect dimerisation.  Thus it is 
likely that there are threonine, serine and/or methionine residues involved in stabilisation of 
the hypusinated dimer. 
 
Mutation of Lys 51 to Arg 51 (K51R) resulted in monomerisation of eIF5A.  It is known that 
Lys 51 is required for the function of eIF5A (Park et al., 1997, this study) and that hypusine is 
required for RNA binding, but there is no direct evidence for a function of hypusine in 
dimerisation.  However, the presence of RNA was found to the critical in the dimerisation of 
hypusinated eIF5A.  Xu & Chen (2001) showed that sequence-specific RNA binding is 
dependent on the presence of hypusine, but in the light of data presented in this thesis, it is 
now apparent that both RNA and the site of hypusination are required for dimerisation.  This 
leads to the following question:  Is the function (activity) of eIF5A dependent on its 
oligomeric state, as proposed for the Halobacterium sp.NRC-1 aIF5A (Wagner & Klug, 
2007)?  In other words, it could be that hypusine alone is not directly required for the function 
of eIF5A, but rather that hypusine plays a structural role to produce a loose dimer. This loose 
dimer allows RNA to bind, which results in stabilisation of the dimer and these two factors 
(hypusine and RNA) in concert ultimately produce a functional (dimeric) protein.  Precisely 
which residues are involved in dimerisation and RNA binding cannot be determined without 
solving the crystal structure of the protein together with its hypusine modification and RNA 
counterpart.  However, the dimer models and biochemical data from this study suggest that 
Asp 61, Glu 69 and Asp 70 are important at the dimer interface, and Phe 128 and Ser 16 are 
residues likely to be interacting with RNA.   
 
6.2.2 In E. coli 
As in yeast, the eIF5A dimer purified from E. coli was disrupted following the addition of 
reducing agents (DTT and β-mercaptoethanol).  The integrity of these eIF5A dimers was 
dependent upon the presence of Cys 39, leading to the conclusion that here dimerisation  was 
due to a folding mechanism making use of disulphide bridging as opposed to an alternate 
dimerisation mechanism in hypusinated eIF5A.  In contrast to dimerisation in yeast the E. coli 
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dimer did not rely on the presence of Lys 51 (the site of hypusination), suggesting that the 
(unhypusinated) dimer might be self-associating as a result of protein misfolding, which is 
sufficiently ordered for the dimer to remain soluble.  This data has important implications for 
the interpretation of available structural data derived from crystals generated from protein 
purified in E. coli.  Firstly, these crystals were produced from recombinant protein using DTT 
(Kim et al., Peat et al., Yao et al., 2003; Sun et al., 2005) which, from data in this study, 
would have resulted in the monomeric form of the protein.  Secondly, the structures did not 
accommodate the RNA molecule, because the protein was unhypusinated.  This would have 
resulted in misfolded, but soluble protein, the structures of which would be affected in the 
highly conserved, but variable loop structures.  The implication is that data derived from such 
models in these regions may not accurately reflect the structure of the protein in vivo. 
 
6.3 Proposed mechanism of dimerisation for yeast eIF5A 
As discussed above, the dimer models of yeast eIF5A produced in this study are limited for 
the following reasons: (1) The structural templates used to generate the monomeric models 
are derived from non-hypusinated protein in the absence of RNA; (2) The templates used to 
generate the monomeric models may represent soluble, but misfolded protein and (3) The 
template structures cannot account for conformational changes that may take place during 
protein-protein interactions (dimerisation) or protein-RNA binding.  
 
If, as data presented in this study suggest, hypusination and RNA binding do result in 
conformational changes, these changes are likely to affect the apparently disordered, but 
highly conserved loop structures of eIF5A, particularly the loop presenting the site of 
hypusination.  The reasoning is that highly structured (ordered) regions such as β-sheets and 
α-helices would not be altered, while the highly conserved, unstructured (loop) regions of the 
protein would be targets of conformational change.  Since the site of hypusination is found in 
such an unstructured region, it is possible that an extension of the lysine to hypusine would 
result in a greater molecular reach, thus allowing for the possible interlocking of two            
N-terminal domains (in the Type II dimer configuration) or between the N-terminal domain of 
one molecule and the C-terminal domain of another molecule (in the Type I dimer 
configuration).  Cano et al. (2008) have recently reported two residue changes in this loop 
region (other than the lysine that becomes hypusinated) that result in the loss of growth in a 
yeast eIF5A null strain.  Since these two mutants (K47D and G49A) are still hypusinated, it 
could be that they may play a role in either dimerisation or in RNA-binding.   
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Other regions likely to be affected by conformational change would be putative RNA contact 
regions.  These include the area preceding and following the highly ordered α-helix (amino 
acids Asp 129 - Leu 134 and Lys 110 - Glu 119), the flexible inter-domain linker region 
(amino acids Pro 83 - Lys 86) and the loop structures on the N-terminal domain preceding the 
anti-parallel β-sheet arrangement (amino acids Ser 45 - Lys 57).  Although the precise           
eIF5A-RNA contact regions have yet to be determined, it may be possible to speculate on the 
nature of the RNA molecule bound to hypusinated eIF5A.  The minimal consensus of the 
single-stranded RNA molecules required to bind eIF5A is AAAUGUCACAC (Xu & Chen, 
2001).  A number of the RNA molecules identified in a subsequent study (Xu et al., 2004) 
have the potential to form hairpins and internal loop structures which serve as potential 
recognition sites for eIF5A.  Since it is not yet possible to precisely predict the RNA contact 
points unless a solution or crystal structure of the eIF5A-RNA molecule is solved, it is worth 
hypothesising how the specified length of sequence-specific RNA could be involved in the 
dimerisation mechanism of eIF5A.  
 
The following model represents a potential mechanism for producing functional eIF5A using 
the Type II dimer based upon a dimer configuration of the structural analogue HEX-1 
(Sections 2.3.5 and 2.3.6).  Since RNA binding requires hypusine it is proposed that the 
protein undergoes the following dimerisation process.  Following translation of eIF5A, the 
hypusination enzymes (DHS and DOHH) perform the post-translational modification of 
Lys51- to HYP-51-eIF5A (Figure 6.2A Step 1).  This is the point where a conformational 
change in the monomer is predicted (denoted in Figure 6.2 as ∆).  The hypusinated eIF5A 
monomers then loosely associate to produce an interlocking finger (Type II) dimer 
configuration in the N-terminal domain which may involve hypusine (Figure 6.2A Step 2).  
This loose dimer configuration creates a groove at the dimer interface that allows specific 
RNA (represented by a 30-mer in Figure 6.2B) to bind, resulting in a further conformational 
change (∆) that locks the dimer in place and enables it to perform its functions in vivo (Figure 
6.2 Step 3).  The RNA molecule is represented here such that the loop regions interact at the 
dimer interface, and each of the RNA termini interact with one of the α-helices.  In the 
absence of hypusine, the loose dimer configuration cannot be achieved, and in the absence of 
RNA, the loose dimer is disassociated (unstable).  Whether the hypusination-dimerisation-
RNA-binding mechanism is achieved in a step-wise approach (as represented in Figure 6.2A 
and B) or whether hypusination and RNA-binding occur simultaneously to result in 
dimerisation (Figure 6.2A and B Steps 2 and 3 combined), is yet to be determined.   This 
could be tested by monomerising the hypusinated protein using DTT and then adding back an 
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RNA transcript (based on the SELEX transcripts identified by Xu et al., 2004) to observe 
whether dimerisation reoccurs.  Alternatively, the hypusinated protein could be monomerised 
using RNAse, re-purified and cross-linked using glutaraldehyde.  Should dimerisation of 
hypusinated eIF5A re-occur, it would be plausible that the step-wise mechanism of 
dimerisation is employed.   
 
 
 
Figure 6.2:  Proposed dimerisation mechanism of yeast eIF5A.  Schematic representation 
of the dimerisation mechanism proposed for yeast eIF5A.  (A)  Step 1 involves hypusination 
of the monomeric eIF5A effecting a conformational change in the protein (represented by ∆).  
The hypusinated monomers associate to form a loose dimer configuration (Step 2).  (B) 
ssRNA (represented as a 30-mer) binds to the loose dimer which effects another 
conformational change (Step 3) to produce the tightly-associated functional dimer.  The 30-
mer RNA molecule (orange strand) was randomly introduced in the tightly-associated dimer 
to give some idea of scale.  The possibility that Steps 2 and 3 occur simultaneously cannot be 
ruled out.  The figure was generated in part using Pymol (DeLano 2002) and DeepView/Swiss 
PDB Viewer (Guex & Peitsch, 1997).  
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6.4 Concluding remarks and opportunities for further research  
While the mechanism of dimerisation is yet to be elucidated, this study has contributed to the 
understanding of which factors may be important for the dimerisation and hence function of 
yeast eIF5A.  The limited information that can be derived from the homology models 
produced during the course of this investigation have highlighted the need for an eIF5A 
crystal or solution structure in its hypusinated form and in the presence of RNA, which 
involves crystallising the native protein in the absence of DTT.  The apparent need for the 
addition of a reducing agent during crystallisation of eIF5A (Kim et al., 1998; Peat et al., 
1998; Yao et al., 2003; Sun et al., 2005)  could be overcome by stabilisation of the dimer in 
the presence of RNA.  Should it not be possible to produce crystals of hypusinated eIF5A, an 
alternative approach could be to use or Nuclear Magnetic Resonance (NMR) solution studies.   
The eIF5A monomer is potentially still within the size limitation for solving solution 
structures of protein structures using NMR.  Comparison of the structures of K51R-eIF5A 
with hypusinated eIF5A as well as the presence or absence of RNA could result in a structure 
for the loop including hypusine. 
 
In the absence of further structural data, the dimerisation model would need to be tested using 
site directed mutagenesis amino acid residues predicted to interact at the dimer interface or 
potentially contacting RNA.  The generation of the yeast experimental system, anti-eIF5A 
antibodies, vectors for heterologous and homologous expression of eIF5A or eIF5A mutants 
and biochemical tools used to detect dimerisation and RNA binding can be used to identify 
further residues and/or regions of eIF5A critical for dimerisation and RNA binding.  
Functional characterisation of these mutants in vivo together with their dimerisation 
characteristics and RNA binding properties would be useful in identifying important domains.  
Potentially important regions could include the unique α-helical region on the C-terminus of 
the protein, the loop structure housing the site of hypusination and internal N-terminal domain 
loop regions preceding this loop.   
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Appendices 
 
Appendix A:  Growth Media 
 
Yeast Extract, Peptone, Dextrose Medium 
(YPD) 
Per liter: 2 % yeast extract (w/v) 
   1 % peptone (w/v) 
   2 % glucose (v/v) 
* 17 g Agar 
. 
* Omit for liquid medium  
 
Yeast Extract, Peptone,Galactose Medium 
(YP-Gal) 
Per liter: 2 % yeast extract (w/v) 
   1 % peptone (w/v) 
   2 % galactose (v/v) 
.* 17 g Agar 
. 
* Omit for liquid medium  
 
Synthetic Minimal Medium (SMM) 
(Kaiser et al., 1994) 
Per liter:  1.7 g yeast nitrogen base (YNB) 
without amino acids and ammonium sulphate 
(Difco). 
5 g Ammonium sulphate 
20 g glucose or 20 g galactose as   required 
* 15 g Agar 
* omit for liquid medium. 
 
Supplements (Sigma) as required for each 
yeast strain, were added subsequent to 
autoclaving at the following final 
concentrations 
Uracil    20 mg/L 
L - Tryptophan  20 mg/L 
L - Histidine   20 mg/L 
L - Leucine   100 mg/L 
 
Luria-Bertani agar/broth (Sambrook et al., 
1989) 
Per litre:  10 g peptone 
            5 g yeast extract 
            5 g NaCl 
          * 15 g Agar 
* omit for liquid medium. 
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Appendix B: E. coli competent cells  
Based on a method by Hanahan, (1985) 
 
E. coli DH5 α or BL21 (DE3) cells were grown in Luria broth to an OD600 nm of between 0.6 
and 0.8, before harvesting cells at 5000 rpm (JA 14 rotor, 10 minutes, 4 oC).  Pellets were 
resuspended in 50 ml RF1 solution and incubated on ice for 20 minutes before harvesting 
again.  The pellet was resuspended in 4 ml of RF2 solution before aliquoting and freezing at -
80 oC. 
 
RF1 Solution (pH 5.8, 1 L) 
100 mM KCl 
50 mM MnCl2 
30 mM CH3COOK 
10 mM CaCl2 
15 % v/v Glycerol 
 
RF2 Solution (pH 6.8, 500 ml) 
10 mM MOPS 
10 mM KCl 
75 mM CaCl2 
15 % v/v Glycerol 
Appendix C:  Primers used in the course of this study 
 
C1: Primers used in DNA sequencing * 
 
Table A1:  List of the primers used for PCR extension during Cycle Sequencing 
Primer 
name 
Sequence Sense/ Antisense Binds 
T7F GGGAGCTGCATGTGTCAGAGG Sense T7-RNA 
polymerase 
T7R CGCTGAGATAGGTGCCTCAC Antisense SP6 RNA 
polymerase 
pUCF CGCCGAGGTTTTCCCAGTCACGAC Sense Lac operon 
pUCR TCACACAGGCAGCTATGAC Antisense Lac operon 
AI2F GGCGAGCTCTAGAAGCCGCCGAGCGGGTGAC Sense PGAL1 
AI1R CCGGCCGCGGATTAAAGCCTTCGAGCGTC Antisense TCYC1 
HISG GTGGTGCARGAACGCARGAGAAAGCCCCC Sense HisG 
URA1 GGAACGTGCTGCTACTCATCCTAGTCC Sense URA3 
 
*For each of the tables in this section: Note:  (S) = Sense Primer; (A) = Antisense Primer; 
Sites introduced are marked either in bold or underlined, corresponding to the site in the 
sequence. 
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C2: Primers used in site-directed mutagenesis * 
Table A2: List of the primers used in site-directed mutagenesis 
Primer 
Name 
Sequence (S)/ 
(A) 
Binds; 
Introduces, 
Mutation 
PG10a TCTAAGACTGGTAGACACGGTCACGCT S TIF51A; 
 Arg 51 
PG10b AGCGTGACCGTGTCTACCAGTCTTAGA A TIF51A; 
 Arg 51 
PG15F GGAAGATTTGTCTGGATCCACTCACAACTTGGAAG S TIF51B; 
 Bam HI 
PG16R CTTCCAAGTTGTGAGTGGATCCAGACAAATCTTCC A TIF51B; 
 Bam HI 
PG17F GGTTGCCATTAGATCTATCTTCACTGG S TIF51A; 
 Bgl II 
PG18R CCAGTGAAGATAGATCTAATGGCAACC A TIF51A; 
 Bgl II 
PG34F ACCTACCCAATGCAATCTTCTGCCTTGAGAAAG S TIF51A; 
 Ser 23 
PG35R CTTTCTCAAGGCAGAAGATTGCATTGGGTAGGT A TIF51A; 
Ser 23 
PG36F GAGTAGACCATCTAAGATTGTTGACATGTCCAGTTCCACTTCT S TIF51A; 
 Hinc II, Ser 39 
PG37R AGAAGTGGAACTGGACATGTCAACAATCTTAGATGGTCTACTC S TIF51A; 
 Hinc II, Ser 39 
 
C3:  PCR Amplification Primers * 
Table A3:  List of the primers used for PCR amplification (cloning) 
Primer 
Name 
Sequence (S)/
(A) 
Binds;  
Introduces 
PG1F AAGCTTACAATGTCTGACGAAGAACATACC S 5’-TIF51A;  
Hind III 
PG2R CCCGGGATCCGTTCTAGCAGCTTCCTTGAA A 3’-TIF51A; 
Sma I, Bam HI 
PG3F GATCCCGGGCATCATCATCATCATCATTAG S 3’-TIF51A; 
6 x His tag, Stop 
PG4R CCGGGCATCATCATCATCATCATTAGAATT A 3’-TIF51A; 
6 x His tag, Stop 
PG5F CATATGTCTGACGAAGAACATACCTTTGAAACT S 5’-TIF51A; 
Nde I 
PG6R GGGATCCTTAATCGGTTCTAGCAG A 3’-TIF51A; 
 Bam HI, Stop 
PG8F ACCGGTGTTTCGAAGGTGAAGGAAC S 5’-PTIF51A; 
Age I  
PG13F GGGCGTTCAAAGTTTCCTATTCC S 5’-TIF51B; 
(none) 
PG14R CATCGCGTATTTTGTAAGCTATAG A 3’-TIF51B; 
(none) 
PG30F ATACAGCTGATGCATCACCATCACCATCACTCTGACGA
AGAACATACC 
S TIF51A; Pvu II 
 N-terminal His tag 
PG31R CATCAGCTGTATATATGAGTTGGTATTTGTGTGTG A TIF51A; Pvu II, N-
terminal His tag 
PG32F GGGGACCGGTGGGCCCTTCAATATGCGCAC S 5’-PADH2/GAPDH; 
 Age I 
PG33R CCCCAAGCTTCAGCTGTGTTTATGTGTGTTTATTCG S 3’- PADH2/GAPDH; 
 Pvu II, Hind III 
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Appendix D:  Yeast genomic DNA extraction procedure 
Adapted from Kaiser et al., (1994) 
 
10 ml yeast culture was grown to saturation in YPD at 30 oC before collecting by 
centrifugation at 2000xg.  The pelleted cells were washed in 500 µl sterile water.  Following 
centrifugation, the pellet was resuspended in 200 µl of chromosomal extraction buffer (2 % 
Triton X-100, 1 % SDS; 100 mM NaCl, 10 mM Tris-HCl (pH 8), 1 mM Na2EDTA) and 200 
µl Phenol: Chloroform: Isoamyl alcohol (25:24:1).  Next, 0.3 g of nitric-acid washed glass 
beads were added before vortexing for 3 minutes (intervals of 30 second on ice, 30 seconds 
vortexing).  Then 200 µl TE buffer (10 mM Tris-HCl, pH 8, 1 mM Na2EDTA) was added 
before microfuging for 5 minutes (13 000 rpm).  The top layer was transferred to a fresh tube 
with 1 ml of ice-cold 100 % ethanol.  The pellet achieved after microfuging again was 
resuspended in 400 µl of TE buffer and 10 µl of RNAse A (10 mg/ml) and incubated at 37 oC 
for 15 minutes.  10 µl ammonium acetate (4M) was used to stop the reaction.  Finally, 1 ml of 
100 % ethanol was added before the final microfuging step.  The pellet obtained was air-dried 
and resuspended in 50 µl of TE buffer.  2-4 µl (equivalent to approximately 10 µg of DNA) 
was used for further experiments.  
 
Appendix E:  SDS- and Native PAGE 
 
The usual procedure was used for SDS-PAGE (12 % SDS-polyacrylamide resolving and 4.5% 
stacking gels) and for native PAGE (10 % polyacrylamide SDS-resolving and 4.5 % stacking 
gels).  The variation was the buffer in which the protein was suspended prior to 
electrophoresis. 
 
Dissociation buffer for SDS-PAGE (2 X) Non-reducing tracking buffer for native 
PAGE (2X) 
 
1.25 ml 1 M Tris-HCl, pH 6.8 
4 ml 10 % SDS 
1 ml β-Mercaptoethanol 
1 ml Glycerol 
0.001 g Bromophenol Blue 
Made up to 10 ml 
1.25 ml 1 M Tris-HCl, pH 8.8 
1 ml Glycerol 
0.001 g Bromophenol Blue 
Made up to 10 ml 
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Appendix F: Western Analysis 
 
Transfer Buffer 
3.03 g Tris 
14.4 g Glycine 
200 ml methanol in 1L 
Made fresh and chilled 
TBS-Tween 
100 ml 1 M Tris pH7.5 
30 ml 5 M NaCl 
1 ml Tween-20 
Made up to 1 L with dH2O 
 
1 % BSA 
1 g BSA (Fraction V) in 100 
ml of TBS-Tween 
5 % Milk Powder (Blocking 
Agent) 
5 g of Fat Free milk powder 
in 100 ml of TBS-Tween 
Dilution of Secondary Antibody 
1:12 500 dilution of the Roche BM Chemiluminescence 
Western Blotting Kit anti-mouse IgG-POD/anti-rabbit IgG-
POD secondary antibody was made in 1 % BSA 
 
Appendix G: Antibody Pre-adsorption protocol  
Adapted from Harlow & Lane, (1988) 
 
BL21 (DE3) cells were transformed with pT7-7.  The cells were harvested and lysed by 
sonication.  This lysate was incubated in a ratio of 1:3 at 4oC for 12 hours at 50 rpm, with the 
antibody (“Day 39” serum) followed by a clearing spin at 2000xg for 20 minutes.  The 
supernatant (pre-adsorbed antiserum) was analysed using lysates of cells harbouring either 
pPG6 (eIF5A-His) or pT7-7 to determine the specificity to eIF5A.   
 
Appendix H:  Extraction of yeast protein  
Adapted from Kaiser et al., (1994) 
 
Cell pellets were resuspended in either 20 µl of EB buffer (2 % SDS, 80 mM Tris-HCl, pH 
6.8, 10 % Glycerol, 1.5 % DTT, 0.01 mg/ml Bromophenol Blue) or in lysis buffer (in 
Appendix K) and  0.3 g of nitric acid washed glass beads  per 2 OD
 600 nm units of cells  before 
vortexing for a total of 4 minutes (30 seconds on ice, 30 seconds vortexing) before a 1 minute 
low-speed (4000 rpm) microfuging.  The supernatant was used for SDS-PAGE analysis. 
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Appendix I:  Southern Blotting Procedure  
Procedure as outlined in Sambrook et al., (1989) and Ausubel et al., (1983) 
 
I1:  General notes 
Following transfer the membrane was washed in 2 x SSPE buffer.  The blot was then 
subjected to pre-hybridization, hybridization with the “hot” probe and washing steps, 
followed by exposure to X-Ray film (Agfa CP-BU Medical X-Ray film, 180 x 240 mm) for a 
period of 2 weeks in a Kodak BioMax intensifying screen and cassette at -80oC. 
 
The “hot” probe was prepared using 50 µCi of α-32P CTP [10 mCi/ml] (Amersham 
Biosciences) at the same time as a “cold” probe. The transcribed RNA from both the “hot” 
and “cold” reactions was precipitated using 70% ice-cold ethanol and the pellet resuspended 
in 100 µl of DEPC-treated water.  Binding of the radioactively-labelled probe was detected by 
incubation of the membrane under film (AGFA CP-BU Medical X-Ray film, 180 x 240 mm) 
at -70oC with an intensifying screen (Kodak Biomax) for a period of two weeks.  
Visualisation of radioactive exposure was performed using standard photographic techniques 
and solutions (Kodak or AGFA).  
 
I2: Hybridisation and wash conditions 
All hybridisation and wash steps were carried out in a Hybaid Omnigene Hybridisation Oven. 
1. The nitrocellulose membrane was incubated at 42 °C in 25 ml pre-hybridisation 
solution containing denatured salmon sperm DNA to block non-specific binding sites for 
8 hours. 
2. The radioactively labelled DNA probe was denatured at 100 °C for 5 minutes on a 
heating block, and then added to the membrane in the pre-hybridisation solution.  The 
membrane was incubated with the probe at 42 °C for at least 12 hours. 
3. Highly stringent washes were carried out as follows: 
i) 2 x SSPE with 0.1 % SDS for 10 minutes at room temperature.  Repeat. 
ii) 0.5 x SSPE with 0.1 % SDS for 15 minutes at room temperature 
iii) 0.5 x SSPE with 0.1 % SDS for 30 minutes at 42°C 
iv) 0.5 x SSPE with 0.1 % SDS for 10 minutes at 65°C 
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20 x SSC 
3 M NaCl 
0.3 M Sodium Citrate 
20 x SSPE 
3.6 M NaCl 
0.2 M Sodium Phosphate 
0.2 M EDTA pH7.7 
Pre-Hybridisation Solution  
5 x SSPE 
5 x Denhardt’s Solution 
0.5 % (w/v) SDS 
50 % formamide 
To 25 ml, add 0.5 ml of a 1 mg 
solution of denatured salmon sperm DNA 
per ml 
 
Neutralising Solution 
1.5 M NaCl    
0.5 M Tris pH 7.2 
0.001 M EDTA 
Denaturing Solution 
1.5 M NaCl 
0.5 M NaOH 
 
Denhardt’s Solution (5x)) 
2 % (w/v) BSA 
2 % (w/v) Ficoll 
2 % (w/v) polyvinylpyrrolidone 
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Appendix J:  Additional plasmids 
 
J1:  Plasmid pPG30  
Plasmid pPG30 was used in making the RNA-transcript for Southern analysis of the various 
yeast strains produced in this study (Figure J1). 
 
 
 
Figure A1:  Plasmid pPG30, used for making the RNA-transcript in the Southern 
Analysis of the yeast strains.  (A)  pPG30, a pGEM-T-Easy-derived plasmid housing the 
TIF51A gene used in making the T7-RNA transcript. (B) The T7-RNA transcript “cold” 
resolved on a 1% agarose gel.  (C)  Diagrammatic representation of the T7-RNA transcript. 
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J2:  Plasmid pPG10-His  
Depicted in Figure J2, is plasmid pPG10-His.  This plasmid was derived from pPG10, which 
was used in the complementation of the TIF51A/TIF51B disrupted strain.  pPG10-His houses 
TIF51A ORF followed by a 6 x His Tag. The plasmid was used to complement  PGY10 to 
show that the tagged eIF5A protein was functional. 
 
 
Figure A2:  Schematic representation of plasmid pPG10-His.  Plasmid pPG10-His, 
derived by digesting, pPG6 (A), the eIF5A-His expression vector with Sal I and Eco RI and 
ligating it to the wild-type complementation plasmid pPG10 (B) digested using the same 
enzymes.  The resulting plasmid, pPG10-His (C) was used in complementation assays of 
strain PGY10 to demonstrate that a 6 x His tag, placed on the C-terminus did not affect the 
function of eIF5A. 
 
 
 
 
 
 
